Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileChristopher Paul Cannon, M.D.

TitleProfessor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women's Hospital
Cardiovascular
75 Francis St
Boston MA 02115
Phone617/278-0146
Fax617/734-7329
vCardDownload vCard (login for email)
Profile Picture

Collapse Biography 
Collapse awards and honors
1980Phi Beta Kappa
1982Magna Cum Laude
1983NIH Students Research Fellowship Award
1985Aldred Steiner Research Award
1985NIH Student Research Fellowship Award
1986Alpha Omega Alpha
1986Robert F. Loeb Award for Excellence in Clinical Medicine
1986Upjohn Achievement in Research Award
2001 - 2001Simon Dack Visiting Professor
2004 - 2004Partners in Excellence Award
2005 - 2007Best Doctors in America
2006 - 2007Partners In Excellence Award
2007 - 2007Best Doctors in Boston
2008Get With The Guidelines Special Recognition,
2010Leadership Award
2012Raymond Bahr Award of Excellence
2014 - 2016Highly Cited Researchers; World’s Most Influential Scientific Minds

Collapse Overview 
Collapse overview
I am a cardiologist at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. I also serve as Executive Director of Cardiometabolic Trials at the Baim Institute of Clinical Research. Over the past 27 years, I have been the principal investigator of more than 18 multicenter clinical trials including TACTICS-TIMI 18, PROVE IT-TIMI 22, IMPROVE IT and currently the RE-DUAL PCI trial.  My research has focused on management and prevention of acute coronary syndromes (ACS) with a goal of trying to directly improve patient care. Collaborating with others, we have helped establish various antithrombotic and interventional strategies for ACS, as well as long-term lipid management approaches for prevention that are included in current international guidelines. More recently, I am also studying prevention approaches in diabetes and in atrial fibrillation. Finally, I help lead registries and quality improvement educational initiatives with an aim toward implementation of research advances in clinical practice.


Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cannon C, Khan I, Sanchez R. Simulation Models of Therapy Intensification in Lipid-Lowering Medicine-Reply. JAMA Cardiol. 2018 Jan 01; 3(1):89. PMID: 29188279.
    View in: PubMed
  2. Steen DL, Umez-Eronini AA, Guo J, Khan N, Cannon CP. The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. Clin Cardiol. 2017 Dec 28. PMID: 29283450.
    View in: PubMed
  3. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT. Circulation. 2017 Dec 20. PMID: 29263150.
    View in: PubMed
  4. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472. PMID: 29253846.
    View in: PubMed
  5. Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, Murphy SA, Park JG, Braunwald E, Giugliano RP. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017 Nov 18; 6(11). PMID: 29151034.
    View in: PubMed
  6. Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Cardiovascular Risk and Statin Eligibility of Young Adults After an Myocardial Infarction: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2017 Nov 08. PMID: 29141201.
    View in: PubMed
  7. Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis G. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation. 2017 Nov 07; 136(19):1860-1862. PMID: 29109198.
    View in: PubMed
  8. Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, Hochman JS, Goodrich EL, Braunwald E, O'Donoghue ML. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10). PMID: 29066436.
    View in: PubMed
  9. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10). PMID: 29066452.
    View in: PubMed
  10. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2017 Oct 24. PMID: 29064626.
    View in: PubMed
  11. Barger LK, Rajaratnam SMW, Cannon CP, Lukas MA, Im K, Goodrich EL, Czeisler CA, O'Donoghue ML. Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2017 Oct 10; 6(10). PMID: 29018021.
    View in: PubMed
  12. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol. 2017 Oct 03; 70(14):1689-1700. PMID: 28958324.
    View in: PubMed
  13. Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PG. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. Eur Heart J. 2017 Oct 01; 38(37):2813-2822. PMID: 28575274.
    View in: PubMed
  14. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19; 136(25):2440-2450. PMID: 28972004.
    View in: PubMed
  15. Rachmin I, O'Meara CC, Ricci-Blair EM, Feng Y, Christensen EM, Duffy JF, Zitting KM, Czeisler CA, Pancoast JR, Cannon CP, O'Donoghue ML, Morrow DA, Lee RT. Soluble interleukin-13ra1: a circulating regulator of glucose. Am J Physiol Endocrinol Metab. 2017 Dec 01; 313(6):E663-E671. PMID: 28874358.
    View in: PubMed
  16. Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 Sep 01; 2(9):959-966. PMID: 28768335.
    View in: PubMed
  17. Yong CM, Liu Y, Apruzzese P, Doros G, Cannon CP, Maddox TM, Gehi A, Hsu JC, Lubitz SA, Virani S, Turakhia MP. Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. Am Heart J. 2018 Jan; 195:50-59. PMID: 29224646.
    View in: PubMed
  18. Bohula EA, Morrow DA, Giugliano RP, Cannon CP, Braunwald E. Reply: Ezetimibe, Risk Stratification, and Secondary Prevention. J Am Coll Cardiol. 2017 Aug 29; 70(9):1200. PMID: 28838375.
    View in: PubMed
  19. Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 09 28; 377(13):1217-1227. PMID: 28847206.
    View in: PubMed
  20. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 10 19; 377(16):1513-1524. PMID: 28844193.
    View in: PubMed
  21. Stewart RAH, Hagström E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, López-Sendón JL, Mohler ER, Hadziosmanovic N, Krug-Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin L. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2017 Aug 22; 6(8). PMID: 28862971.
    View in: PubMed
  22. Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagström E, Held C, Koenig W, Östlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, März W, Wallentin L. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017 Aug 15; 70(7):813-826. PMID: 28797349.
    View in: PubMed
  23. Ference BA, Cannon CP, Landmesser U, Lüscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2017 Aug 14. PMID: 29020411.
    View in: PubMed
  24. Lowenstern A, Storey RF, Neely M, Sun JL, Angiolillo DJ, Cannon CP, Himmelmann A, Huber K, James SK, Katus HA, Morais J, Siegbahn A, Steg PG, Wallentin L, Becker RC. Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis. 2017 Aug; 44(2):145-153. PMID: 28608165.
    View in: PubMed
  25. Lemesle G, Ducrocq G, Elbez Y, Van Belle E, Goto S, Cannon CP, Bauters C, Bhatt DL, Steg PG. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clin Cardiol. 2017 Oct; 40(10):932-939. PMID: 28692742.
    View in: PubMed
  26. El Shahawy M, Cannon CP, Blom DJ, McKenney JM, Cariou B, Lecorps G, Pordy R, Chaudhari U, Colhoun HM. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). Am J Cardiol. 2017 Sep 15; 120(6):931-939. PMID: 28750828.
    View in: PubMed
  27. Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol. 2017 Jun; 40(6):390-398. PMID: 28598510.
    View in: PubMed
  28. Mancini GBJ, Gupta M, Tsigoulis M, Cannon CP, Genest J, Ray KK, Santos RD, Watts GF, Raggi P. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis. 2017 Aug; 263:112-118. PMID: 28623740.
    View in: PubMed
  29. Reed GW, Cannon CP. STREAM characterisation correction - Authors' reply. Lancet. 2017 May 27; 389(10084):2102-2103. PMID: 28561001.
    View in: PubMed
  30. Stanifer JW, Charytan DM, White J, Lokhnygina Y, Cannon CP, Roe MT, Blazing MA. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol. 2017 Oct; 28(10):3034-3043. PMID: 28507057.
    View in: PubMed
  31. Pokharel Y, Chinnakondepalli K, Vilain K, Wang K, Mark DB, Davies G, Blazing MA, Giugliano RP, Braunwald E, Cannon CP, Cohen DJ, Magnuson EA. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes. 2017 May; 10(5). PMID: 28506979.
    View in: PubMed
  32. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 May 01; 2(5):547-555. PMID: 28291866.
    View in: PubMed
  33. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB, Massaro JM, Mauri L. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 May 01; 2(5):478-487. PMID: 28297015.
    View in: PubMed
  34. Kastelein JJ, Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, Maroni J, Farnier M. Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coron Artery Dis. 2017 May; 28(3):190-197. PMID: 27740972.
    View in: PubMed
  35. Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 Jul; 19(7):989-996. PMID: 28206704.
    View in: PubMed
  36. Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc. 2017 Apr 14; 6(4). PMID: 28411246.
    View in: PubMed
  37. Bergmark BA, Cannon CP, White WB, Jarolim P, Liu Y, Bonaca MP, Zannad F, Morrow DA. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017 Jul; 19(7):962-969. PMID: 28195387.
    View in: PubMed
  38. Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921. PMID: 28246236.
    View in: PubMed
  39. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28; 69(8):911-921. PMID: 28231942.
    View in: PubMed
  40. Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671. PMID: 28058763.
    View in: PubMed
  41. Deedwania P, Acharya T, Kotak K, Fonarow GC, Cannon CP, Laskey WK, Peacock WF, Pan W, Bhatt DL. Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. Am Heart J. 2017 May; 187:78-87. PMID: 28454811.
    View in: PubMed
  42. Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, Stevens W, Valdes- Marquez E, Wiviott S, Cannon CP, Braunwald E, Collins R, Landray MJ. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017 05; 187:182-190. PMID: 28454801.
    View in: PubMed
  43. Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC, James SK, Katus HA, Lopes RD, Sorbets E, Wallentin L, Steg PG. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. Am Heart J. 2017 Apr; 186:91-99. PMID: 28454837.
    View in: PubMed
  44. Eisen A, Cannon CP, Braunwald E, Steen DL, Zhou J, Goodrich EL, Im K, Dalby AJ, Spinar J, Daga S, Lukas MA, O'Donoghue ML. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc. 2017 Jan 11; 6(1). PMID: 28077384.
    View in: PubMed
  45. Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb; 63(2):573-584. PMID: 27932413.
    View in: PubMed
  46. Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017 Jan; 63(1):325-333. PMID: 27811204.
    View in: PubMed
  47. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016 Nov; 9(11). PMID: 27803042.
    View in: PubMed
  48. Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943. PMID: 27777279.
    View in: PubMed
  49. Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension. 2016 12; 68(6):1355-1364. PMID: 27977392.
    View in: PubMed
  50. Blazing MA, Giugliano RP, de Lemos JA, Cannon CP, Tonkin A, Ballantyne CM, Lewis BS, Musliner TA, Tershakovec AM, Lokhnygina Y, White JA, Reist C, McCagg A, Braunwald E. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96. PMID: 27914504.
    View in: PubMed
  51. Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP. Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. J Am Coll Cardiol. 2016 Aug 30; 68(9):981-2. PMID: 27561775.
    View in: PubMed
  52. Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald E. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016 Dec 21; 37(48):3576-3584. PMID: 27569841.
    View in: PubMed
  53. Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol. 2016 Oct; 39(10):555-564. PMID: 27565018.
    View in: PubMed
  54. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017 01 14; 389(10065):197-210. PMID: 27502078.
    View in: PubMed
  55. White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13. PMID: 27480840.
    View in: PubMed
  56. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, Tershakovec AM, Braunwald E. Reply: Personalize and Optimize Lipid-Lowering Therapies. J Am Coll Cardiol. 2016 Jul 19; 68(3):326. PMID: 27417014.
    View in: PubMed
  57. Bonaca MP, O'Malley RG, Jarolim P, Scirica BM, Murphy SA, Conrad MJ, Cannon CP, White HD, Braunwald E, Morrow DA, Sabatine MS. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 Jul 19; 68(3):322-323. PMID: 27417011.
    View in: PubMed
  58. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, Tershakovec AM, Braunwald E. Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? J Am Coll Cardiol. 2016 Jun 28; 67(25):3025-6. PMID: 27339506.
    View in: PubMed
  59. Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Östlund O, White HD. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 Jun 21; 5(6). PMID: 27329448; PMCID: PMC4937279.
  60. White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 07; 39(7):1267-73. PMID: 27289121.
    View in: PubMed
  61. Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, Sasiela WJ. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. J Am Heart Assoc. 2016 Jun 10; 5(6). PMID: 27287699; PMCID: PMC4937273.
  62. O'Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, Murphy SA, Gerszten RE, Sabatine MS. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016 May 20; 5(5). PMID: 27207959; PMCID: PMC4889163.
  63. Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016 Sep; 129(9):1002-5. PMID: 27143321.
    View in: PubMed
  64. Doll JA, Wang TY, Choudhry NK, Cannon CP, Cohen DJ, Fonarow GC, Henry TD, Bhandary DD, Khan N, Davidson-Ray LD, Anstrom K, Peterson ED. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. Am Heart J. 2016 Jul; 177:33-41. PMID: 27297847.
    View in: PubMed
  65. Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CP. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8. PMID: 27297843.
    View in: PubMed
  66. Giannitsis E, Wallentin L, James SK, Bertilsson M, Siegbahn A, Storey RF, Husted S, Cannon CP, Armstrong PW, Steg PG, Katus HA. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. Eur Heart J Acute Cardiovasc Care. 2017 Sep; 6(6):500-510. PMID: 27044282.
    View in: PubMed
  67. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White J, Tershakovec AM, Blazing MA, Braunwald E. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29; 133(13):e463. PMID: 27022050.
    View in: PubMed
  68. Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12; 67(14):1661-71. PMID: 27012778.
    View in: PubMed
  69. Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman AD. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation. 2016 Apr 19; 133(16):1574-81. PMID: 26945047.
    View in: PubMed
  70. Reed GW, Cannon CP, Waalen J, Teirstein PS, Tanguay JF, Berger PB, Angiolillo DJ, Price MJ. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):190-198. PMID: 26909669.
    View in: PubMed
  71. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 02; 67(4):353-361. PMID: 26821621.
    View in: PubMed
  72. Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A, Held C, Varenhorst C, Wallentin L, Scirica BM. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol. 2016 Feb; 9(2):e002951. PMID: 26810596.
    View in: PubMed
  73. Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, Zannad F, White WB. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27. PMID: 27179720.
    View in: PubMed
  74. Mathews R, Fonarow GC, Li S, Peterson ED, Rumsfeld JS, Heidenreich PA, Roe MT, Oetgen WJ, Jollis JG, Cannon CP, de Lemos JA, Wang TY. Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. Am Heart J. 2016 May; 175:1-8. PMID: 27179718.
    View in: PubMed
  75. Tickoo S, Bhardwaj A, Fonarow GC, Liang L, Bhatt DL, Cannon CP. Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines--Coronary Artery Disease Data Set). Am J Cardiol. 2016 Jan 15; 117(2):201-5. PMID: 26651452.
    View in: PubMed
  76. Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E, Wallentin L, Steg PG. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45. PMID: 25254357.
    View in: PubMed
  77. Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015 Oct 09; 4(10):e002490. PMID: 26452988; PMCID: PMC4845124.
  78. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015 Dec; 17(12):1180-93. PMID: 26343814.
    View in: PubMed
  79. Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a Statin after Acute Coronary Syndromes. N Engl J Med. 2015 Oct 08; 373(15):1476-7. PMID: 26444734.
    View in: PubMed
  80. Cannon CP. Should all surgery patients get statins pre-operatively? Clear or blurry VISION? Eur Heart J. 2016 Jan 07; 37(2):186-8. PMID: 26450011.
    View in: PubMed
  81. Pokorney SD, Radder C, Schulte PJ, Al-Khatib SM, Tricocci P, Van de Werf F, James SK, Cannon CP, Armstrong PW, White HD, Califf RM, Gibson CM, Giugliano RP, Wallentin L, Mahaffey KW, Harrington RA, Newby LK, Piccini JP. High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. Am Heart J. 2016 Jan; 171(1):25-32. PMID: 26699597; PMCID: PMC4692180 [Available on 01/01/17].
  82. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015 Sep 29; 132(13):1224-33. PMID: 26330412.
    View in: PubMed
  83. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec; 9(6):758-769. PMID: 26687696.
    View in: PubMed
  84. Reed GW, Guo J, Cannon CP, Kumar A, Aranki S, Shekar P, Agnihotri A, Maree AO, McLean DS, Rosenfield K. Authors' Reply. Clin Cardiol. 2015 Jul; 38(7):444-5. PMID: 26216006.
    View in: PubMed
  85. Khera AV, Qamar A, Murphy SA, Cannon CP, Sabatine MS, Rader DJ. On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). Am J Cardiol. 2015 Sep 01; 116(5):694-8. PMID: 26119654.
    View in: PubMed
  86. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97. PMID: 26039521.
    View in: PubMed
  87. Chilton R, Tikkanen I, Cannon CP, Crowe S, Hach T, Woerle HJ, Broedl UC, Johansen OE. 4B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES. J Hypertens. 2015 Jun; 33 Suppl 1:e53. PMID: 26102848.
    View in: PubMed
  88. Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Aliment Pharmacol Ther. 2015 Aug; 42(3):365-74. PMID: 26032114; PMCID: PMC4494867 [Available on 08/01/16].
  89. Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015 Sep 21; 36(36):2415-24. PMID: 25971287.
    View in: PubMed
  90. Cannon C, Borgatti A, Henson M, Husbands B. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract. 2015 Jul; 56(7):425-9. PMID: 25828786.
    View in: PubMed
  91. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WB. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015 May 12; 131(19):e435-70. PMID: 25829340.
    View in: PubMed
  92. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015 May 12; 65(18):1998-2038. PMID: 25840655.
    View in: PubMed
  93. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015 Jun; 9(6):453-98. PMID: 25840695.
    View in: PubMed
  94. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WB. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015 Jun; 65(6):1372-407. PMID: 25828847.
    View in: PubMed
  95. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun; 169(6):906-915.e13. PMID: 26027630.
    View in: PubMed
  96. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76. PMID: 25765696.
    View in: PubMed
  97. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 06; 385(9984):2264-2271. PMID: 25748612; PMCID: PMC4608367.
  98. Patti G, Bennett R, Seshasai SR, Cannon CP, Cavallari I, Chello M, Nusca A, Mega S, Caorsi C, Spadaccio C, Keun On Y, Mannacio V, Berkan O, Yilmaz MB, Katrancioglu N, Ji Q, Kourliouros A, Baran Ç, Pasceri V, Rüçhan Akar A, Carlos Kaski J, Di Sciascio G, Ray KK. Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. Europace. 2015 Jun; 17(6):855-63. PMID: 25733550.
    View in: PubMed
  99. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015 May 14; 36(19):1186-94. PMID: 25687353; PMCID: PMC4430683.
  100. Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin LÅ, Cannon CP, Harrington RA, Mark DB. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10; 65(5):465-76. PMID: 25660925.
    View in: PubMed
  101. Reed GW, Kumar A, Guo J, Aranki S, Shekar P, Agnihotri A, Maree AO, McLean DS, Rosenfield K, Cannon CP. Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. Clin Cardiol. 2015 Feb; 38(2):92-8. PMID: 25655085.
    View in: PubMed
  102. Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Deedwania P, Grau-Sepulveda M, Schwamm LH, Bhatt DL. Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med. 2015 Apr; 128(4):426.e1-9. PMID: 25433302.
    View in: PubMed
  103. Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71. PMID: 25670362.
    View in: PubMed
  104. Lytle BL, Li S, Lofthus DM, Thomas L, Poteat JL, Bhatt DL, Cannon CP, Fonarow GC, Peterson ED, Wang TY, Alexander KP. Targeted versus standard feedback: results from a randomized quality improvement trial. Am Heart J. 2015 Jan; 169(1):132-41.e2. PMID: 25497258.
    View in: PubMed
  105. Blankstein R, Cannon C, Udelson J. Update on pharmacological cardiac stress testing: efficacy, risk stratification and patient selection. Am J Med. 2014 Nov; 127(11):e16-7. PMID: 25447629.
    View in: PubMed
  106. Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L, Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2015 Jan; 101(2):119-25. PMID: 25227704; PMCID: PMC4316918.
  107. O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014 Sep 10; 312(10):1006-15. PMID: 25173516.
    View in: PubMed
  108. Krygier JE, Lewis VO, Cannon CP, Satcher RL, Moon BS, Lin PP. Operative management of metastatic melanoma in bone may require en bloc resection of disease. Clin Orthop Relat Res. 2014 Oct; 472(10):3196-203. PMID: 24989125; PMCID: PMC4160486.
  109. Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HA, Mahaffey KM, Pieper KS, Storey RF, Steg PG, Harrington RA. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2. PMID: 25005338.
    View in: PubMed
  110. Varenhorst C, Alström U, Braun OÖ, Storey RF, Mahaffey KW, Bertilsson M, Cannon CP, Scirica BM, Himmelmann A, James SK, Wallentin L, Held C. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014 Nov; 100(22):1762-9. PMID: 24957530.
    View in: PubMed
  111. Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug; 168(2):205-12.e1. PMID: 25066560.
    View in: PubMed
  112. Sarma A, Cannon CP, de Lemos J, Rouleau JL, Lewis EF, Guo J, Mega JL, Sabatine MS, O'Donoghue ML. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. J Am Heart Assoc. 2014 May 01; 3(3):e000784. PMID: 24786143; PMCID: PMC4309063.
  113. Gotto AM, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther. 2014 Nov; 19(6):543-9. PMID: 24737712.
    View in: PubMed
  114. Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014 Jul; 168(1):68-75.e2. PMID: 24952862.
    View in: PubMed
  115. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014 Aug 14; 35(31):2083-93. PMID: 24727884; PMCID: PMC4132637.
  116. White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 01; 370(18):1702-11. PMID: 24678955.
    View in: PubMed
  117. Xian Y, Chen AY, Thomas L, Roe MT, Subherwal S, Cannon CP, Pollack CV, Fonarow GC, Kosiborod M, Peterson ED, Alexander KP. Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014 Mar; 7(2):236-43. PMID: 24594548.
    View in: PubMed
  118. Cavender MA, Rassi AN, Schwamm LH, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Bhatt DL. Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. Clin Cardiol. 2014 May; 37(5):323. PMID: 24596074.
    View in: PubMed
  119. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014 Nov 01; 35(41):2864-72. PMID: 24585266; PMCID: PMC4216432.
  120. Bainey KR, Armstrong PW, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Zhao X, Schwamm LH, Bhatt DL. Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. Circ Cardiovasc Qual Outcomes. 2014 Mar; 7(2):227-35. PMID: 24569634.
    View in: PubMed
  121. Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu CM, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin L. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22; 63(15):1493-9. PMID: 24561148.
    View in: PubMed
  122. Vardi M, Debidda M, Bhatt DL, Mauri L, Cannon CP. Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. Clin Cardiol. 2014 Feb; 37(2):103-7. PMID: 24672813.
    View in: PubMed
  123. Waks JW, Sabatine MS, Cannon CP, Morrow DA, Gibson CM, Wiviott SD, Giugliano RP, Sloan S, Scirica BM. Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6. PMID: 24452727.
    View in: PubMed
  124. Thukkani AK, Fonarow GC, Cannon CP, Cox M, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Schwamm LH, Bhatt DL. Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD. Clin Cardiol. 2014 May; 37(5):285-92. PMID: 24452828.
    View in: PubMed
  125. Kohli P, Steg PG, Cannon CP, Smith SC, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014 Jan; 127(1):53-60.e1. PMID: 24280110.
    View in: PubMed
  126. Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HS, Mahaffey KW, Pieper KS, Storey RF, Steg PG, Harrington RA. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 01; 170(3):e59-62. PMID: 24299581.
    View in: PubMed
  127. Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21; 129(3):293-303. PMID: 24170388.
    View in: PubMed
  128. Ellrodt AG, Fonarow GC, Schwamm LH, Albert N, Bhatt DL, Cannon CP, Hernandez AF, Hlatky MA, Luepker RV, Peterson PN, Reeves M, Smith EE. Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013 Nov 26; 128(22):2447-60. PMID: 24166574.
    View in: PubMed
  129. Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, Ohman EM, Umez-Eronini AA, Hoffman E, Bhatt DL. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013 Dec; 36(12):721-7. PMID: 24166484.
    View in: PubMed
  130. O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MS. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014 Feb 18; 63(6):520-7. PMID: 24161323; PMCID: PMC3945105.
  131. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23; 310(16):1711-20. PMID: 24150467.
    View in: PubMed
  132. Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014 Jan 28; 63(3):225-32. PMID: 24140678.
    View in: PubMed
  133. Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin L. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014; 25(7):517-25. PMID: 24127651; PMCID: PMC4220996.
  134. Gotto AM, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83. PMID: 24188894.
    View in: PubMed
  135. Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR. Very large database of lipids: rationale and design. Clin Cardiol. 2013 Nov; 36(11):641-8. PMID: 24122913.
    View in: PubMed
  136. Nazer B, Ray KK, Murphy SA, Gibson CM, Cannon CP. Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. J Thromb Thrombolysis. 2013 Oct; 36(3):233-9. PMID: 23212806.
    View in: PubMed
  137. Cavender MA, Rassi AN, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Schwamm LH, Bhatt DL. Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Clin Cardiol. 2013 Dec; 36(12):749-56. PMID: 24085713.
    View in: PubMed
  138. Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RP. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9. PMID: 24064010.
    View in: PubMed
  139. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35. PMID: 23992602.
    View in: PubMed
  140. Peacock WF, Kontos MC, Amsterdam E, Cannon CP, Diercks D, Garvey L, Graff L, Holmes D, Holmes KS, McCord J, Newby K, Roe M, Dadkhah S, Siler-Fisher A, Ross M. Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis. Crit Pathw Cardiol. 2013 Sep; 12(3):116-20. PMID: 23892940.
    View in: PubMed
  141. Cannon CP. Should we measure quality by the dose? J Am Coll Cardiol. 2013 Nov 05; 62(19):1802-3. PMID: 23973702.
    View in: PubMed
  142. Cannon C, Ezekowitz MD, Granger C. Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. Am J Cardiol. 2013 Aug 15; 112(4):S3. PMID: 23910054.
    View in: PubMed
  143. Reed GW, Cannon CP. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. Clin Cardiol. 2013 Oct; 36(10):585-94. PMID: 23873635.
    View in: PubMed
  144. James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L, Harrington RA. Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6. PMID: 23800556.
    View in: PubMed
  145. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Hoffman E, Goto S, Ohman EM, Bhatt DL. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013 Aug; 126(8):693-700.e1. PMID: 23800583.
    View in: PubMed
  146. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Crit Pathw Cardiol. 2013 Jun; 12(2):65-105. PMID: 23680811.
    View in: PubMed
  147. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79. PMID: 23726390; PMCID: PMC3778977.
  148. James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9. PMID: 23572474.
    View in: PubMed
  149. Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RP. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7. PMID: 23520015.
    View in: PubMed
  150. Steen DL, Cannon CP, Lele SS, Rajapurkar MM, Mukhopadhyay B, Scirica BM, Murphy SA, Morrow DA. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol. 2013 Mar; 36(3):139-45. PMID: 23377899.
    View in: PubMed
  151. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013 Mar 05; 127(9):1052-89. PMID: 23357718.
    View in: PubMed
  152. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). J Am Coll Cardiol. 2013 Mar 05; 61(9):992-1025. PMID: 23369353.
    View in: PubMed
  153. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013 Feb 12; 127(6):673-80. PMID: 23277305.
    View in: PubMed
  154. Statement on matching language to the type of evidence used in describing outcomes data. Clin Cardiol. 2012 Dec; 35(12):713. PMID: 23192967.
    View in: PubMed
  155. Kohli P, Cannon CP. The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data. Clin Cardiol. 2012 Dec; 35(12):714-7. PMID: 23192955.
    View in: PubMed
  156. Cannon P. Statement on matching language to the type of evidence used in describing observational studies vs. randomized trials. Eur Heart J. 2013 Jan; 34(1):20-1. PMID: 23178643.
    View in: PubMed
  157. Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72. PMID: 23172660; PMCID: PMC3588873.
  158. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14. PMID: 23144048.
    View in: PubMed
  159. Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald E. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6. PMID: 23131034.
    View in: PubMed
  160. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 08; 61(1):35-40. PMID: 23137936.
    View in: PubMed
  161. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL. ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 03; 308(13):1340-9. PMID: 23032550.
    View in: PubMed
  162. Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012 Oct 23; 60(17):1623-30. PMID: 23021325.
    View in: PubMed
  163. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16; 60(16):1581-98. PMID: 22958960.
    View in: PubMed
  164. Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Schwamm L, Saxon LA. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):654-61. PMID: 22949493.
    View in: PubMed
  165. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):680-8. PMID: 22991347.
    View in: PubMed
  166. Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Pan W, Schwamm LH, Bhatt DL. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013 Jan; 126(1):74.e1-9. PMID: 22925314.
    View in: PubMed
  167. Boyer NM, Laskey WK, Cox M, Hernandez AF, Peterson ED, Bhatt DL, Cannon CP, Fonarow GC. Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. J Am Heart Assoc. 2012 Aug; 1(4):e001206. PMID: 23130159; PMCID: PMC3487339.
  168. Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol. 2012 Aug 21; 60(8):747-8. PMID: 22898071.
    View in: PubMed
  169. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012 Sep 04; 60(10):875-81. PMID: 22902202.
    View in: PubMed
  170. Bui AH, Bonaca MP, Sabatine MS, Ray KK, Rifai N, Cannon CP, Morrow DA. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis. 2012 Aug; 34(2):222-8. PMID: 22446996.
    View in: PubMed
  171. O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10; 60(2):106-11. PMID: 22766336.
    View in: PubMed
  172. Medina HM, Cannon CP, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Frank Peacock W, Laskey W, Peterson ED, Schwamm L, Bhatt DL. Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. Clin Cardiol. 2012 Oct; 35(10):632-40. PMID: 22744844.
    View in: PubMed
  173. Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, Liang L, Hernandez AF, Peterson ED, Rosas SE, Bhatt DL. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep; 35(9):541-7. PMID: 22744797.
    View in: PubMed
  174. Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol. 2012 Nov; 35(11):673-81. PMID: 22740110.
    View in: PubMed
  175. Bangalore S, Fonarow GC, Peterson ED, Hellkamp AS, Hernandez AF, Laskey W, Peacock WF, Cannon CP, Schwamm LH, Bhatt DL. Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012 Oct; 125(10):1000-9. PMID: 22748404.
    View in: PubMed
  176. Kohli P, Cannon CP. Dabigatran associated with increased risk of acute coronary events. Evid Based Med. 2013 Feb; 18(1):e9. PMID: 22740361.
    View in: PubMed
  177. Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. Science. 2012 Jun 15; 336(6087):1386-7. PMID: 22700906.
    View in: PubMed
  178. Joshi PH, Chaudhari S, Blaha MJ, Jones SR, Martin SS, Post WS, Cannon CP, Fonarow GC, Wong ND, Amsterdam E, Hirshfeld JW, Blumenthal RS. A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology. Clin Cardiol. 2012; 35(7):404-9. PMID: 22674150.
    View in: PubMed
  179. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 03; 126(1):65-75. PMID: 22615345.
    View in: PubMed
  180. Kohli P, Cannon CP. A new approach to managing the 'statin-intolerant' patient? Eur Heart J. 2012 May; 33(9):1040-3. PMID: 22507980.
    View in: PubMed
  181. Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumenthal RS. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol. 2012 Jul 15; 110(2):307-13. PMID: 22497674.
    View in: PubMed
  182. Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, Coba V. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol. 2012 Jun; 78(6):712-24. PMID: 22447123.
    View in: PubMed
  183. Sampath J, Dietze DT, Toth PP, Cannon CP, Breslan SA. Are continuing medical education activities effective in improving the competence and performance of clinicians? Evidence from activities for primary care clinicians who manage patients with acute coronary syndromes. Crit Pathw Cardiol. 2012 Mar; 11(1):1-9. PMID: 22337214.
    View in: PubMed
  184. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28; 125(8):978-86. PMID: 22261200.
    View in: PubMed
  185. Qian F, Ling FS, Deedwania P, Hernandez AF, Fonarow GC, Cannon CP, Peterson ED, Peacock WF, Kaltenbach LA, Laskey WK, Schwamm LH, Bhatt DL. Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes. 2012 Jan; 5(1):126-33. PMID: 22235068.
    View in: PubMed
  186. Kohli P, Cannon CP. Triglycerides: how much credit do they deserve? Med Clin North Am. 2012 Jan; 96(1):39-55. PMID: 22391250.
    View in: PubMed
  187. Steen DL, Cannon CP. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Rev Cardiovasc Med. 2012; 13(1):e48-51. PMID: 22754969.
    View in: PubMed
  188. Huang PH, Kim CX, Lerman A, Cannon CP, Dai D, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Smith EE, Fonarow GC, Schwamm LH, Bhatt DL. Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. Clin Cardiol. 2012; 35(7):396-403. PMID: 22753250.
    View in: PubMed
  189. Northfield J, Beale A, Cannon C, Gonzalez L. Enough to bring a lump to the throat: two emergency presentations to the acute medical take. Acute Med. 2012; 11(3):154-6. PMID: 22993746.
    View in: PubMed
  190. Kohli P, Cannon CP. Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol. 2011 Dec 20; 9(2):69-71. PMID: 22182956.
    View in: PubMed
  191. Reed GW, Cannon CP. Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. J Am Coll Cardiol. 2011 Dec 13; 58(25):2640-1. PMID: 22152949.
    View in: PubMed
  192. Stowell SA, Cannon CP, Hoekstra JW, Peterson ED, Miller SC. Take heart: a one-on-one peer-based strategy to improve acute coronary syndrome patient care. Crit Pathw Cardiol. 2011 Dec; 10(4):164-8. PMID: 22089271.
    View in: PubMed
  193. Kohli P, Cannon CP. Statins and safety: can we finally be reassured? Lancet. 2011 Dec 10; 378(9808):1980-1981. PMID: 22115875.
    View in: PubMed
  194. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, Morrow DA. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012 Jan; 58(1):267-73. PMID: 22110019.
    View in: PubMed
  195. Cannon CP. High-density lipoprotein cholesterol as the Holy Grail. JAMA. 2011 Nov 16; 306(19):2153-5. PMID: 22089726.
    View in: PubMed
  196. Motivala AA, Cannon CP, Srinivas VS, Dai D, Hernandez AF, Peterson ED, Bhatt DL, Fonarow GC. Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011 Oct 18; 58(17):1760-5. PMID: 21996387.
    View in: PubMed
  197. Eapen ZJ, Fonarow GC, Dai D, O'Brien SM, Schwamm LH, Cannon CP, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):610-8. PMID: 22010200.
    View in: PubMed
  198. Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, Liau CS, Wilson PW, Salette G, Smith SC, Steg PG. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011 Oct; 86(10):960-7. PMID: 21964173; PMCID: PMC3184025.
  199. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, Maggioni AP, Bode C, Weaver D, Johnson JL, Cicconetti G, Lukas MA, Tarka E, Cannon CP. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):613-619.e1. PMID: 21982651.
    View in: PubMed
  200. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1. PMID: 21982652.
    View in: PubMed
  201. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST, Cannon CP, Katus HA, Wallentin L. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6. PMID: 21890085.
    View in: PubMed
  202. Bird GC, Cannon CP, Kennison RH. Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medications. Crit Pathw Cardiol. 2011 Sep; 10(3):134-41. PMID: 21989034.
    View in: PubMed
  203. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011 Sep 06; 124(10):1132-7. PMID: 21875913.
    View in: PubMed
  204. Medina HM, Cannon CP, Zhao X, Hernandez AF, Bhatt DL, Peterson ED, Liang L, Fonarow GC. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011 Aug; 162(2):283-290.e2. PMID: 21835289.
    View in: PubMed
  205. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec; 32(23):2945-53. PMID: 21804104.
    View in: PubMed
  206. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 02; 124(5):544-54. PMID: 21709065.
    View in: PubMed
  207. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24):2556-64. PMID: 21693744.
    View in: PubMed
  208. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17; 342:d3527. PMID: 21685437; PMCID: PMC3117310.
  209. Acharjee S, Cannon CP. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. Crit Pathw Cardiol. 2011 Jun; 10(2):84-6. PMID: 21988948.
    View in: PubMed
  210. Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012 Dec; 30(6):342-50. PMID: 21884017.
    View in: PubMed
  211. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun; 161(6):1147-55.e1. PMID: 21641362.
    View in: PubMed
  212. Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16. PMID: 21545948.
    View in: PubMed
  213. Ahmed S, Michael Gibson C, Cannon CP, Murphy SA, Sabatine MS. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolysis. 2011 May; 31(4):493-500. PMID: 21318582.
    View in: PubMed
  214. Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011 May; 4(3):328-36. PMID: 21487089; PMCID: PMC3097284.
  215. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, Di Sciascio G. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011 Apr 19; 123(15):1622-32. PMID: 21464051.
    View in: PubMed
  216. Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol. 2011 Jun; 38(6):1071-8. PMID: 21459935.
    View in: PubMed
  217. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6. PMID: 21420059; PMCID: PMC3743416.
  218. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16; 305(11):1097-105. PMID: 21406646.
    View in: PubMed
  219. Natarajan P, Cannon CP. Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. Eur Heart J. 2011 Jul; 32(14):1701-3. PMID: 21406438.
    View in: PubMed
  220. Cannon CP. Clopidogrel: to test or not to test? That is the question--still. Clin Chem. 2011 May; 57(5):659-61. PMID: 21402801.
    View in: PubMed
  221. Cannon CP, Hoekstra JW, Larson DM, Karcher RB, Mencia WA, Berry CA, Stowell SA. A report of quality improvement in the care of patients with acute coronary syndromes. Crit Pathw Cardiol. 2011 Mar; 10(1):29-34. PMID: 21562372.
    View in: PubMed
  222. Nazer B, Ray KK, Sloan S, Scirica B, Morrow DA, Cannon CP, Braunwald E. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011 Jun; 32(11):1390-7. PMID: 21345849.
    View in: PubMed
  223. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KP. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011 Apr 15; 107(8):1136-43. PMID: 21324428.
    View in: PubMed
  224. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez A, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J. 2011 Feb; 161(2):418-424.e1-3. PMID: 21404720.
    View in: PubMed
  225. Vaughan-Shaw PG, Cannon C. Venous thromboembolism prevention in medical patients: a framework for improving practice. Phlebology. 2011 Mar; 26(2):62-8. PMID: 21228357.
    View in: PubMed
  226. Alexander KP, Wang TY, Li S, Lytle BL, Slattery LE, Calhoun S, Poteat J, Roe MT, Rumsfeld JS, Cannon CP, Peterson ED. Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. Circ Cardiovasc Qual Outcomes. 2011 Jan 01; 4(1):129-35. PMID: 21245461; PMCID: PMC3061815.
  227. Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, Cannon C. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol. 2011 Jan; 75(1):63-9. PMID: 21176752.
    View in: PubMed
  228. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Roe MT. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011 Jan; 161(1):113-122.e2. PMID: 21167342.
    View in: PubMed
  229. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 08; 57(6):672-84. PMID: 21194870.
    View in: PubMed
  230. Marchini J, Morrow D, Resnic F, Manica A, Kirshenbaum J, Cannon C, Croce K. An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Crit Pathw Cardiol. 2010 Dec; 9(4):192-8. PMID: 21119336; PMCID: PMC3039920.
  231. Acharjee S, Cannon CP. Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence. Crit Pathw Cardiol. 2010 Dec; 9(4):203-6. PMID: 21119338.
    View in: PubMed
  232. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010 Dec; 160(6):1130-6, 1136.e1-3. PMID: 21146668.
    View in: PubMed
  233. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15. PMID: 21082868.
    View in: PubMed
  234. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23; 122(21):2131-41. PMID: 21060072.
    View in: PubMed
  235. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010 Nov 23; 122(21):2142-51. PMID: 21060068.
    View in: PubMed
  236. Cannon CP, Stecker EC. New options for stroke prevention in atrial fibrillation. Am J Manag Care. 2010 Nov; 16(10 Suppl):S291-7. PMID: 21517644.
    View in: PubMed
  237. Natarajan P, Cannon CP. Could direct inhibition of inflammation be the "next big thing" in treating atherosclerosis? Arterioscler Thromb Vasc Biol. 2010 Nov; 30(11):2081-3. PMID: 20962294.
    View in: PubMed
  238. Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77. PMID: 21087753.
    View in: PubMed
  239. Cannon CP. An overview of stroke and the impact of atrial fibrillation. Am J Manag Care. 2010 Nov; 16(10 Suppl):S273-7. PMID: 21517641.
    View in: PubMed
  240. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27; 304(16):1821-30. PMID: 20978260; PMCID: PMC3048820.
  241. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010 Oct 26; 56(18):1456-62. PMID: 20832963.
    View in: PubMed
  242. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10. PMID: 20966402.
    View in: PubMed
  243. Rich JD, Cannon CP, Murphy SA, Qin J, Giugliano RP, Braunwald E. Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19; 56(17):1376-85. PMID: 20946994.
    View in: PubMed
  244. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17. PMID: 20925534.
    View in: PubMed
  245. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010 Oct; 160(4):655-61. PMID: 20934559.
    View in: PubMed
  246. Krishnaswamy A, Lincoff AM, Cannon CP. Bleeding complications of unfractionated heparin. Expert Opin Drug Saf. 2011 Jan; 10(1):77-84. PMID: 20868290.
    View in: PubMed
  247. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010 Nov; 32(10):1240-8. PMID: 20955443.
    View in: PubMed
  248. Acharjee S, Cannon CP. Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers. Crit Pathw Cardiol. 2010 Sep; 9(3):156-9. PMID: 20802270.
    View in: PubMed
  249. Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB, Steg PG, Bhatt DL. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25. PMID: 20802264.
    View in: PubMed
  250. Birtcher KK, Pan W, Labresh KA, Cannon CP, Fonarow GC, Ellrodt G. Performance achievement award program for Get With The Guidelines--Coronary Artery Disease is associated with global and sustained improvement in cardiac care for patients hospitalized with an acute myocardial infarction. Crit Pathw Cardiol. 2010 Sep; 9(3):103-12. PMID: 20802262.
    View in: PubMed
  251. Bangalore S, Bhatt DL, Röther J, Alberts MJ, Thornton J, Wolski K, Goto S, Hirsch AT, Smith SC, Aichner FT, Topakian R, Cannon CP, Steg PG. Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2010 Sep 14; 122(11):1091-100. PMID: 20805431.
    View in: PubMed
  252. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67. PMID: 20805430.
    View in: PubMed
  253. Peterson ED, Roe MT, Chen AY, Fonarow GC, Lytle BL, Cannon CP, Rumsfeld JS. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart. 2010 Nov; 96(22):1798-802. PMID: 20736202.
    View in: PubMed
  254. Khera AV, Wolfe ML, Cannon CP, Qin J, Rader DJ. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol. 2010 Aug 15; 106(4):451-6. PMID: 20691300.
    View in: PubMed
  255. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JS. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010 Jul 20; 56(4):254-63. PMID: 20633817.
    View in: PubMed
  256. Ray KK, Nazer B, Cairns R, Michael Gibson C, Cannon CP. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. J Thromb Thrombolysis. 2010 Jul; 30(1):10-3. PMID: 20354760.
    View in: PubMed
  257. Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J, Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH, Braunwald E. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 Aug; 31(16):1993-2005. PMID: 20558431.
    View in: PubMed
  258. Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, Gibson CM, Cannon CP, Braunwald E, Sabatine MS. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1. PMID: 20569707; PMCID: PMC2892399.
  259. Cannon CP. Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction. Crit Pathw Cardiol. 2010 Jun; 9(2):55-81. PMID: 20520214.
    View in: PubMed
  260. Vidovich MI, Vasaiwala S, Cannon CP, Peterson ED, Dai D, Hernandez AF, Fonarow GC. Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program. Am Heart J. 2010 Jun; 159(6):1026-36. PMID: 20569716.
    View in: PubMed
  261. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44. PMID: 20435228; PMCID: PMC2864403.
  262. Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol. 2010 Apr; 33(4):206-12. PMID: 20394040.
    View in: PubMed
  263. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010 Mar 30; 55(13):1283-99. PMID: 20338488.
    View in: PubMed
  264. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May; 159(5):705-9. PMID: 20435175.
    View in: PubMed
  265. Acharjee S, Qin J, Murphy SA, McCabe C, Cannon CP. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). Am J Cardiol. 2010 Mar 01; 105(5):619-23. PMID: 20185006.
    View in: PubMed
  266. Krishnaswamy A, Lincoff AM, Cannon CP. The use and limitations of unfractionated heparin. Crit Pathw Cardiol. 2010 Mar; 9(1):35-40. PMID: 20215909.
    View in: PubMed
  267. Cannon CP, Hoekstra JW, Larson DM, Carter RD, Cornish J, Karcher RB, Mencia WA, Berry CA, Stowell SA. Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program. Crit Pathw Cardiol. 2010 Mar; 9(1):23-9. PMID: 20215907.
    View in: PubMed
  268. Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CP. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit Pathw Cardiol. 2010 Mar; 9(1):14-8. PMID: 20215905.
    View in: PubMed
  269. Mega S, Patti G, Cannon CP, Di Sciascio G. Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials. Crit Pathw Cardiol. 2010 Mar; 9(1):19-22. PMID: 20215906.
    View in: PubMed
  270. Laskey W, Spence N, Zhao X, Mayo R, Taylor R, Cannon CP, Hernandez AF, Peterson ED, Fonarow GC. Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease program. Crit Pathw Cardiol. 2010 Mar; 9(1):1-7. PMID: 20215903.
    View in: PubMed
  271. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010 Mar 16; 121(10):1176-87. PMID: 20194881.
    View in: PubMed
  272. Cannon CP. Balancing the benefits of statins versus a new risk-diabetes. Lancet. 2010 Feb 27; 375(9716):700-1. PMID: 20167360.
    View in: PubMed
  273. Xian Y, Pan W, Peterson ED, Heidenreich PA, Cannon CP, Hernandez AF, Friedman B, Holloway RG, Fonarow GC. Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. Am Heart J. 2010 Feb; 159(2):207-14. PMID: 20152218.
    View in: PubMed
  274. Maree AO, Vangjeli C, Jneid H, Ryan J, Cox D, Cannon CP, Shields DC, Fitzgerald DJ. G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial. J Thromb Haemost. 2010 May; 8(5):934-41. PMID: 20096003.
    View in: PubMed
  275. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93. PMID: 20079528.
    View in: PubMed
  276. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010 Jan 26; 121(3):357-65. PMID: 20065168; PMCID: PMC2874063.
  277. Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DL. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52. PMID: 20152237.
    View in: PubMed
  278. Waheed S, Cannon CP. Cardiac rehabilitation. Cardiac rehabilitation reduces the long-term risk of death and cardiovascular complications. Rev Cardiovasc Med. 2010; 11(3):e181-4. PMID: 21045772.
    View in: PubMed
  279. Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62. PMID: 20102867.
    View in: PubMed
  280. Kumar A, Cannon CP. News and views from the literature. Antiplatelet therapy. Ticagrelor in acute coronary syndrome: a new frontier in platelet inhibition. Rev Cardiovasc Med. 2010; 11(2):117-20. PMID: 20700096.
    View in: PubMed
  281. Truong QA, Garrido-Castro AC, Cannon CP. Patent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair? Rev Cardiovasc Med. 2010; 11(1):53-6. PMID: 20495519; PMCID: PMC2990776.
  282. Truong Q, Kallianos K, Cannon C. Coronary artery disease. Calcium score of zero: not a gatekeeper to rule out coronary artery disease. Rev Cardiovasc Med. 2010; 11(4):271-3. PMID: 21389919; PMCID: PMC3083450.
  283. Cannon C. The NICE Guideline on chest pain of recent onset: what does it mean for the acute physician? Acute Med. 2010; 9(2):98-9. PMID: 21597584.
    View in: PubMed
  284. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15; 54(25):2358-62. PMID: 20082923.
    View in: PubMed
  285. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009 Dec 08; 54(24):2290-5. PMID: 19958964.
    View in: PubMed
  286. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC, Wilson PW, Watson KE, Steg PG. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J. 2009 Dec; 158(6):1038-45. PMID: 19958873.
    View in: PubMed
  287. Kumbhani DJ, Cannon CP, Fonarow GC, Liang L, Askari AT, Peacock WF, Peterson ED, Bhatt DL. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA. 2009 Nov 25; 302(20):2207-13. PMID: 19934421.
    View in: PubMed
  288. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45. PMID: 19909874.
    View in: PubMed
  289. Ambardekar AV, Fonarow GC, Dai D, Peterson ED, Hernandez AF, Cannon CP, Krantz MJ. Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). Am J Cardiol. 2010 Jan 15; 105(2):139-43. PMID: 20102907.
    View in: PubMed
  290. Depta JP, Cannon CP, Fonarow GC, Zhao X, Peacock WF, Bhatt DL. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8. PMID: 19840557.
    View in: PubMed
  291. Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, part II. Mayo Clin Proc. 2009 Nov; 84(11):1021-36. PMID: 19880693; PMCID: PMC2770915.
  292. Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA, Cannon CP, Pan W, Fonarow GC. Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):633-41. PMID: 20031902.
    View in: PubMed
  293. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA. 2009 Oct 21; 302(15):1658-65. PMID: 19843900.
    View in: PubMed
  294. Cannon CP, Dansky HM, Davidson M, Gotto AM, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3. PMID: 19781408.
    View in: PubMed
  295. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009 Oct; 84(10):917-38. PMID: 19797781; PMCID: PMC2755812.
  296. Smith EE, Liang L, Hernandez A, Reeves MJ, Cannon CP, Fonarow GC, Schwamm LH. Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. Neurology. 2009 Sep 01; 73(9):709-16. PMID: 19720978; PMCID: PMC2734292.
  297. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11. PMID: 19726929.
    View in: PubMed
  298. Peterson ED, Roe MT, Rumsfeld JS, Shaw RE, Brindis RG, Fonarow GC, Cannon CP. A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):491-9. PMID: 20031882.
    View in: PubMed
  299. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57. PMID: 19717846.
    View in: PubMed
  300. Cannon CP. Should we manage patients with non-ST segment elevation myocardial infarction with renal failure with an invasive strategy? Circulation. 2009 Sep 08; 120(10):828-30. PMID: 19704091.
    View in: PubMed
  301. Wang TY, Fonarow GC, Hernandez AF, Liang L, Ellrodt G, Nallamothu BK, Shah BR, Cannon CP, Peterson ED. The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. Arch Intern Med. 2009 Aug 10; 169(15):1411-9. PMID: 19667305.
    View in: PubMed
  302. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009 Sep; 29(9):1310-5. PMID: 19667110.
    View in: PubMed
  303. Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Piña IL, Safford MM, Fonarow GC. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. J Am Coll Cardiol. 2009 Aug 04; 54(6):515-21. PMID: 19643312; PMCID: PMC2760436.
  304. Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, Cannon CP, Bhatt DL. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009 Aug 18; 120(7):560-7. PMID: 19652090.
    View in: PubMed
  305. Storey RF, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H, Cannon CP, Heptinstall S, Armstrong M. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009 Aug; 20(5):341-8. PMID: 19637098.
    View in: PubMed
  306. Roe MT, Chen AY, Cannon CP, Rao S, Rumsfeld J, Magid DJ, Brindis R, Klein LW, Gibler WB, Ohman EM, Peterson ED. Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):414-20. PMID: 20031871.
    View in: PubMed
  307. Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009 Oct; 30(7):767-74. PMID: 19594486.
    View in: PubMed
  308. Gilbert NF, Yasko AW, Oates SD, Lewis VO, Cannon CP, Lin PP. Allograft-prosthetic composite reconstruction of the proximal part of the tibia. An analysis of the early results. J Bone Joint Surg Am. 2009 Jul; 91(7):1646-56. PMID: 19571087.
    View in: PubMed
  309. Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CM. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. Am J Cardiol. 2009 Aug 15; 104(4):475-9. PMID: 19660597.
    View in: PubMed
  310. Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Steg PG, Cannon CP, Brennan DM, Bhatt DL. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol. 2009 Jun; 8(2):91-7. PMID: 19417637.
    View in: PubMed
  311. Charytan DM, Wallentin L, Lagerqvist B, Spacek R, De Winter RJ, Stern NM, Braunwald E, Cannon CP, Choudhry NK. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009 Jun; 4(6):1032-43. PMID: 19423566; PMCID: PMC2689886.
  312. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009 May; 157(5):818-24, 824.e1. PMID: 19376306.
    View in: PubMed
  313. Forman DE, Cannon CP, Hernandez AF, Liang L, Yancy C, Fonarow GC. Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). Am Heart J. 2009 Jun; 157(6):1010-7. PMID: 19464411.
    View in: PubMed
  314. Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009 Jun; 11(6):542-50. PMID: 19380329.
    View in: PubMed
  315. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009 Apr 14; 53(15):1273-8. PMID: 19358940; PMCID: PMC2675920.
  316. Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr; 27(4):886-93. PMID: 19516186.
    View in: PubMed
  317. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009 Apr; 157(4):599-605. PMID: 19332184.
    View in: PubMed
  318. Husted S, Harrington RA, Cannon CP, Storey RF, Mitchell P, Emanuelsson H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract. 2009 Apr; 63(4):667-70. PMID: 19335707.
    View in: PubMed
  319. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MT. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202. PMID: 19339264.
    View in: PubMed
  320. Cannon CP. Can the polypill save the world from heart disease? Lancet. 2009 Apr 18; 373(9672):1313-4. PMID: 19339044.
    View in: PubMed
  321. Pollack CV, Hollander JE, Chen AY, Peterson ED, Bangalore S, Peacock FW, Cannon CP, Canto JG, Gibler BW, Ohman ME, Roe MT. Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. Crit Pathw Cardiol. 2009 Mar; 8(1):29-33. PMID: 19258835.
    View in: PubMed
  322. Cannon CP, Hoekstra JW, Larson DM, Mencia WA, Cornish J, Carter RD, Berry CA, Karcher RB. Individual quality improvement in acute coronary syndromes: a performance improvement initiative. Crit Pathw Cardiol. 2009 Mar; 8(1):43-8. PMID: 19258838.
    View in: PubMed
  323. Nallamothu BK, Krumholz HM, Peterson ED, Pan W, Bradley E, Stern AF, Masoudi FA, Janicke DM, Hernandez AF, Cannon CP, Fonarow GC. Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance. Am J Cardiol. 2009 Apr 15; 103(8):1051-5. PMID: 19361588.
    View in: PubMed
  324. Truong QA, Cannon CP, Zakai NA, Rogers IS, Giugliano RP, Wiviott SD, McCabe CH, Morrow DA, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1. PMID: 19332194; PMCID: PMC2694948.
  325. Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). Am J Cardiol. 2009 Apr 15; 103(8):1056-60. PMID: 19361589.
    View in: PubMed
  326. Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009 Apr; 48(4):425-32. PMID: 19223284.
    View in: PubMed
  327. Cannon CP, Paraliticci GU, Lin PP, Lewis VO, Yasko AW. Functional outcome following endoprosthetic reconstruction of the proximal humerus. J Shoulder Elbow Surg. 2009 Sep-Oct; 18(5):705-10. PMID: 19186077.
    View in: PubMed
  328. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb; 104(2):356-62. PMID: 19174782.
    View in: PubMed
  329. Diercks DB, Kontos MC, Chen AY, Pollack CV, Wiviott SD, Rumsfeld JS, Magid DJ, Gibler WB, Cannon CP, Peterson ED, Roe MT. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009 Jan 13; 53(2):161-6. PMID: 19130984.
    View in: PubMed
  330. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):424-30. PMID: 19122170.
    View in: PubMed
  331. Truong QA, Okada DR, Cannon CP. Cardiac risk - coronary calcium scoring for all? Rev Cardiovasc Med. 2009; 10(2):121-4. PMID: 19593326; PMCID: PMC2989801.
  332. Hartwig KA, Burich D, Cannon C, Massari L, Mueller L, Dembry LM. Critical challenges ahead in bioterrorism preparedness training for clinicians. Prehosp Disaster Med. 2009 Jan-Feb; 24(1):47-53. PMID: 19557957.
    View in: PubMed
  333. Gelfand CV, Cannon CP. Unstable angina and non-ST-elevation myocardial infarction. Gelfand CV, Cannon CP, editors. Management of Acute Coronary Syndromes. 2009; 37-78.
  334. Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone. 2009; 9(4):55-68; discussion 69-71. PMID: 19789064.
    View in: PubMed
  335. Cannon CP, Waheed S. Evaluating medical, percutaneous coronary intervention, and coronary artery bypass surgery options for chronic angina: an update of the revised guidelines. Rev Cardiovasc Med. 2009; 10 Suppl 1:S21-9. PMID: 19898284.
    View in: PubMed
  336. Cannon CP. Introduction: Update on the evaluation and treatment of chronic angina. Rev Cardiovasc Med. 2009; 10 Suppl 1:S1-2. PMID: 19898282.
    View in: PubMed
  337. Truong QA, Siegel E, Cannon CP. Cardiac CT angiography--radiation dose-how effective are we in reducing radiation dose from cardiac CT angiography? Rev Cardiovasc Med. 2009; 10(4):236-9. PMID: 20065937; PMCID: PMC2997385.
  338. Truong QA, Cannon CP. Cardiac resynchronization therapy. A perspective on PROSPECT and the continued search for predictors to CRT response. Rev Cardiovasc Med. 2009; 10(1):59-61. PMID: 19367237.
    View in: PubMed
  339. Gelfand CV, Cannon CP. ST-segment-elevation myocardial infarction. Gelfand CV, Cannon CP, editors. Management of Acute Coronary Syndromes. 2009; 79-121.
  340. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008 Dec 22; 102(12A):5L-9L. PMID: 19084083.
    View in: PubMed
  341. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E, Labresh KA. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009 Jan 06; 119(1):107-15. PMID: 19075103.
    View in: PubMed
  342. Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DA. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73. PMID: 19074516.
    View in: PubMed
  343. Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, Heidenreich PA, Ho KK, Krumholz HM, Leber C, Magid DJ, Nilasena DS, Rumsfeld JS, Smith SC, Wharton TP. ACC/AHA 2008 statement on Performance Measurement and Reperfusion Therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of Performance Measurement and Reperfusion Therapy). J Am Coll Cardiol. 2008 Dec 09; 52(24):2100-12. PMID: 19056001.
    View in: PubMed
  344. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, Wells Q, Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E, Wexler L. Sex differences in medical care and early death after acute myocardial infarction. Circulation. 2008 Dec 16; 118(25):2803-10. PMID: 19064680.
    View in: PubMed
  345. Cannon CP. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit. Crit Pathw Cardiol. 2008 Dec; 7(4):223-31. PMID: 19050418.
    View in: PubMed
  346. Syed Z, Scirica BM, Mohanavelu S, Sung P, Michelson EL, Cannon CP, Stone PH, Stultz CM, Guttag JV. Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. Am J Cardiol. 2009 Feb 01; 103(3):307-11. PMID: 19166680.
    View in: PubMed
  347. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009 Feb 01; 103(3):295-300. PMID: 19166678.
    View in: PubMed
  348. Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Sabatine MS, Resnic FS. Validation of an automated safety surveillance system with prospective, randomized trial data. Med Decis Making. 2009 Mar-Apr; 29(2):247-56. PMID: 19015285; PMCID: PMC2743924.
  349. Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, Heidenreich PA, Ho KK, Krumholz HM, Leber C, Magid DJ, Nilasena DS, Rumsfeld JS, Smith SC, Wharton TP, DeLong E, Estes NA, Goff DC, Grady K, Green LA, Loth AR, Peterson ED, Radford MJ, Rumsfeld JS, Shahian DM. ACC/AHA 2008 statement on performance measurement and reperfusion therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of performance measurement and reperfusion therapy). Circulation. 2008 Dec 09; 118(24):2649-61. PMID: 19001026.
    View in: PubMed
  350. Lewis WR, Fonarow GC, LaBresh KA, Cannon CP, Pan W, Super DM, Sorof SA, Schwamm LH. Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol. 2009 Jan 15; 103(2):227-31. PMID: 19121441; PMCID: PMC3086549.
  351. Truong QA, Singh JP, Cannon CP, Sarwar A, Nasir K, Auricchio A, Faletra FF, Sorgente A, Conca C, Moccetti T, Handschumacher M, Brady TJ, Hoffmann U. Quantitative analysis of intraventricular dyssynchrony using wall thickness by multidetector computed tomography. JACC Cardiovasc Imaging. 2008 Nov; 1(6):772-81. PMID: 19212461; PMCID: PMC2638758.
  352. Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC, Dai D, Hernandez A, Fonarow GC. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009 Jan; 157(1):111-117.e2. PMID: 19081406.
    View in: PubMed
  353. Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J. 2008 Dec; 156(6):1074-9. PMID: 19033001.
    View in: PubMed
  354. Ambardekar AV, Pan W, Peterson SL, Fonarow GC, Webb LE, Hernandez AF, Cannon CP, Peterson ED, Krantz MJ. Features and hospital outcomes for nonadherent patients with heart failure: Findings from GWTG-HF. Scientific Meeting Heart Failure Society of America. 2008.
  355. Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008 Sep 09; 52(11):914-20. PMID: 18772061.
    View in: PubMed
  356. Cannon CP, Greenberg BH. Risk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol. 2008 Sep 08; 102(5A):13G-20G. PMID: 18722187.
    View in: PubMed
  357. Lewis WR, Peterson ED, Cannon CP, Super DM, LaBresh KA, Quealy K, Liang L, Fonarow GC. An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. Arch Intern Med. 2008 Sep 08; 168(16):1813-9. PMID: 18779470; PMCID: PMC3086550.
  358. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32. PMID: 19061694.
    View in: PubMed
  359. Albanese J, Birnbaum M, Cannon C, Cappiello J, Chapman E, Paturas J, Smith S. Fostering disaster resilient communities across the globe through the incorporation of safe and resilient hospitals for community-integrated disaster responses. Prehosp Disaster Med. 2008 Sep-Oct; 23(5):385-90. PMID: 19189606.
    View in: PubMed
  360. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov; 135(5):1517-25. PMID: 18823986.
    View in: PubMed
  361. Alexander D, Ou FS, Roe MT, Pollack CV, Ohman EM, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J. 2008 Sep; 156(3):606-12. PMID: 18760147.
    View in: PubMed
  362. Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Ballantyne CM, Cannon CP. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27. PMID: 18926153.
    View in: PubMed
  363. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 02; 300(1):71-80. PMID: 18594042.
    View in: PubMed
  364. Cannon CP, Chen C, Curtis SP, Viscusi J, Ahmed T, Dibattiste PM. A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Arch Drug Inf. 2008 Jul; 1(1):4-13. PMID: 20157362.
    View in: PubMed
  365. Tickoo S, Fonarow GC, Hernandez AF, Liang L, Cannon CP. Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database). Am J Cardiol. 2008 Sep 15; 102(6):663-7. PMID: 18773984.
    View in: PubMed
  366. Steinberg BA, French WJ, Peterson E, Frederick PD, Cannon CP. Is coding for myocardial infarction more accurate now that coding descriptions have been clarified to distinguish ST-elevation myocardial infarction from non-ST elevation myocardial infarction? Am J Cardiol. 2008 Sep 01; 102(5):513-7. PMID: 18721504.
    View in: PubMed
  367. Mega JL, Morrow DA, de Lemos JA, Mohanavelu S, Cannon CP, Sabatine MS. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2008 Jun 24; 51(25):2422-9. PMID: 18565400.
    View in: PubMed
  368. Krum H, Curtis SP, Brater DC, Laine L, Kaur A, Wang H, Smugar SS, Swergold G, Cannon CP, for the MEDAL Steering Committee. Which baseline parameters influence risk of congestive heart failure in arthritis patients receiving NSAIDs & COX-2 inhibitors? Multivariate analysis of 34,701 patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Program. Joint Congress of the European Society & International Society of Hypertension, Berlin, Germany. 2008.
  369. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 01; 102(5):552-8. PMID: 18721511.
    View in: PubMed
  370. Hill NS, Farber HW. Pulmonary hypertension. Cannon CP, series editor. Contemporary Cardiology. 2008.
  371. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):708S-775S. PMID: 18574277.
    View in: PubMed
  372. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S. PMID: 18574276.
    View in: PubMed
  373. Cannon CP. Acute coronary syndrome and peripheral arterial disease: Applying diagnostics for early detection and intervention. 2008.
  374. Pollack C, Agostinelli N, Jiang S, Cannon C, Sabatine M. Impact of delay to lysis on outcomes and efficacy of clopidogrel in STEMI: An analysis from CLARITY-TIMI 28. Academic Emergency Medicine. 2008.
  375. Jneid H, Fonarow GC, Cannon CP, Palacios IF, Kilic T, Moukarbel GV, Maree AO, LaBresh KA, Liang L, Newby LK, Fletcher G, Wexler L, Peterson E. Impact of time of presentation on the care and outcomes of acute myocardial infarction. Circulation. 2008 May 13; 117(19):2502-9. PMID: 18427127.
    View in: PubMed
  376. Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J Intern Med. 2008 Apr; 263(4):353-65. PMID: 18324928.
    View in: PubMed
  377. Kumar A, Cannon CP. The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Fail Clin. 2008 Apr; 4(2):129-39. PMID: 18433693.
    View in: PubMed
  378. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 02; 299(13):1547-60. PMID: 18387931.
    View in: PubMed
  379. Kumar A, Cannon CP. The role of statins in the prevention of heart failure after acute coronary syndrome. Fonarow GC, editor. Heart Failure Clinics. 2008; 4(2):129-39.
  380. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008 Apr 15; 117(15):1936-44. PMID: 18378613; PMCID: PMC4273564.
  381. O'Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, Sabatine MS. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J. 2008 Apr; 29(8):984-91. PMID: 18346960.
    View in: PubMed
  382. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008 May; 29(9):1096-102. PMID: 18339606; PMCID: PMC2829435.
  383. O'Donoghue M, Boden WE, Cannon CP, Clayton TC, de Winter RJ, Fox KAA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. The benefit of an invasive strategy in diabetic versus non-diabetic subjects with non-ST-elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials. JACC. 2008; 51(10):A216.
  384. Roe MT, Cannon CP, Chen AY, Rao SV, Rumsfield JS, Klein LW, Ohman EM, Gibler WB, Peterson ED. Decline in the use of drug-eluting stents for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Results from the CRUSADE and ACTION Registries. JACC. 2008; 51(10):A211.
  385. Mega JL, Thakuria JV, Cannon CP, Sabatine MS. Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: Insights from the CLARITY-TIMI 28 genomic study. JACC. 2008; 51(10):A206.
  386. Desai NR, Mega JL, Guo W, Cannon CP, Sabatine MS. The smoker's paradox with a clopidogrel twist: Insights from CLARITY-TIMI 28. JACC. 2008; 51(10):A203.
  387. Forman DE, Cannon CP, Albert NM, Fonarow GC, Yancy CW, Liang L, Hernandez AF, . Are guideline recommended therapies being applied to elderly patients hospitalized with heart failure?. JACC. 2008; 51(10):A239.
  388. Krum H, Curtis SP, Brater DC, Laine L, Weir MR, Kaur A, Wang H, Smugar SS, Swergold G, Cannon CP. Differential effect of baseline antihypertensive medications on blood pressure changes in patients with osteoarthritis long-term (MEDAL) study: A multivariate analysis. JACC. 2008; 51(10):A380.
  389. Harkness JR, Scirica BM, Sabatine MS, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Cannon CP, Braunwald E. Extent of ST segment resolution after fibrinolysis adds dynamic risk stratification to the TIMI rick score for STEMI. JACC. 2008; 51(10):A221.
  390. Mega JL, Cannon CP, Sabatine MS. Influence of the Xbal polymorphism in the APOB gene on lipids, statin response, and recurrent cardiovascular events. JACC. 2008; 51(10):A331.
  391. Gibson CM, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald E. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Am J Cardiol. 2008 May 01; 101(9):1232-8. PMID: 18435949.
    View in: PubMed
  392. Albert NM, Birtcher KK, Cannon CP, Goff DC, Mulgund J, Liang L, Fonarow GC. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database). Am J Cardiol. 2008 May 01; 101(9):1242-6. PMID: 18435951.
    View in: PubMed
  393. Mehta RH, Bufalino VJ, Pan W, Hernandez AF, Cannon CP, Fonarow GC, Peterson ED. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. Am Heart J. 2008 Jun; 155(6):1059-67. PMID: 18513520.
    View in: PubMed
  394. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9. PMID: 18481818.
    View in: PubMed
  395. Cannon CP, Roe MT, Chen AY, Rumsfeld JS, Brindis RG, Ohman EM, Gibler WB, Fonarow GC, Lambrew CT, Penney J, Peterson ED. Temporal improvements in door-to-balloon times for primary percutaneous coronary intervention. Results from the CRUSADE and ACTION Registries. 2008.
  396. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35. PMID: 18481820.
    View in: PubMed
  397. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7. PMID: 18481819.
    View in: PubMed
  398. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1. PMID: 18481815.
    View in: PubMed
  399. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20. PMID: 18481817.
    View in: PubMed
  400. Cannon CP. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. Crit Pathw Cardiol. 2008 Mar; 7(1):43-81. PMID: 18458666.
    View in: PubMed
  401. Karha J, Cannon CP. ADP Receptor Antagonists. Bhatt DL, editor. Platelets in Cardiovascular Disease. 2008; 87-123.
  402. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6. PMID: 18481816.
    View in: PubMed
  403. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36. PMID: 18481821.
    View in: PubMed
  404. Cannon CP, Gruberg L. Antiplatelet regimens in NSTEMI: Current and future approaches CME. 2008.
  405. Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J. 2008 May; 155(5):910-7. PMID: 18440341.
    View in: PubMed
  406. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008 May; 155(5):954-8. PMID: 18440347.
    View in: PubMed
  407. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008 Feb 19; 51(7):724-30. PMID: 18279736.
    View in: PubMed
  408. Gibson CM, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson ME. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 05; 51(5):546-51. PMID: 18237683.
    View in: PubMed
  409. McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J. 2008 Feb; 155(2):298-302. PMID: 18215600.
    View in: PubMed
  410. Cannon CP. I recently had a heart attack treated with a stent. Can I drive my car?. 2008.
  411. Cannon CP. I have severe angina. Should I ask for supplemental oxygen during a commercial flight?. 2008.
  412. Cannon CP. Efficacy and safety of the CBI cannabinoid receptor blocker rimonabant: Pooled analysis of the RIO Program. 2008.
  413. Cannon CP. What is the difference between stable and unstable angina. Is it safe to fly when you have stable angina?. 2008.
  414. Cannon CP. I have been taking one of the statins. I heard that other brands of statins may be betters. Is this true?. 2008.
  415. Cannon CP. Is it true that I should start taking the high dose of statin possible after a heart attack?. 2008.
  416. Cannon CP. I have angina. Is it safe for me to drive my car?. 2008.
  417. Cannon CP. What other symptoms besides angina can signal a heart attack?. 2008.
  418. Cannon CP. When is it safe to take a plane after I have had a heart attack?. 2008.
  419. Cannon CP. Is it true that some statins are better than others at raising good cholesterol?. 2008.
  420. Cannon CP. What symptoms are suggestive of heart disease?. 2008.
  421. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008 Jan 29; 51(4):449-55. PMID: 18222355.
    View in: PubMed
  422. Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CM. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12. PMID: 18187215.
    View in: PubMed
  423. Cannon CP. Angioplasty for Sir Paul? Docs say possible. 2008.
  424. Cannon CP, Chen C, Curtis SP, Viscusi J, Ahmed T, DiBattiste PM. A comparison of cardiovascular biomarkers in patients treated for three months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives Drug Information. 2008; 1:4-13.
  425. Kumar A, Cannon CP. The Role of Thrombolysis in the Era of STEMI Interventions. Mehta S, editor. Textbook of STEMI Interventions. 2008.
  426. Kwong RY, editor. Cardiovascular magnetic resonance imaging. Cannon CP, series editor. Contemporary Cardiology. 2008.
  427. Storey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Husted S. Final aggregation response is a more sensitive marker of the effects of P2Y12 receptor antagonists than maximal aggregation response. Eur Heart J. 2008.
  428. Dawson B, Browning SR, Dai D, Hernandez AF, Cannon CP, Steinhub I. Quality improvement in patients with coronary artery disease from Rural America: Insightsfrom the AHA's GWTG-CAD Database [aka](Comparing the quality of cardiovascular care in rural and urban hospitals: Insights from the American Heart Association Get With the Guidelines CAD Program). QCOR. 2008.
  429. Sabatine MS, Cannon CP. Unstable Angina/non-ST-segment-elevation myocardial infarction. Irwin RS, Rippe JM, editors. Irwin and Rippe's Intensive Care Medicine. 2008; 408-27.
  430. Cannon CP. Obesity-related cardiometabolic complications. Clin Cornerstone. 2008; 9(1):11-9; discussion 20-2. PMID: 19046736.
    View in: PubMed
  431. Krum H, Curtis SP, Brater DC, Laine L, Kaur A, Wang H, Smugar SS, Cannon CP, for the MEDAL Steering Committee. Multivariate analysis of blood pressure change in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study. Am Soc Hypertension. 2008.
  432. Husted S, Cannon CP. Direct oral P2Y12 inhibition: AZD6140 (Ticagrelor). Clinical guide to the use of antithrombotic drugs in coronary artery disease. 2008; 85-97.
  433. Wackers F J Th, Bruni W, Zaret BL. Nuclear cardiology: The basics. Cannon CP, series editor. Contemporary Cardiology. 2008.
  434. Cannon CP, Acharjee S. Acute coronary syndrome. Cardiovascular events after clopidogrel discontinuation. Rev Cardiovasc Med. 2008; 9(3):212-4. PMID: 18953283.
    View in: PubMed
  435. Krum H, Curtis SP, Brater DC, Laine L, Weir MR, Kaur A, Wang H, Smugar SS, Cannon CP, for the MEDAL Steering Committee. Differential effect of baseline antihypertensive medications of bood pressure changes in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study. Am Soc Hypertension. 2008.
  436. Wang T, Hernandez A, Fonarow G, Liang L, Ellrodt G, Cannon CP, Peterson E. Consistency of acute myocardial infarction (AMI) hospital quality performance improvement with efforts to improve door to balloon times. QCOR. 2008.
  437. Cannon CP. Can cholesterol make your heart healthy?. 2008.
  438. Kaur A, Curtis S, Cannon CP, Griffin M, Connors LG, Laine L. Physicians fail to provide protective co-therapy for high GI risk patients taking NSAIDS--even with direct interactive communication and free PPI: Results of a prospective outcomes trial. Gastroenterology. 2008.
  439. Upchurch Jr. GR, Criado E, editors. Aortic aneurysms. Cannon CP, series editor. Contemporary Cardiology. 2008.
  440. Olenchock BA, Fonarow GC, Wenqin P, Hernandez A, Cannon CP. Current use of beta-blockers in patients with reactive airway diseases who are hospitalized with acute coronary syndromes. QCOR. 2008.
  441. Danias PG. Cardiovascular MRI: 150 multiple choice questions and answers. Cannon CP, series editor. Contemporary Cardiology. 2008.
  442. Natale A, Jalife J. Atrial fibrillation: From bench to bedside. Cannon CP, series editor. Contemporary Cardiology. 2008.
  443. Brown T, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Pina IL, Safford MM, Fonarow GC. Predictors of non-referral to cardiac rehabilitation in the American Heart Association's Get With the Guidelines Program. QCOR. 2008.
  444. Ray KK, Cannon CP. Lipid lowering in coronary artery disease. Topol EJ, editor. Textbook of Interventional Cardiology. 2008; 183-201.
  445. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2008; 9(2):24-38; discussion 39-41. PMID: 19410160.
    View in: PubMed
  446. Cannon CP, Acharjee S. Percutaneous coronary intervention. Cardiovascular outcomes and long-term clopidogrel use after PCI in patients with diabetes. Rev Cardiovasc Med. 2008; 9(4):280-2. PMID: 19122587.
    View in: PubMed
  447. Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CM. Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol. 2008 Feb 01; 101(3):303-7. PMID: 18237589.
    View in: PubMed
  448. Steinberg BA, Cannon CP. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am J Cardiol. 2007 Dec 17; 100(12A):27P-32P. PMID: 18154743.
    View in: PubMed
  449. Schreiner GC, Laine L, Murphy SA, Cannon CP. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. Crit Pathw Cardiol. 2007 Dec; 6(4):169-72. PMID: 18091407.
    View in: PubMed
  450. Kumar A, Cannon CP. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J Interv Cardiol. 2007 Dec; 20(6):447-57. PMID: 18042049.
    View in: PubMed
  451. Kumar A, Cannon CP. Efficacy and safety of cholesterol-lowering treatment. Cardiology International. 2007; 128-36.
  452. Kumar A, Cannon CP. The current role of statins in acute coronary syndrome. Arch Med Sci. 2007; 3(4A):S115-25.
  453. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem. 2008 Mar; 41(4-5):210-21. PMID: 18048022.
    View in: PubMed
  454. Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald E. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J. 2008 Jan; 155(1):133-9. PMID: 18082504.
    View in: PubMed
  455. Dibble CT, Gelfand EV, Cannon CP. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Curr Atheroscler Rep. 2007 Nov; 9(5):359-66. PMID: 18001618.
    View in: PubMed
  456. Morrow JP, Cannon CP, Reiffel JA. New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond? Am Heart J. 2007 Nov; 154(5):824-9. PMID: 17967585.
    View in: PubMed
  457. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DI. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008 Jan; 155(1):49-55. PMID: 18082488; PMCID: PMC2645040.
  458. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 06; 50(19):1852-6. PMID: 17980251.
    View in: PubMed
  459. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51. PMID: 17980250.
    View in: PubMed
  460. Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, Newby LK, Ravkilde J, Tang WH, Christenson RH, Cannon CP, Storrow AB. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007 Dec; 53(12):2086-96. PMID: 17954494.
    View in: PubMed
  461. Buros JL, Nguyen MC, Murphy SA, Southard MC, Ciaglo K, Takao ST, Hochberg C, Sabatine MS, Cannon CP, Braunwald E, Gibson CM. The association of culprit and non-culprit myocardial perfusion with clinical events following and ST-elevation MI (STEMI): An analysis from the CLARITY-TIMI 28 study. Circulation. 2007; 116(16):II-673.
  462. Brikakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting. Results from the Pravastatin or Atorvastatin evaluation and infection therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. Circulation. 2007; 116(16):II-314.
  463. Sabatine MS, Morrow DA, Jiang S, Rifai N, Cannon CP, Gerszten RE. Elevated levels of the atherosclerotic lesion metalloproteinase PAPPA are an independent predictor of cardiovascular death of CHF in STEMI: Results from the CLARITY-TIMI 28 biomarker study. Circulation. 2007; 116(16):II-363.
  464. Deedwania PC, Fonarow GC, Cannon CP, Dai D. Are contemporary patients hospitalized with acute coronary syndrome being discharged on intensive lipid lowering therapy?: An analysis of 22,807 hospitalizations in GWTG-CAD. Circulation. 2007; 116(16):II-315.
  465. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol RJ, Berger PB. The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA. Circulation. 2007; 116(16):II-483.
  466. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts M, Goto S, Wilson PW, Steg PG on behalf of the REACH Registry Investigators. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in outpatients with peripheral arterial disease: Insights from the REACH Registry. Circulation. 2007; 116(16):II-775.
  467. Pride YB, Buros JL, Lord E, Harrigan CJ, Lew M, Abraham J, Murphy SA, Cannon CP, Sabatine MS, Gibson CM. Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. Circulation. 2007; 116(16):II-352.
  468. Bhatt DL, Peterson ED, Harrington RA, Ou F, Cannon CP, Gibson CM, Kleiman N, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MT for the CRUSADE Investigators. Polyvascular disease - a novel risk factor for worse ischemic and bleeding outcomes in acute coronary syndromes. Circulation. 2007; 116(16):II-482.
  469. Lackland DT, Cannon CP, Egan BM, Fonarow G, Yu Y, Hernandez AF, Robertson RM, Jones DW. Hypertension treatment and control among patients hospitalized with heart failure: An analysis of get with the guidelines heart failure. Circulation. 2007; 116(16):II-784.
  470. Ho KK, Anderson HV, Shaw RE, Klein LW, Beachy JH, Cannon CP, Krumholz HM, Fitzgerald S, Hermann A, Mitchell K, Rumsfeld J, Brindis RG on behalf of the National Cardiovascular Data Registry. Absence of flow-limiting coronary artery disease among patients undergoing emergent cardiac catheterization for ST segment elevation myocardial infarction in the national cardiovascular data registry cathPCI registry: Implications for primary angioplasty programs. Circulation. 2007; 116(16):II-624.
  471. Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Resnic FS. Validating an automated outcomes surveillance application using data from a terminated randomized, controlled trial (OPUS [TIMI-16]). AMIA Annu Symp Proc. 2007 Oct 11; 1043. PMID: 18694141.
    View in: PubMed
  472. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008 Oct; 26(2):79-84. PMID: 17917707.
    View in: PubMed
  473. Truong QA, Singh JP, Hoffmann U, Cannon CP. Case studies. 2007.
  474. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7. PMID: 17717132.
    View in: PubMed
  475. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007 Aug 15; 298(7):765-75. PMID: 17699010.
    View in: PubMed
  476. Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Am J Cardiol. 2007 Nov 01; 100(9):1331-5. PMID: 17950785.
    View in: PubMed
  477. Cannon CP. Translating evidence into guidelines and applying them in practice: The long chain of quality. 2007.
  478. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007 Aug; 89(8):1794-801. PMID: 17671020.
    View in: PubMed
  479. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 01; 100(7):1047-51. PMID: 17884359.
    View in: PubMed
  480. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007 Jul 31; 116(5):e99-109. PMID: 17630410.
    View in: PubMed
  481. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair J. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation. 2007 Jul 31; 116(5):e95-8. PMID: 17630411.
    View in: PubMed
  482. Pride YB, Buros JL, Lord E, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Gibson CM. Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. J Thromb Thrombolysis. 2008 Oct; 26(2):106-12. PMID: 17624497.
    View in: PubMed
  483. Cannon CP. Cardiosource 2.0-An editorial from Chris Cannon, MD, FACC, new cardiosouce editor-in-chief. 2007.
  484. Cannon CP. Logging in at Cardiosource 2.0. Cardiology. 2007; 36(7):18-9.
  485. Gelfand EV, Cannon CP. Myocardial infarction: contemporary management strategies. J Intern Med. 2007 Jul; 262(1):59-77. PMID: 17598815.
    View in: PubMed
  486. Ray KK, Cannon CP, Braunwald E. Recent trials of lipid lowering. Int J Clin Pract. 2007 Jul; 61(7):1145-59. PMID: 17577297.
    View in: PubMed
  487. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007 Jun 19; 115(24):3071-8. PMID: 17548728.
    View in: PubMed
  488. Cannon CP. Introduction: rationale for tight control of hyperglycemia. Am J Cardiol. 2007 Jun 04; 99(11A):1H-4H. PMID: 17665746.
    View in: PubMed
  489. Cannon CP. Managing ST-segment elevation MI: An update on the alternatives. J Crit Illness. 2007; 5-6.
  490. Normand AN, Cannon CP, Lewis VO, Lin PP, Yasko AW. Curettage of biopsy-diagnosed grade 1 periacetabular chondrosarcoma. Clin Orthop Relat Res. 2007 Jun; 459:146-9. PMID: 17452919.
    View in: PubMed
  491. Steinberg BA, Ballantyne CM, Bhatt DL, Montalescot G, Mehta S, O'Hagan P, Poole-Wilson PA, Cannon CP. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5. PMID: 17667869.
    View in: PubMed
  492. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 May 15; 115(19):2570-89. PMID: 17502591.
    View in: PubMed
  493. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 May 15; 115(19):2549-69. PMID: 17502590.
    View in: PubMed
  494. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007 May 29; 115(21):2761-88. PMID: 17502569.
    View in: PubMed
  495. Tickoo S, Roe MT, Peterson ED, Milford-Beland S, Ohman EM, Gibler WB, Pollack CV, Cannon CP. Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. Am J Cardiol. 2007 Jun 01; 99(11):1496-9. PMID: 17531568.
    View in: PubMed
  496. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, Gibson CM, Braunwald E. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007 Apr; 28(7):806-13. PMID: 17403721.
    View in: PubMed
  497. Cannon CP, Lin PP, Lewis VO, Yasko AW. Acetabular outcome after hip hemiarthroplasty in patients with tumors. Clin Orthop Relat Res. 2007 Apr; 457:183-7. PMID: 17119457.
    View in: PubMed
  498. Cannon CP, Conti CR, Boden WE, Wenger NK. The paradigm of ischemic heart disease-implications for optimizing patient management. 2007.
  499. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV, Ohman EM, Gibler WB, Roe MT. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93. PMID: 17493466.
    View in: PubMed
  500. Cannon CP. Managing multiple risk factors to target global cardiometabolic risk. 2007.
  501. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH, Cannon CP, Francis G, Morrow DA, Ravkilde J, Storrow AB, Tang W, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Panteghini M, Tate J. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007 Apr; 53(4):547-51. PMID: 17384000.
    View in: PubMed
  502. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007 Apr 03; 115(13):e356-75. PMID: 17384331.
    View in: PubMed
  503. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang W. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007 Apr; 53(4):552-74. PMID: 17384001.
    View in: PubMed
  504. Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007 May 01; 99(9):1212-5. PMID: 17478144.
    View in: PubMed
  505. Armani A, Qin J, Murphy SA, McCabe CH, Cannon CP. Effects of intensive vs standard statin therapy on lipids and inflammation in racial/ethnic groups. An analysis from PROVE-IT-TIMI 22. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):408A.
  506. Ray KK, Morrow DA, Cannon CP, Sabatine MS, Guo W, Rifai N, Braunwauld E. Von willebrand factor but not tissue factor or soluble CD40 ligand are associated with increased risk of recurrent events after ACS in PROVE-IT-TIMI 22. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):188A.
  507. Storey RF, Harrington RA, Husted S, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Wickens M, Peters G, Emanuelsson H, Cannon CP. AZD6140 suppresses platelet aggregation in clopidogrel-treated patients even in those with high aggregation levels. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):208A.
  508. Hernandez AF, Fonarow GC, Dai D, O'Brien SM, LaBresh KA, Schwamm LH, Cannon CP, GWTG Steering Committee. What is the best measure for rewarding quality of care: Defect-free vs composite scoring? An analysis from the American Heart Association's get with the guidelines-coronary artery disease (GWTG-CAD) program?. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):291A.
  509. Cannon CP, Rhee K, Bhatt DL, Boden WE. Use of aspirin among patients with atherothrombotic disease in the United States: The reduction of atherothrombosis for continued health (REACH) Registry. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):409A.
  510. Cannon CP. Multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes following long-term treatment with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. 2007.
  511. Lemme SD, Kevin Raymond A, Cannon CP, Normand AN, Smith KC, Hughes DP. Primary tuberculosis of bone mimicking a lytic bone tumor. J Pediatr Hematol Oncol. 2007 Mar; 29(3):198-202. PMID: 17356403.
    View in: PubMed
  512. McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis. 2007 Oct; 24(2):85-91. PMID: 17323134.
    View in: PubMed
  513. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10; 369(9560):465-73. PMID: 17292766.
    View in: PubMed
  514. Ray KK, Cannon CP. Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. Curr Treat Options Cardiovasc Med. 2007 Feb; 9(1):46-51. PMID: 17378975.
    View in: PubMed
  515. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood A. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil. 2007 Feb; 14(1):3-11. PMID: 17301621.
    View in: PubMed
  516. Lin PP, Pino ED, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PW, Pollock RE, Lewis VO, Zagars GK, Yasko AW. Periosteal margin in soft-tissue sarcoma. Cancer. 2007 Feb 01; 109(3):598-602. PMID: 17183556.
    View in: PubMed
  517. Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS, Patel SR, Madewell JE, Lewis VO, Cannon CP, Benjamin RS, Yasko AW. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer. 2007 Feb 01; 109(3):603-11. PMID: 17177205.
    View in: PubMed
  518. Rich JD, Maraganore JM, Young E, Lidon RM, Adelman B, Bourdon P, Charenkavanich S, Hirsh J, Theroux P, Cannon CP. Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis. 2007 Apr; 23(2):93-100. PMID: 17221324.
    View in: PubMed
  519. Non-ST-Segment Elevation ACS. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues. 2007.
  520. Penn MS, editor. Stem cells and myocardial regeneration. Cannon CP, series editor. Contemporary Cardiology. 2007.
  521. Piazza G, Cannon CP. Clinical outcomes of patients with cardiometabolic risk factors. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 105-136..
  522. Cannon CP. Clopidogrel: who, when, and how? Rev Cardiovasc Med. 2007; 8 Suppl 3:S27-34. PMID: 17917618.
    View in: PubMed
  523. Cannon CP. Contemporary Diagnosis and Management of the Acute Coronary Syndrome. 2007.
  524. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007.
  525. Acute Myocardial Infarction. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Medical Issues. 2007.
  526. Opotowsky AR, McWilliams JM, Cannon CP. Gender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med. 2007 Jan; 22(1):55-61. PMID: 17351840; PMCID: PMC1824779.
  527. Steinberg BA, Cannon CP. Managing cardiometabolic risk - a brief review. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 137-165..
  528. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; e356-75.
  529. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007; 8(3):11-28. PMID: 18452839.
    View in: PubMed
  530. Ray KK, Cannon CP. Traditional metabolic risk factors. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 69-86..
  531. Cannon CP, O'Gara PT. Critical pathways following thrombosis. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007; 93-9..
  532. Duckers HJ, Nabel EG, Serruys PW, editors. Essentials of Restenosis for the interventional cardiologist. Cannon CP, series editor. Contemporary Cardiology. 2007.
  533. Cannon CP, O'Gara P, editors. Critical Pathways In Cardiovascular Medicine. 2007.
  534. Steinberg BA, Cannon CP, Bhatt DL, Montalescot G, Mehta S, O'Hagan, Poole-Wilson PA, Ballantyne CM. Contemporary Therapies for Diabetes in the Cardiovascular Populations of the US and Europe. Eur Heart J. 2007.
  535. Ryan RJ, Cannon CP, Gibler WB. Non-ST elevation ACS in the Emergency Department. Critical Pathways in Cardiovascular Medicine. 2007; 27-38..
  536. Cannon CP. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone. 2007; 8 Suppl 6:S14-23. PMID: 17948363.
    View in: PubMed
  537. Kraus WE, Keteyian SJ, editors. Cardiac Rehabilitation. Cannon CP, series editor. Contemporary Cardiology. 2007.
  538. Solomon SD. Essential Echocardiography. Cannon CP, series editor. Contemporary Cardiology. 2007.
  539. Epidemiology, Physiopathology and Diagnosis of ACS. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues. 2007.
  540. Cannon CP. ACS and antiplatelet management: Updated guidelines and current trials. Adv Stud Med. 2007; 7(17):540-5.
  541. Ray KK, Cannon CP. Non-traditional risk factors of cardiometabolic risk. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 87-103..
  542. Kraus WE, Keteyian SJ, editors. Cardiac Rehabilitation. Cannon CP, series editor. Contemporary Cardiology. 2007.
  543. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair J, National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines. Analytical issues for biomarkers of heart failure. Circulation. 2007; e95-8.
  544. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007.
  545. Cannon CP, O'Gara PT. Cardiac catheterization and percutaneous coronary intervention. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007; 155--9..
  546. Laine L, Curtis SP, Cryer B, Zhang Y, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term double-blind study of 34, 701 arthritis patients. Eur League Against Rheum. 2007.
  547. Cannon CP. Non-PCI Approaches in ACS: Guidelines for Risk Stratification and Medical Management. 2007.
  548. Khan MG, editor. Cardiac Drug Therapy. Cannon CP, series editor. Contemporary Cardiology. 2007.
  549. Davidson MH, Toth PP, Maki KC. Therapeutic Lipidology. Cannon CP, series editor. Contemporary Cardiology. 2007.
  550. Saw J, Exaire JE, Lee DS, Yadav JS, editors. Handbook of Complex Percutaneous Carotid Intervention. Cannon CP, series editor. Contemporary Cardiology. 2007.
  551. Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, Adgey J, Cannon CP. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis. 2007 Jun; 23(3):173-9. PMID: 17160548.
    View in: PubMed
  552. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006 Dec; 17(6):626-30. PMID: 17095906.
    View in: PubMed
  553. Cannon CP, Bhatt DL. Clinical trials update from the annual scientific session of the American College of Cardiology. 2006; 98(12A):36Q-41Q.
  554. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18; 368(9549):1771-81. PMID: 17113426.
    View in: PubMed
  555. Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PW. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006 Nov 15; 107(10):2455-61. PMID: 17036354.
    View in: PubMed
  556. Cannon CP. Evolving management of ST-segment elevation myocardial infarction: update on recent data. Am J Cardiol. 2006 Dec 18; 98(12A):10Q-21Q. PMID: 17169625.
    View in: PubMed
  557. Suk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PM. Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006 Nov; 70(Pt 6):705-16. PMID: 17044845.
    View in: PubMed
  558. Cannon CP. Introduction. Am J Cardiol. 2006; 98(10S1):S1.
  559. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP, Gibson CM. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006 Nov 07; 114(19):2019-25. PMID: 17075010.
    View in: PubMed
  560. Cannon CP, Bhatt DL. Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18; 98(12A):36Q-41Q. PMID: 17169629.
    View in: PubMed
  561. Cannon CP, McLean DS. Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy. Am J Cardiol. 2006 Nov 20; 98(10A):33N-38N. PMID: 17097416.
    View in: PubMed
  562. Ray KK, Cannon CP. Intensive statin therapy for treating acute coronary syndromes. Expert Opin Investig Drugs. 2006 Oct; 15(10):1151-9. PMID: 16989592.
    View in: PubMed
  563. Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct; 22(2):95-102. PMID: 17008974.
    View in: PubMed
  564. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006 Dec 04; 98(11A):18P-25P. PMID: 17126675.
    View in: PubMed
  565. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006 Oct; 27(19):2323-9. PMID: 16954134.
    View in: PubMed
  566. Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Yasko AW, Lewis VO, Lin PP, Cannon CP, Zagars GK, Pollock RE, Pisters PW. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol. 2006 Sep; 13(9):1209-15. PMID: 16952046.
    View in: PubMed
  567. Kugelmass AD, Sadanandan S, Lakkis N, Dibattiste PM, Robertson DH, Demopoulos LA, Gibson CM, Weintraub WS, Murphy SA, Cannon CP. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. Crit Pathw Cardiol. 2006 Sep; 5(3):167-72. PMID: 18340233.
    View in: PubMed
  568. Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC, Roe MT. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6. PMID: 17056321.
    View in: PubMed
  569. Ray KK, Morrow DA, Shui A, Rifai N, Cannon CP. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol. 2006 Oct 01; 98(7):861-5. PMID: 16996863.
    View in: PubMed
  570. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct; 27(19):2310-6. PMID: 16887854.
    View in: PubMed
  571. Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol. 2006 Sep 15; 98(6):761-3. PMID: 16950180.
    View in: PubMed
  572. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med. 2006 Aug; 3(8):424-36. PMID: 16874355.
    View in: PubMed
  573. Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006 Aug; 152(2):237-45. PMID: 16875903.
    View in: PubMed
  574. Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, Braunwald E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006 Aug; 22(1):71-6. PMID: 16786236.
    View in: PubMed
  575. O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MS. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006 Aug 08; 114(6):550-7. PMID: 16880323.
    View in: PubMed
  576. Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, Gibson CM. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J. 2006 Sep; 27(17):2040-5. PMID: 16847010.
    View in: PubMed
  577. Akoum FH, Boxer R, Cannon CP, Pina IL, Scirica BM. Improving management of high-risk cardiovascular patients. 2006.
  578. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 01; 48(3):438-45. PMID: 16875966.
    View in: PubMed
  579. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006 Sep 01; 98(5):681-4. PMID: 16923461.
    View in: PubMed
  580. Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler WB, Pollack CV, Smith SC, Ferguson TB, Peterson ED. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006 Jul 18; 48(2):281-6. PMID: 16843176.
    View in: PubMed
  581. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42. PMID: 16814646.
    View in: PubMed
  582. Cannon CP. Statins, diet, and low cholesterol. (Letter). JAMA. 2006; 295(21):2479-80.
  583. McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Crit Pathw Cardiol. 2006 Jun; 5(2):103-13. PMID: 18340222.
    View in: PubMed
  584. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31. PMID: 16750703.
    View in: PubMed
  585. Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22. PMID: 16687939.
    View in: PubMed
  586. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006 May; 151(5):976.e1-6. PMID: 16644315.
    View in: PubMed
  587. McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiol. 2006 May; 2(3):255-67. PMID: 19804082.
    View in: PubMed
  588. Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, Gibson CM. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006 Jul 01; 98(1):1-5. PMID: 16784909.
    View in: PubMed
  589. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006 May 16; 47(10):1919-26. PMID: 16697306.
    View in: PubMed
  590. Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC, Pollack CV, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11. PMID: 16606819.
    View in: PubMed
  591. Bhadriraju S, Ray KK, DeFranco AC, Barber K, Bhadriraju P, Murphy SA, Morrow DA, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol. 2006 Jun 01; 97(11):1573-7. PMID: 16728216.
    View in: PubMed
  592. Ahmed S, Antman EM, Murphy SA, Giugliano RP, Cannon CP, White H, Morrow DA, Braunwald E. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29. PMID: 16622607.
    View in: PubMed
  593. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11; 113(14):1745-52. PMID: 16537575.
    View in: PubMed
  594. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21; 113(11):1406-14. PMID: 16534008.
    View in: PubMed
  595. Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15. PMID: 16503766.
    View in: PubMed
  596. Steinberg BA, French WJ, Peterson ED, Frederick PD, Cannon CP. Missed diagnosis of the diagnosis codes: comparison of International Classification of Diseases, 9th Revision coding and ST- versus non-ST-elevation myocardial infarction diagnosis in the National Registry of Myocardial Infarction. Crit Pathw Cardiol. 2006 Mar; 5(1):59-63. PMID: 18340219.
    View in: PubMed
  597. O'Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Gibson CM. Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY TIMI-28 substudy. J Am Coll Cardiol. 2006; 47(4):222A.
  598. Steinberg BA, O'Hagan P, Chadwell P, Turner G, Cannon CP. Current trends in the prevalence of metabolic syndrome risk factors. J Am Coll Cardiol. 2006; 47(4):312A.
  599. Ahmed S, Sabatine MS, Cannon CP, Murphy SA, Braunwald E, Gibson CM, the TIMI Study Group. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28. J Am Coll Cardiol. 2006; 47(4):159A.
  600. Scirica BM, Sabatine MS, Cannon CP, McCabe CH, Braunwald E, Stone PH. Clopidogrel attenuates the complications associated with poor early reperfusion in patients with STEMI undergoing lysis in the CLARITY - TIMI 28. J Am Coll Cardiol. 2006; 47(4):213A.
  601. Husted S, Storey RF, Harrington RA, Sanders N, Peters G, Emanuelsson H, Cannon CP. The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). J Am Coll Cardiol. 2006; 47(4):200A.
  602. Wiviott SD, Morrow DA, O'Donoghue M, Sabatine MS, Murphy SA, Cannon CP. The TIMI risk index for myocardial infarction predicts post-MI LV ejection fraction: A CLARITY - TIMI 28 substudy. J Am Coll Cardiol. 2006; 47(4):224A.
  603. Steinberg BA, O'Hagan P, Chadwell P, Turner G, Cannon CP. Statin use and low-density lipoprotein cholsterol goals in 2004: How are we doing applying national cholesterol education program III guidelines. J Am Coll Cardiol. 2006; 47(4):209A.
  604. Ahmed S, Cannon CP, Giugliano RP, Shui A, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CM. The independent and combined risks of diabetes and non-endstage renal impairment in non ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006; 47(4):207A.
  605. Cannon CP. Outcomes in patients with ECG changes. 2006.
  606. Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald E. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb; 151(2):360-6. PMID: 16442899.
    View in: PubMed
  607. Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2006 Feb; 151(2):338-44. PMID: 16442896.
    View in: PubMed
  608. Cannon CP, Schwartz S. Cost-effectiveness of intensive therapy compared to moderate statin therapy in patients with acute coronary syndrome: Analysis from Canada, Germany and the UK. ISPOR. 2006.
  609. Gelfand EV, Cannon CP. Management of unstable angina and non-ST-elevation myocardial infarction. Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine. 2006; 190-4.
  610. Morrow DA, editor. Cardiovascular Biomarkers, Pathophysiology and Disease Management. Cannon CP, series editor. Contemporary Cardiology. 2006.
  611. Kociol RD, Cannon CP. Time to treatment in acute myocardial infarction. Literature Review. 2006; 1-8.
  612. Gelfand EV, Cannon CP. Acute coronary syndromes. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SW, editors. Hemostasis and Thrombosis. 2006; 1387-404..
  613. Bonaca MP, Morrow DA, Sabatine MS, Ray KK, Rifai N, Cannon CP. Elevated levels of placental growth factor (PIGF) and long term risk in patients with acute coronary syndrome in PROVE IT-TIMI 22. Circulation. 2006; 114(8):II-649.
  614. Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CP. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J. 2006 Jan; 151(1):25-31. PMID: 16368287.
    View in: PubMed
  615. Cannon CP, Ganz, LJ, Stone PH, Becker RC. Complicated myocardial infarction. Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine. 2006; 202-10.
  616. McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3):1-13.
  617. Foody JM, editor. Preventive Cardiology. Cannon CP, series editor. Contemporary Cardiology. 2006.
  618. McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Critical Pathways Cardiol. 2006; 5(2):103-13.
  619. Steinberg BA, Ballantyne CM, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Cannon CP. International comparisons of the prevalence of obesity in patients with overt cardiovascular disease. Eur Heart J. 2006; P1509.
  620. Wolfe ML, Shui A, Harris M, Cannon CP, Rader DJ. On-treatment cholesteryl ester transfer protein mass and risk for MI in the PROVE-IT study. Circulation. 2006; 114(18):II-461.
  621. Cannon CP, Vierck E. The Complete Idiot's Guide: The Anti-Inflammation Diet. 2006.
  622. Steinberg BA, Fonarow GC, Hernandez AF, Liang L, Peterson ED, Cannon CP, GWTG Scientific Advisory Committee and Investigators. Metabolic syndrome in patients with CAD: Is it more than obesity? Analysis of 79,677 hospitalizations in get with the guidelines. Circulation. 2006; 114(18):II-894.
  623. Cannon CP, Steinberg BA. Special report: Chronic stable angina: Past, present, and future. Cardiol Quarterly. 2006; 12.
  624. Storey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Price D, Husted S. AZD6140 Exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease. Circulation. 2006; 114(18):II-698.
  625. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice. 2006; 3(8):424-36.
  626. Ranganathan N, Sivaciyan V, Saksena FB, editors. The art and science of cardiac physical examination. Cannon CP, series editor. Contemporary Cardiology. 2006.
  627. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, Fish P, McCabe CH, Braunwald E, for the TIMI Study Group (Cannon CP, Co-Principal, Investigator). Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the time to integrilin therapy in acute myocardial infarction (TITAN) - TIMI 34 Trial. Am Heart J. 2006; 152:668-75.
  628. Wiviott SD, Morrow DA, Sabatine MS, Giugliano GR, Guo W, Jarolim P, Gibson CM, Cannon CP, Braunwald E. Baseline cystatin C measurement is a potent predictor of adverse cardiovascular outcomes following ACS: A PROVE IT - TIMI 22 analysis. Circulation. 2006; 114(18):II-418.
  629. McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3):255-67.
  630. Steinberg BA, Braganza AJ, Eminowicz G, Dibattiste PM, Flaker GC, Murphy SA, Cannon CP. Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. Crit Pathw Cardiol. 2005 Dec; 4(4):169-73. PMID: 18340203.
    View in: PubMed
  631. Cannon CP. Interview with: Christopher Cannon, MD. 2005.
  632. Cannon CP. Practice implications of endpoint trials in CV risk factor management. 2005.
  633. Cannon, CP. The Johns Hopkins distinguished author series for cardiology: Acute coronary syndromes. 2005.
  634. Cannon CP. Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMI. Crit Pathw Cardiol. 2005 Dec; 4(4):185-6. PMID: 18340207.
    View in: PubMed
  635. Cannon CP. The IDEAL cholesterol: lower is better. JAMA. 2005 Nov 16; 294(19):2492-4. PMID: 16287961.
    View in: PubMed
  636. Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald E. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005 Dec 20; 112(25):3846-54. PMID: 16291601.
    View in: PubMed
  637. Ryan JW, Peterson ED, Chen AY, Roe MT, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV, Cohen DJ. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation. 2005 Nov 15; 112(20):3049-57. PMID: 16275863.
    View in: PubMed
  638. Cannon CP. The need for a national heart attack treatment strategy. 2005.
  639. Cannon CP. Clopidogrel as adjunctive reperfusion therapy (CLARITY): Thrombolysis in myocardial infarction (TIMI) 28. 2005.
  640. Cannon CP. Acute coronary syndromes: risk stratification and initial management. Cardiol Clin. 2005 Nov; 23(4):401-9, v. PMID: 16278114.
    View in: PubMed
  641. Ray KK, Cannon CP. Optimal goals for statin use in patients with coronary artery disease. Curr Opin Cardiol. 2005 Nov; 20(6):525-9. PMID: 16234625.
    View in: PubMed
  642. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005 Oct 18; 46(8):1411-6. PMID: 16226163.
    View in: PubMed
  643. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1417-24. PMID: 16226164.
    View in: PubMed
  644. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1405-10. PMID: 16226162.
    View in: PubMed
  645. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005 Oct 18; 46(8):1425-33. PMID: 16226165.
    View in: PubMed
  646. Levine GN, Lincoff AM, Ferguson JJ, Mahaffey KW, Goodman SG, Cannon CP, Theroux P, Fox KA. Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Interv. 2005 Oct; 66(2):149-57. PMID: 16152646.
    View in: PubMed
  647. Dupuis J, Tardif JC, Rouleau JL, Ricci J, Arnold M, Lonn E, Roux R, Title LM, Amyot R, Bonafede N, Woo A, Cannon CP. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol. 2005 Nov 01; 96(9):1207-13. PMID: 16253583.
    View in: PubMed
  648. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005 Sep 05; 96(5A):54F-60F. PMID: 16126024.
    View in: PubMed
  649. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14; 294(10):1224-32. PMID: 16143698.
    View in: PubMed
  650. Cannon CP. Update on ACS from the ESC 2005. 2005.
  651. Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, Gibson CM, Braunwald E, Cannon CP. C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). Am J Cardiol. 2005 Sep 01; 96(5):635-8. PMID: 16125484.
    View in: PubMed
  652. Cannon CP. Early invasive vs conservative strategies in non-ST-elevation acute coronary syndromes: What has been learned from recent trials?. 2005.
  653. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CV. Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. Ann Emerg Med. 2005 Aug; 46(2):185-97. PMID: 16046952.
    View in: PubMed
  654. Cannon CP, Mehta SR, Aranki SF. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann Thorac Surg. 2005 Aug; 80(2):768-79. PMID: 16039260.
    View in: PubMed
  655. Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial. Bone. 2005 Aug; 37(2):190-1. PMID: 15936996.
    View in: PubMed
  656. Cannon CP, Murphy SA, Braunwald E. Intensive lipid lowering with atorvastatin in coronary disease. N Engl J Med. 2005 Jul 07; 353(1):93-6; author reply 93-6. PMID: 16003832.
    View in: PubMed
  657. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jul 05; 46(1):178-80. PMID: 15992655.
    View in: PubMed
  658. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005 Jun 15; 293(23):2908-17. PMID: 15956636.
    View in: PubMed
  659. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karmpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson CM. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol. 2005 Jun 07; 45(11):1781-6. PMID: 15936606.
    View in: PubMed
  660. Cannon CP. Implementation of critical pathways in the "real world". Crit Pathw Cardiol. 2005 Jun; 4(2):110-4. PMID: 18340193.
    View in: PubMed
  661. Gurjeva OS, Roe MT, Murphy SA, Moliterno DJ, Cannon CP. Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). Crit Pathw Cardiol. 2005 Jun; 4(2):81-7. PMID: 18340189.
    View in: PubMed
  662. Morrow DA, Cannon CP. Brigham and Women's Hospital admission order set for unstable angina/non-ST elevation myocardial infarction. Crit Pathw Cardiol. 2005 Jun; 4(2):107-9. PMID: 18340192.
    View in: PubMed
  663. Ray KK, Cannon CP. Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother. 2005 Jun; 6(6):915-27. PMID: 15952920.
    View in: PubMed
  664. Scirica BM, Cannon CP. Treatment of elevated cholesterol. Circulation. 2005 May 31; 111(21):e360-3. PMID: 15927980.
    View in: PubMed
  665. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CV. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation. 2005 May 24; 111(20):2699-710. PMID: 15911720.
    View in: PubMed
  666. Januzzi JL, Buros J, Cannon CP. Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. Clin Cardiol. 2005 May; 28(5):238-42. PMID: 15971459.
    View in: PubMed
  667. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17; 45(10):1644-8. PMID: 15893181.
    View in: PubMed
  668. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005 Apr 21; 352(16):1646-54. PMID: 15843667.
    View in: PubMed
  669. Gurjeva OS, Bukhman G, Murphy S, Cannon CP. Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16. Int J Cardiol. 2005 Apr 08; 100(1):101-7. PMID: 15820292.
    View in: PubMed
  670. Gomberg-Maitland M, Murphy SA, Moliterno DJ, Cannon CP. Are we appropriately triaging patients with unstable angina? Am Heart J. 2005 Apr; 149(4):613-8. PMID: 15990742.
    View in: PubMed
  671. Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson CM, Cannon CP. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005 Mar 15; 111(10):1217-24. PMID: 15769761.
    View in: PubMed
  672. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24; 352(12):1179-89. PMID: 15758000.
    View in: PubMed
  673. Cannon CP. What is the optimal timing of clopidogrel in acute coronary syndromes? Crit Pathw Cardiol. 2005 Mar; 4(1):46-50. PMID: 18340185.
    View in: PubMed
  674. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005 Mar; 149(3):444-50. PMID: 15864232.
    View in: PubMed
  675. Ray KK, Cannon CP. Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. Crit Pathw Cardiol. 2005 Mar; 4(1):43-5. PMID: 18340184.
    View in: PubMed
  676. Lader EW, Cannon CP. How to join a clinical trial. Crit Pathw Cardiol. 2005 Mar; 4(1):26-9. PMID: 18340181.
    View in: PubMed
  677. Cantor WJ, Goodman SG, Cannon CP, Murphy SA, Charlesworth A, Braunwauld E, Langer A. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Am Heart J. 2005 Feb; 149(2):275-83. PMID: 15846265.
    View in: PubMed
  678. Kirtane AJ, Kosmidou I, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42. PMID: 15670541.
    View in: PubMed
  679. Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62. PMID: 15680712.
    View in: PubMed
  680. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J. 2005 Feb; 149(2):227-33. PMID: 15846259.
    View in: PubMed
  681. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, Gibson CM. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3. PMID: 15653037.
    View in: PubMed
  682. Kirtane AJ, Weisbord A, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Ohman EM, Roe MT, Braunwald E, Gibson CM. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7. PMID: 15642554.
    View in: PubMed
  683. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 06; 352(1):20-8. PMID: 15635109.
    View in: PubMed
  684. Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A, Morrow DA, Cannon CP, Braunwald E, Lakkis N. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol. 2005 Jan 04; 45(1):19-24. PMID: 15629367.
    View in: PubMed
  685. Runge MS, Patterson C, editors. Principles of molecular cardiology. Cannon CP, series editor. Contemporary Cardiology. 2005; 617.
  686. Wiviott SD, Cannon CP. Unstable angina non-ST-elevation myocardial infarction in the elderly. Gerstenblith G, editor. Cardiovascular Disease in the Elderly. 2005; 141-58.
  687. Khan MG, editor. Heart disease diagnosis and therapy: A practical approach. Cannon CP, series editor. Contemporary Cardiology. 2005; 529.
  688. Cannon CP, Ballantyne CM, Feldman T, Ridker PM, Stone NJ. Lower is better (on LDL and CRP) but how can we meet the challenge?. 2005.
  689. Cannon CP. Latest advances in aggressive lipid management. Formulary. 2005; 40:3-12.
  690. Cannon CP. A new addition to the treatment of STEMI: The CLARITY TIMI-28 COMMITT/CCS-2 Trials. 2005.
  691. Wiviott SD, Cannon CP, Ray KK, Murphy S, Darius H, Castaigne A, Velasco JA, McCabe CH, Gibson CM. Seasonal variations in lipid values in patients following acs: PROVE IT-TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):394.
  692. Cannon CP. Unstable Angina: Clinical presentation. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment Program. 2005.
  693. Tcheng JE, editor. Primary angioplasty in acute myocardial infarction. Cannon CP, series editor. Contemporary Cardiology. 2005; 182.
  694. Gerstenblith G, editor. Cardiovascular disease in the elderly. Cannon CP, series editor. Contemporary Cardiology. 2005; 417.
  695. Scirica BM, Sabatine MS, Murphy SA, Kirtane J, Aroesty J, Cannon CP, Gibson CM. Improved findings on late angiography are associated with lower rates of new Q-waves in patients receiving fibrinolysis for ST elevation myocardial infarction - Results from CLARITY-TIMI 28. Circulation. 2005; 112(17):II-693.
  696. Schoepf JU, editor. CT of the heart. Cannon CP, series editor. Contemporary Cardiology. 2005; 407.
  697. Ray KK, Cannon CP, Morrow DA, Cairns R, Braunwald E. Percutaneous intervention for ACS is associated with a long-term reduction in CRP: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005.
  698. Cannon CP. Implementation of crtical pathways in the "Real World". Crit Pathways Cardiol. 2005; 4(2):110-4.
  699. Kirtane AJ, Sabatine MS, Aroesty JM, Murphy SA, Scirica BM, Pinto DS, Southard M, Stein E, Cannon CP, Braunwald E, Gibson CM. Differences between streptokinase and fibrin-specific fibrinolytic therapy with co-administered with adjunctive clopidogrel: A CLARITY-TIMI 28 substudy. Circulation. 2005; 112(17):II-567.
  700. Cannon CP. Commentary on early post-thrombolysis catherization may be preferable to a conservative strategy for people with myocardial infarction. Evidence-based Cardiovascular Medicine. 2005; 9:55-6.
  701. Cannon CP, Libby P, Smith S, Ballantyne CM. Advances in lipid management. 2005; 1-30.
  702. Cannon CP. C-reactive protein: A marker for assessing and managing cardiac risk. J Respiratory Diseases. 2005; 26(7):290-4.
  703. Cannon CP. Treating both cholesterol and inflammation. 2005.
  704. Wiviott SD, Cannon CP, Morrow DA, Scirica BM, McCabe CH, Braunwald E. Elevations in creatine kinase (CK) with intensive statin treatment: a PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol. 2005; 45(Suppl A):413.
  705. Dasta J, Cannon CP. Confronting challenges in aggressive lipid lowering: A managed care perspective. Formulary. 2005; 40:3-14.
  706. Ray KK, Cannon CP, Morrow DA, TIMI Study Group. CRP is additive and independent of apo B/A1 ratio in explaining the clinical benefits of atorvastatin 80mg in ACS patients in PROVE IT-TIMI 22. Circulation. 2005; 112(17):II-483-4.
  707. Deo R, Cannon CP, de Lemos JA. Rosendorf C, editor. ST segment elevation myocardial infarction. Essential Cardiology. 2005; 489-520.
  708. Cannon CP. ACS at the 2005 ACC. 2005.
  709. Herrmann HC, editor. Interventional cardiology-percutaneous noncoronary intervention. Cannon CP, series editor. Contemporary Cardiology. 2005; 433.
  710. Hasdai D, Berger PB, Batter A, Holmes DR, editors. Cardiogenic shock-diagnosis and treatment. Cannon CP, series editor. Contemporary Cardiology. 2005; 381.
  711. Ornato JP, Peberdy MA, editors. Cardiopulmonary resuscitation. Cannon CP, series editor. Contemporary Cardiology. 2005; 764.
  712. Cannon CP. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 2005.
  713. Bugiardini R, Manfrini O, Murphy SA, De Ferrari GM, Cannon CP. Long-term prognosis of nonobstructive coronary artery disease in the setting of acute coronary syndrome: A TIMI 22 Substudy. J Am Coll Cardiol. 2005; 45(Suppl A):208.
  714. Constant J, editor. Essentials of bedside cardiology. Cannon CP, series editor. Contemporary Cardiology. 2005; 298.
  715. Cannon CP. C-reactive Protein. 2005.
  716. Ray KK, Cannon CP, Rader DJ, Cairns R, McCabe CH, Sacks FM, Braunwald E. Baseline ApoB predicts benefits of intensive statin therapy in patients with ACS: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005.
  717. Cannon CP. Expert column: Lessons learned (so far) from the PROVE IT - TIMI 22 trial. 2005.
  718. Fang JC, Couper GS, editors. Surgical management of congestive heart failure. Cannon CP, series editor. Contemporary Cardiology. 2005; 328.
  719. The Occluded Artery Trial (OAT) Research Group (Cannon CP, Morbidity and Mortality Committee, Member OAT). Design and methodology of the occcluded artery trial (OAT). Am Heart J. 2005; 150:627-42.
  720. Laham RD, Baim DS, editors. Angiogenesis and direct myocardial revascularization. Cannon CP, series editor. Contemporary Cardiology. 2005; 357.
  721. Quinn M, Fitzgerald G, editors. Platelet function. Cannon CP, series editor. Contemporary Cardiology. 2005; 397.
  722. Rose E, McCabe CH, Cairns R, Cannon CP, Braunwald E. Dramatic benefit of intensive statin therapy in women: Results from PROVE IT - TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):12.
  723. Ray KK, Cannon CP, Cairns R, Wiviott SD, Kirtane AJ, Sabatine MS, McCabe CH, Braunwald E, Gibson CM. Beyond LDL control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):332.
  724. Cannon CP. The endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone. 2005; 7(2-3):17-26. PMID: 16473257.
    View in: PubMed
  725. Sabatine MS, Cannon CP. Recent advances with clopidogrel in acute myocardial infarction. Acute Coronary Syndromes. 2005; 7(2):56-60.
  726. Ballantyne CM, Feldman T, Ricker PM, Stone NJ, Cannon CP. Lower is better (on LDL and CRP). Medical Crossfire Special Edition. 2005; 6:121.
  727. Cannon CP, Hawkins D, McKeever A. Guide to cardiovascular events. Cardiology Special Edition. 2005; 11:39-49.
  728. Scirica BM, Murphy S, Wiviott SD, Morrow DA, Sabatine MS, Gibson CM, Cannon CP. Chest Pain at presentation and delayed resolution of pain patients admitted with non-ST segment elevation acute coronary syndromes predicts short-term outcomes. J Am Coll Cardiol. 2005; 45(Suppl A):199.
  729. Weintraub WS, editor. Cardiovascular health care economics. Cannon CP, series editor. Contemporary Cardiology. 2005; 436.
  730. Cannon CP. Meeting today's treatment goals in lipid lowering. 2005.
  731. Gelfand EV, Cannon CP. Does anti-infective therapy reduce cardiovascular event rates. Contagion. 2005; 2(10):1-5.
  732. Ray KK, Cannon CP, Gibson CM, Cairns R, Kirtane AJ, McCabe CH, Braunwald E. What are the future targets of therapy beyond intensive statin therapy? An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005.
  733. Cannon CP. Unstable angina: Medical treatment. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment Program. 2005.
  734. Karha J, Gibson CM, Murphy SA, Dibattiste PM, Cannon CP. Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. Am J Cardiol. 2004 Dec 15; 94(12):1537-9. PMID: 15589011.
    View in: PubMed
  735. Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol. 2004 Dec; 15(6):637-43. PMID: 15529022.
    View in: PubMed
  736. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10. PMID: 15566912.
    View in: PubMed
  737. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC, Pollack CV, Gibler WB, Ohman EM. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104. PMID: 15523070.
    View in: PubMed
  738. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005. PMID: 15541835.
    View in: PubMed
  739. Karmpaliotis D, Turakhia MP, Kirtane AJ, Murphy SA, Kosmidou I, Morrow DA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7. PMID: 15518603.
    View in: PubMed
  740. Ray KK, Cannon CP. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis. 2004 Oct; 18(2):89-101. PMID: 15789175.
    View in: PubMed
  741. Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, Theroux P. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004 Sep 15; 94(6):774-6. PMID: 15374786.
    View in: PubMed
  742. Cannon C. Overview of clinical trials. J Invasive Cardiol. 2004 Sep; 16 Suppl E:7E-10E. PMID: 23573650.
    View in: PubMed
  743. Cannon CP. Revascularisation for everyone? Eur Heart J. 2004 Sep; 25(17):1471-2. PMID: 15342161.
    View in: PubMed
  744. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schünemann HJ, Ohman EM. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S. PMID: 15383484.
    View in: PubMed
  745. Fonarow G, Cannon C, Epstein A. Questions and answers. J Invasive Cardiol. 2004 Sep; 16 Suppl E:16E-17E. PMID: 23573652.
    View in: PubMed
  746. Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7. PMID: 15337207.
    View in: PubMed
  747. Sadanandan S, Cannon CP, Gibson CM, Murphy SA, DiBattiste PM, Braunwald E. A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):799-803. PMID: 15312862.
    View in: PubMed
  748. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9. PMID: 15312859.
    View in: PubMed
  749. Gibson CM, Singh KP, Murphy SA, DiBattiste PM, Demopoulos LA, Cannon CP, Braunwald E. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2004 Aug 15; 94(4):492-4. PMID: 15325937.
    View in: PubMed
  750. Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PM, Morrow DA, de Lemos JA, Braunwald E, Gibson CM. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 04; 44(3):564-8. PMID: 15358021.
    View in: PubMed
  751. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004 Aug 03; 141(3):186-95. PMID: 15289215.
    View in: PubMed
  752. Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM. Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. Am J Cardiol. 2004 Jul 01; 94(1):108-11. PMID: 15219518.
    View in: PubMed
  753. Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, Michael Gibson C, McCabe CH, Barron HV, Van De Werf F, Braunwald E. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45. PMID: 15231372.
    View in: PubMed
  754. Wylie JV, Murphy SA, Morrow DA, de Lemos JA, Antman EM, Cannon CP. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Am Heart J. 2004 Jul; 148(1):173-80. PMID: 15215808.
    View in: PubMed
  755. Kirtane AJ, Bui A, Murphy SA, Karmpaliotis D, Kosmidou I, Boundy K, Rahman A, Pinto DS, Aroesty JM, Giugliano RP, Cannon CP, Antman EM, Gibson CM. Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. J Thromb Thrombolysis. 2004 Jun; 17(3):177-84. PMID: 15353915.
    View in: PubMed
  756. Moyer P, Feldman J, Levine J, Beshansky J, Selker HP, Barnewolt B, Brown DF, Cardoza JP, Grossman SA, Jacobs A, Kerman BJ, Kimmelstiel C, Larson R, Losordo D, Pearlmutter M, Pozner C, Ramirez A, Rosenfield K, Ryan TJ, Zane RD, Cannon CP. Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experience. Crit Pathw Cardiol. 2004 Jun; 3(2):53-61. PMID: 18340140.
    View in: PubMed
  757. Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting. Circulation. 2004 Jun 01; 109(21):2672-9. PMID: 15173050.
    View in: PubMed
  758. Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Circulation. 2004 Jun 01; 109(21):e305-7. PMID: 15173053.
    View in: PubMed
  759. Byrne CE, Fitzgerald A, Cannon CP, Fitzgerald DJ, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Med Genet. 2004 Jun 01; 5:13. PMID: 15171792; PMCID: PMC425582.
  760. Herrmann HC, Murphy SA, Dibattiste PM, Delucca PT, Demopoulos LA, Gibson CM, Cannon CP. Greater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2004 Jun; 3(2):95-100. PMID: 18340148.
    View in: PubMed
  761. Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. Circulation. 2004 Jun 01; 109(21):e302-4. PMID: 15173052.
    View in: PubMed
  762. Cannon CP. Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy. Crit Pathw Cardiol. 2004 Jun; 3(2):83-6. PMID: 18340145.
    View in: PubMed
  763. Cannon CP. Interview with: Christopher Cannon, MD. 2004.
  764. Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6. PMID: 15063425.
    View in: PubMed
  765. McCullough PA, Gibson CM, Dibattiste PM, Demopoulos LA, Murphy SA, Weintraub WS, Neumann FJ, Khanal S, Cannon CP. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol. 2004 Apr; 17(2):81-6. PMID: 15104769.
    View in: PubMed
  766. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 08; 350(15):1495-504. PMID: 15007110.
    View in: PubMed
  767. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6. PMID: 14769678.
    View in: PubMed
  768. Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80. PMID: 14757697.
    View in: PubMed
  769. Gelfand EV, Cannon CP. Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J. 2004 Feb; 147(2):202-9. PMID: 14760314.
    View in: PubMed
  770. Cannon CP. Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease. J Thromb Thrombolysis. 2004 Feb; 17(1):45-9. PMID: 15277787.
    View in: PubMed
  771. Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJ. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004 Feb; 27(2):80-6. PMID: 14979625.
    View in: PubMed
  772. Cannon CP. Atherothrombosis: Bridging the Gap Between Clinical Evidence and Current Practice. 2004.
  773. Cannon CP, Peterson ED. Changing the model of care for patients with acute coronary syndromes. 2004.
  774. Cannon CP. ACC 2004 PROVE IT. 2004.
  775. Cannon CP. Cost-effectiveness of clopidogrel. Pharmacoeconomics. 2004; 22 Suppl 4:1-3. PMID: 15876006.
    View in: PubMed
  776. Cannon CP. Big news on cholesterol. 2004.
  777. Cannon CP, Januzzi JL. Peripheral arterial disease in people with diabetes. 2004.
  778. Hutter A, Abramson W, Califf RM Cannon CP. ACC conversations with experts. 2004.
  779. Ridker PM, Cannon CP, Pasternak R, Sacks F. "How low can you go? Pearls from the pros.". 2004.
  780. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl III):834.
  781. Wackers FJT, Bruni W, Zaret BL. Nuclear cardiology, The basics: How to set up and maintain a laboratory. Cannon CP, series editor. Contemporary Cardiology. 2004; 293.
  782. Herrmann HC, Murphy SA, DiBattiste P, DeLucca PT, Demopoulos L, Gibson CM, Cannon CP. Greater benefit and early invasive strategy for unstable angina and non-ST elevation myocardial infarction ain United States compated with non-United States patients: A TACTICS-TIMI 18 Substudy. Crit Path Cardiol. 2004; 3:95-100..
  783. Cannon CP, Peacock WF, Reiner JS. IMPACT: Optimal management of the AMI patient: Medical decision point. 2004.
  784. Menon V, Harrington RA, Hochman J, Cannon CP, Goodman SD, Wilcox RG, Schunemann H, Ohman EM. Thrombolysis and adjunctive therapy in acute myocardial infarction. Chest. 2004; 126:549S-575S.
  785. Edwards NM, Chen JM, Mazzeo PA, editors. Cardiac transplantation. Cannon CP, series editor. Contemporary Cardiology. 2004; 286.
  786. Cannon CP. Acute coronary syndromes II. 2004.
  787. Kloner RA, editor. Heart disease and erectile dysfunction. Cannon CP, series editor. Contemporary Cardiology. 2004.
  788. Cannon CP. Atherothrombosis: Bridging the gap between clinical evidence and current practice. 2004.
  789. Cannon CP. Innovative directions in the future role of antiplatelet agents. 2004.
  790. Cannon CP. Efficacy of percutaneous coronary intervention after thrombolysis for acute ST-elevation (Q wave) myocardial infarction. 2004.
  791. Mehta RH, Montoye CK, Faul J, Nagle DJ, Kure J, Raj E, Fattal P, Sharriff S, Amlani M, Changezi H, Skorcz S, Bailey N, La Tarte M, McLean D, Savoy S, Werner P, Baker PL, Defranco A, Eagle K, Cannon CP on behalf of GAP Steering Committee of the American College of Cardiology (CP Cannon, GAP Steering Committee Member). Enhancing quality of care for acute myocardial infraction: Shifting the focus of improvement from key indicators to process of care and tool use. J Am Coll Cardiol. 2004; 43:2167-73..
  792. Cannon CP. Guidelines for unstable angina and non-ST-segment elevation myocardial infarction. Bhatt DL, Flather MD, editors. Handbook of Acute Coronary Syndromes. 2004; 223-40.
  793. Stein RA, Oz MC, editors. Complementary and alternative cardiovascular medicine. Cannon CP, series editor. Contemporary Cardiology. 2004; 286.
  794. Cannon CP, Hawkins D, Wallace-Hixson J. Guide to antithrombotic agents. Pharmacy Practice News Special Edition. 2004; 57-62.
  795. Cannon CP. Forward. Gertsch M, editor. Two-step approach to diagnosis. 2004; 607.
  796. Martinezclark P, Karmpaliotis D, Murphy S, Wiviott SD, Bigelow B, Kosmidou I, Chang A, Cannon CP, Giugliano R, Gibson CM. The association of race with angiographic and clinical outcomes following fibrinolytic administration. J Am Coll Cardiol. 2004; 43(Suppl A):305.
  797. Cannon CP, Golden WE. Secondary prevention in patients with unstable angina and non-ST-segment elevation myocardial infarction: Which drugs are mandatory?. Consultant. 2004; 44:1053-6.
  798. Cannon CP, Feske SK. Ten-year survival after first-ever stroke in the perth community stroke study. 2004.
  799. Gibson CM, Sabatine MS, Murphy E, Morrow DA, Wiviott SD, Smith S, McCabe CH, Cannon CP, Braunwald E. Association of intensive lipid lowering with reductions in target vessel revascularization (clinical restenois) and non-target vessel revascularization (lesion progression): A PROVE IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl III):696.
  800. Wiviott SD, Sabatine MS, Morrow D, Dumaine R, Murphy S, Boundy KE, Cannon CP, Gibson CM. Distinct modes of cardiovascular death associated with impaired epicardial and myocardial perfusion following fibrinolysis for ST elevation myocardial infarction. J Am Coll Cardiol. 2004; 43(Suppl A):290.
  801. Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MA. Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. Crit Pathw Cardiol. 2003 Dec; 2(4):239-46. PMID: 18340127.
    View in: PubMed
  802. Budaj A, Brieger D, Steg PG, Goodman SG, Dabbous OH, Fox KA, Avezum A, Cannon CP, Mazurek T, Flather MD, Van De Werf F. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2003 Dec; 146(6):999-1006. PMID: 14660991.
    View in: PubMed
  803. Cannon CP, Eckardt JJ, Kabo JM, Ward WG, Kelly CM, Wirganowicz PZ, Asavamongkolkul A, Nieves R, Eilber FR. Custom cross-pin fixation of 32 tumor endoprostheses stems. Clin Orthop Relat Res. 2003 Dec; (417):285-92. PMID: 14646728.
    View in: PubMed
  804. Cannon CP. The next step in cardiovascular protection. Atheroscler Suppl. 2003 Dec; 4(5):3-9. PMID: 14980229.
    View in: PubMed
  805. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43. PMID: 14607434.
    View in: PubMed
  806. Cannon CP. Treatment algorithms and critical pathways for acute coronary syndromes. Semin Vasc Med. 2003 Nov; 3(4):425-32. PMID: 15199450.
    View in: PubMed
  807. Januzzi JL, Cannon CP, Theroux P, Boden WE. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Am Heart J. 2003 Nov; 146(5):764-74. PMID: 14597924.
    View in: PubMed
  808. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003 Oct 27; 163(19):2345-53. PMID: 14581255.
    View in: PubMed
  809. Karha J, Murphy SA, Kirtane AJ, de Lemos JA, Aroesty JM, Cannon CP, Antman EM, Braunwald E, Gibson CM. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. Am J Cardiol. 2003 Oct 15; 92(8):913-8. PMID: 14556865.
    View in: PubMed
  810. Eckardt JJ, Kabo JM, Kelly CM, Ward WG, Cannon CP. Endoprosthetic reconstructions for bone metastases. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S254-62. PMID: 14600617.
    View in: PubMed
  811. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003 Oct; 24(20):1815-23. PMID: 14563340.
    View in: PubMed
  812. Cannon CP, Braunwald E. Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit. Crit Pathw Cardiol. 2003 Sep; 2(3):153-77. PMID: 18340119.
    View in: PubMed
  813. Cannon CP. PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome. Crit Pathw Cardiol. 2003 Sep; 2(3):188-96. PMID: 18340121.
    View in: PubMed
  814. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II. Clin Cardiol. 2003 Sep; 26(9):401-6. PMID: 14524594.
    View in: PubMed
  815. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003 Sep 02; 108(9):1049-52. PMID: 12912804.
    View in: PubMed
  816. Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, de Lemos JA, Braunwald E, Cannon CP. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003 Aug; 49(8):1396-8. PMID: 12881457.
    View in: PubMed
  817. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I. Clin Cardiol. 2003 Aug; 26(8):358-64. PMID: 12918637.
    View in: PubMed
  818. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16. PMID: 12849652.
    View in: PubMed
  819. Cannon CP. Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. Am J Geriatr Cardiol. 2003 Jul-Aug; 12(4):259-62. PMID: 12888707.
    View in: PubMed
  820. Cannon CP, Turpie AG. Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy. Circulation. 2003 Jun 03; 107(21):2640-5. PMID: 12782615.
    View in: PubMed
  821. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96. PMID: 14739628.
    View in: PubMed
  822. Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai R, James D, Kraimer N, Katsiyiannis PT, Marble SJ, DiBattiste PM, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, Gibson CM. Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. Am J Cardiol. 2003 May 15; 91(10):1163-7. PMID: 12745096.
    View in: PubMed
  823. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003 Apr 16; 41(8):1264-72. PMID: 12706919.
    View in: PubMed
  824. Pinto DS, Lorenz DP, Murphy SA, Marble SJ, DiBattiste PM, Demopoulos LA, Cannon CP, Gibson CM. Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2003 Apr 15; 91(8):976-8, A4. PMID: 12686341.
    View in: PubMed
  825. Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003 Apr; 145(4):622-7. PMID: 12679757.
    View in: PubMed
  826. Cannon C. Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. J Invasive Cardiol. 2003 Mar; 15 Suppl B:22B-27B; discussion 27B-29B. PMID: 12724583.
    View in: PubMed
  827. Serrano CV, Nicolau JC, Venturinelli M, Baracioli LM, Anders RJ, Cannon CP, Ramires JA. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther. 2003 Mar; 17(2):129-32. PMID: 12975594.
    View in: PubMed
  828. Cannon CP. Foreword to lessons learned. Crit Pathw Cardiol. 2003 Mar; 2(1):54. PMID: 18340320.
    View in: PubMed
  829. Cannon CP. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. J Am Coll Cardiol. 2003 Feb 19; 41(4 Suppl S):43S-48S. PMID: 12644340.
    View in: PubMed
  830. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 Feb 11; 107(5):690-5. PMID: 12578870.
    View in: PubMed
  831. Cannon CP. Platelet glycoprotein IIb/IIIa inhibitors and an invasive strategy. Lincoff AM, editor. Contempory Cardiology: Platelet Glyocoprotein IIa/IIIb Inhibitors in Cardiovascular Disease. 2003; 263-73.
  832. Lincoff AM, editor. Platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 2003; 476.
  833. Cannon CP, Fonarow GC. ASC Update. Strive. 2003.
  834. Cannon CP. Platelet glycoprotein IIb/IIIa inhibitors and an invasive strategy. Lincoff AM, editor. Platelet glycoprotein IIb/IIIa inhibitors in Cardiovascular Medicine. 2003; 263-73.
  835. Cannon CP, Topol EJ. Randomized, double blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebovascular disease. 2003.
  836. Cannon CP, Hawkins D, Wallace-Hixson J. Guide to cardiovascular agents. Cardiology Special Edition. 2003; 9:27-37.
  837. Cannon CP, Rikers PM. AHA/CDC scientific statement-markers of inflammation and cardiovascular disease: Application to clinical and public health practice. 2003.
  838. Cannon CP, Topol E. Cannon chronicles: Aspirin therapy: What is the appropriate dose?. 2003.
  839. Harrington R, Ferguson J, Tcheng JE, Cannon CP, Denardo S, Gibson CM, Peterson E. Interventional. 2003.
  840. Bhatt D, Cannon CP, Peacock F, Reiner J. Evolving treatment strategies in acute myocardial infarction. 2003.
  841. Cannon CP, Kearon C. Comparison of low-intensity warafin therapy with conventional-intensity warafin therapy for long-term prevention of recurrent venous thromboembolism. 2003.
  842. Wong GC, Murphy S, Morrow D, Giugliano R, Cannon CP, De Lemos J, Sabatine MS, Gibson CM. A simple ECG method using high-risk infarct territory is superior to ECGs using summed ST elevation for assessing risk in ST elevation myocardial infarction. J Am Coll Cardiol. 2003; 41:402A.
  843. Cannon CP, Steinhubl S, Topol E, Easton D. Clinical implications of CREDO: New evidence for long-term dual antiplatelet therapy. 2003.
  844. Cannon CP, Mehta S. Early and late effects of clopidogrel in patients with acute coronary syndromes. 2003.
  845. Cannon CP. Role of newer antiplatelet and antithrombotic agents. 2003.
  846. Constant J, editor. Essentials of Bedside Cardiology. Cannon CP, series editor. Contemporary Cardiology. 2003.
  847. Young J, Fonarow G, Hill J, Cannon CP, Heywood T, Peacock F, Berstein-Sackner J. Heart failure. 2003.
  848. Cannon CP, Gibson CM. Equivalence trials: Understanding the statistical and clinical issues. 2003.
  849. Coffman JD, Eberhardt RT, editors. Peripheral arterial disease diagnosis and tretment. Cannon CP, series editor. Contemporary Cardiology. 2003; 356.
  850. Cannon CP. Recent update to the ACC/AHA guidelines for the management of patients with UA/NSTEMI. American College Cardiology Oregon Chapter Newsletter. 2003; 8.
  851. Cannon CP. Practical applications of the ACC/AHA guidelines for unstable angina and non-ST-segment elevation myocardial infarction. Pharmacy Practice News Special Edition. 2003; 47-50.
  852. Fuster V, Cannon CP, Ferguson J, Weber M. Confirming knowledge. 2003.
  853. Gussak I, Antzelevitch C, editors. Cardiac repolarization bridging basic and clinical science. Commerce Series Edition Contemporary Cardiology. 2003; 548.
  854. Cannon CP, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. 2003.
  855. Greenbaum AB, Kleiman NS, Berger PB, Cohen DJ, Cannon CP, Brindis R, Li Y, Roe MT, Harrington RA, Peterson E, Gibler WB, Ohman EM. Clinical trials in acute myocardial infarction and acute coronary syndrome. Transcatheter Cardiovascular Therapeutics. 2003.
  856. Cannon CP, O'Gara P. Critical pathways for acute coronary syndromes. Cannon CP, editor. Contemporary Cardiology: Management of Acute Coronary Syndromes. 2003; 745-69.
  857. Cannon CP, Ferguson J, Kereiakes D, Roe M. Taking ACS to the bedside. 2003.
  858. Cannon CP. Case study: A woman with rest chest discomfort: What is the optimal treatment?. 2003.
  859. Cannon CP, Denard SJ, Ferguson J, Gibson CM, Harrington R, Peterson ED, Popma J, Roe M, Tcheng JE. GP IIb/IIIa inhibitors: Examining the evidence. 2003.
  860. Cannon CP. Statin use in acute coronary syndromes: The next step in cardiovascular protection. 2003.
  861. Cannon CP, Braunwald E. The spectrum of myocardial ischemia: The paradigm of acute coronary syndromes. Cannon CP, editor. Contemporary Cardiology: Management of Acute Coronary Syndromes. 2003; 3-18.
  862. Jordan M, Dotani MI, Dumaine R, Wong G, Aroesty JM, Cannon CP, McCabe C, Braunwald E, Gibson CM. Association of multivessel disease, inflammatory markers and impaired tissue level perfusion in the setting of acute coronary syndromes: A TACTICS-TIMI 18 substudy. Circulation. 2003; 108(Suppl I):2157.
  863. Weintraub WS, editor. Cardiovascular health care economics. Cannon CP, series editor. Contemporary Cardiology. 2003; 436.
  864. Cannon CP. Critical pathways for acute myocardial infarction. Rev Cardiovasc Med. 2003; 4 Suppl 3:S47-53. PMID: 14564234.
    View in: PubMed
  865. Cannon CP. Optimizing care of the post-myocardial infarction low-ef patient. 2003.
  866. Edwards NM, Maurer MS, Wellner RB, editors. Aging, heart disease, and it's management facts and controversies. Cannon CP, series editor. Contemporary Cardiology. 2003; 389.
  867. Bhadriraju S, Defranco AC, Barber K, Murphy S, Gibson CM, DiBattiste P, Cannon CP. Major bleeding incidence after coronary artery bypass grafting in patients with unstable angina/non-ST elevation myocardial infarction based on coronary artery bypass graft timing in TACTICS-TIMI 18. J Am Coll Cardiol. 2003; 41:374A.
  868. Fonarow GC, Abraham WT, Cannon CP, Gheorghiade M, Sackner-Bernstein JD, Udelson JE. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med. 2003; 4 Suppl 3:S54-9. PMID: 14584479.
    View in: PubMed
  869. Cannon CP. Cannon Chronicles: The CREDO trial. 2003.
  870. Cannon CP. Case study: Acute coronary syndrome. 2003.
  871. Cogan J, Cannon CP, de Lemos J. Treatment of unstable angina and non-ST elevation myocardial infarction. Llevadot J, editor. Acute Coronary Syndromes. 2003; 229-55.
  872. Cannon CP, Lincoff AM, Zidar M, Dippel E, Gibson CM, Popma J, Topol E. Thrombocardiology. 2003.
  873. Sharis PJ, Cannon CP. Evidence-based Cardiology. 2003; 370.
  874. Cannon CP. Quality of care in atherothrombosis: From acute to long-term care. 2003.
  875. Cannon CP. Cannon chronicles: Guidelines for CRP. 2003.
  876. Cannon CP, Creager MA. Critical issues in peripheral arterial disease detection management. 2003.
  877. Cannon CP, Topol EJ, Steinhubl S. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. 2003.
  878. Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald E. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan; 145(1):109-17. PMID: 12514662.
    View in: PubMed
  879. Cannon CP. New guidelines for the management of unstable angina and non-ST-elevation myocardial infarction. Cardiology Rounds. 2003; 1-7.
  880. Cannon CP, Hamm CW. Correspondence soluble CD40 ligand in acute coronary syndromes. 2003.
  881. Cannon CP. Antithrombostic therapy. 2003.
  882. Cannon CP, editor. Management of Acute Coronary Syndromes. 2003; 781.
  883. Cannon CP. Bivalirudin: Efficacy and cost effectiveness in PCI. Coron Artery Dis. 2003; 3.
  884. Cannon CP. Advantages and hazards of early revascularization. Theroux P, editor. Acute Coronary Syndromes Companion to Braunwald's Heart Disease. 2003; 752.
  885. Fuster V, Cannon CP, Ferguson J, Weber M. ACC 2003: Sportif II and ascot. 2003.
  886. Cannon CP, Braunwald E. AHA/ACC 2002 guideline update for the management of patients with unstable angina and non-ST-segment-elevation myocardial infarction. 2003.
  887. Cannon CP, Walls RM. Is it safe to send this patient home ed markers of ACS move upstream?. J Emergency Med. 2003; 7.
  888. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002 Dec 25; 288(24):3124-9. PMID: 12495392.
    View in: PubMed
  889. Lakkis N, Tsyboulev V, Gibson CM, Murphy SA, Weintraub WS, DiBattiste PM, Cannon CP. Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2002 Dec; 1(4):232-7. PMID: 18340309.
    View in: PubMed
  890. Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost. 2002 Dec; 88(6):892-7. PMID: 12529735.
    View in: PubMed
  891. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002 Dec 01; 90(11):1246-9. PMID: 12450608.
    View in: PubMed
  892. Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Braunwald E, Gibson CM. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol. 2002 Nov 20; 40(10):1761-8. PMID: 12446059.
    View in: PubMed
  893. Sharis PJ, Cannon CP, Rogers WJ, McCabe C, Murphy S, Gibson CM, Stone PH, Braunwald E. Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). Am J Cardiol. 2002 Nov 15; 90(10):1154-6. PMID: 12423724.
    View in: PubMed
  894. Freedman JE, Becker RC, Adams JE, Borzak S, Jesse RL, Newby LK, O'Gara P, Pezzullo JC, Kerber R, Coleman B, Broderick J, Yasuda S, Cannon C. Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation. 2002 Nov 12; 106(20):2623-9. PMID: 12427661.
    View in: PubMed
  895. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002 Oct 16; 288(15):1851-8. PMID: 12377083.
    View in: PubMed
  896. Scirica BM, Cannon CP, McCabe CH, Murphy SA, Anderson HV, Rogers WJ, Stone PH, Braunwald E. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002 Oct 15; 90(8):821-6. PMID: 12372567.
    View in: PubMed
  897. Angeja BG, de Lemos J, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson CM. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J. 2002 Oct; 144(4):649-56. PMID: 12360161.
    View in: PubMed
  898. Murphy SA, Chen C, Cannon CP, Antman EM, Gibson CM. Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. Am J Cardiol. 2002 Oct 01; 90(7):766-70. PMID: 12356395.
    View in: PubMed
  899. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol. 2002 Oct 01; 90(7):760-2. PMID: 12356393.
    View in: PubMed
  900. Cannon CP. Evidence-based risk stratification to target therapies in acute coronary syndromes. Circulation. 2002 Sep 24; 106(13):1588-91. PMID: 12270844.
    View in: PubMed
  901. Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2002 Sep 18; 40(6):1044-50. PMID: 12354426.
    View in: PubMed
  902. Brener SJ, Murphy SA, Gibson CM, DiBattiste PM, Demopoulos LA, Cannon CP. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002 Sep 15; 90(6):631-3. PMID: 12231091.
    View in: PubMed
  903. Scirica BM, Cannon CP, Gibson CM, Murphy SA, Moliterno DJ, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Braunwald E. Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Crit Pathw Cardiol. 2002 Sep; 1(3):150-8. PMID: 18340298.
    View in: PubMed
  904. Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow DA, Sabatine MS, McCabe CH, Gibson CM, Braunwald E. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5. PMID: 12127617.
    View in: PubMed
  905. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17; 40(2):238-44. PMID: 12106926.
    View in: PubMed
  906. Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP, Gibson CM. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation. 2002 Jul 09; 106(2):202-7. PMID: 12105159.
    View in: PubMed
  907. Murphy SA, Gibson CM, Van de Werf F, McCabe CH, Cannon CP. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002 Jul 01; 90(1):51-4. PMID: 12088781.
    View in: PubMed
  908. Cannon CP, Baim DS. Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol. 2002 Jun 05; 39(11):1720-2. PMID: 12039481.
    View in: PubMed
  909. Cannon CP. Oral glycoprotein IIb/IIIa inhibition--great idea, but it didn't work. Am J Med. 2002 Jun 01; 112(8):673-5. PMID: 12034420.
    View in: PubMed
  910. Kloner RA, Poole K, Shook T, Przyklenk K, Perritt K, Cannon CP. Comparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period. Am J Cardiol. 2002 Jun 01; 89(11):1291-3. PMID: 12031730.
    View in: PubMed
  911. Bahit MC, Murphy SA, Gibson CM, Cannon CP. Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry. Crit Pathw Cardiol. 2002 Jun; 1(2):107-12. PMID: 18340294.
    View in: PubMed
  912. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E, Gibson CM. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002 Jun; 13(3):133-9. PMID: 12355029.
    View in: PubMed
  913. Cannon CP. Palm Pilot programs to improve quality of care in acute coronary syndromes. Crit Pathw Cardiol. 2002 Jun; 1(2):113-5. PMID: 18340295.
    View in: PubMed
  914. Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP, Selker HP, Steele P, Zalenski RJ. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J. 2002 May; 143(5):777-89. PMID: 12040337.
    View in: PubMed
  915. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr 23; 105(16):1909-13. PMID: 11997276.
    View in: PubMed
  916. Cannon CP. Primary percutaneous coronary intervention for all? JAMA. 2002 Apr 17; 287(15):1987-9. PMID: 11960542.
    View in: PubMed
  917. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002 Apr 16; 105(15):1760-3. PMID: 11956114.
    View in: PubMed
  918. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002 Apr 01; 89(7):860-1. PMID: 11909576.
    View in: PubMed
  919. Cannon CP. Enoxaparin in ST elevation MI - a bright future. Eur Heart J. 2002 Apr; 23(8):591-2. PMID: 11969270.
    View in: PubMed
  920. Cannon CP, Bahit MC, Haugland JM, Henry TD, Schweiger MJ, McKendall GR, Shah PK, Murphy S, Gibson CM, McCabe CH, Antman EM, Braunwald E. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol. 2002 Mar; 1(1):44-52. PMID: 18340288.
    View in: PubMed
  921. Sharayeva ML, Tcheng JE, Cannon CP. Assessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit. Crit Pathw Cardiol. 2002 Mar; 1(1):22-5. PMID: 18340286.
    View in: PubMed
  922. Cannon CP, Ornato JP. How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program. Crit Pathw Cardiol. 2002 Mar; 1(1):53-60. PMID: 18340289.
    View in: PubMed
  923. Cannon CP. Critical pathway for unstable angina and non-ST elevation myocardial infarction: February 2002. Crit Pathw Cardiol. 2002 Mar; 1(1):12-21. PMID: 18340285.
    View in: PubMed
  924. Cannon CP. Critical Pathways in Cardiology: a journal of evidence-based medicine: translating evidence into practice. Crit Pathw Cardiol. 2002 Mar; 1(1):1-2. PMID: 18340283.
    View in: PubMed
  925. Cannon CP. To cath or not to cath? That used to be the question. Am Heart J. 2002 Mar; 143(3):377-80. PMID: 11868039.
    View in: PubMed
  926. Leebeek FW, Boersma E, Cannon CP, van de Werf FJ, Simoons ML. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J. 2002 Mar; 23(6):444-57. PMID: 11863347.
    View in: PubMed
  927. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15; 89(4):463-5. PMID: 11835931.
    View in: PubMed
  928. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis. 2002 Feb; 13(1):13-9. PMID: 11994555.
    View in: PubMed
  929. Gibson CM, Chen M, Angeja BG, Murphy SA, Marble SJ, Barron HV, Cannon CP. Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. J Thromb Thrombolysis. 2002 Feb; 13(1):9-12. PMID: 11994554.
    View in: PubMed
  930. Cannon C. Clopidogrel and percutaneous coronary intervention. Lancet. 2002 Jan 12; 359(9301):169. PMID: 11809292.
    View in: PubMed
  931. Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJ. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J. 2002; 2(3):182-90. PMID: 12082590.
    View in: PubMed
  932. Cannon CP. Practical applications of the 2002 ACC/AHA guidelines for unstble angina and non-ST-segment elevation myocardial infarction. Cardio Special Edition. 2002; 8:29-36.
  933. Bombardier C, Cannon CP. Placing the evidence in perspective: Cardiovascular and renal risks with pharmacologic therapy in osteoarthritis. 2002.
  934. Cannon CP. Platelet glyocoprotein IIb/IIIa inhibition in acute coronary syndromes. Goldhaber SZ, Ridker PM, editors. Thrombosis and Thromboembolism. 2002; 101-24.
  935. Cannon CP. Unstable Angina: Treatment strategies. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002.
  936. Murphy S, Guigliano RP, Wong G, Cannon CP, Antman E, Gibson CM. Comparison of frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A TIMI 14 and TIMI 9 substudy. J Am Coll Cardiol. 2002; 39:279A.
  937. Cannon CP. A new standard of care in acute coronary syndromes. 2002.
  938. Steg PG, Dabbous O, Cohen-Solal A, Aumont M, Cannon CP, Lopez-Sendon J, Budaj A, Klein W. Determinants and outcomes of congestive heart failure complicating acute coronary syndromes: observations from the global registry of acute coronary events. J Am Coll Cardiol. 2002; 39:154A.
  939. Cannon CP, King S, Ohman M. Day in review-inhibiting platelets in the cath lab. 2002.
  940. Cannon CP. Unstable angina: Medical treatment. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002.
  941. Cannon CP. Guideline for UA/NSTEMI. 2002.
  942. King S, Cannon CP, Mehta SR, Roe M. Integrating antiplatelet therapy with early invasive management for acute coronary syndromes. 2002.
  943. Cannon CP, Ferguson J, Ohman M. Thrombocardiology series. 2002.
  944. Cannon CP, Granger CB, Armstrong PW, Roe M. Implementing a critical pathway based on the ACC/AHA guidelines. 2002.
  945. Cannon CP. Commentary on SYMPHONY II. Evid Based Cardiovasc Med. 2002.
  946. Giugliano RP, Cannon CP. Antiplatelet therapy. Antman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2002; 601-54.
  947. Harrington R, Cannon CP, Topol E, Rose M. Defining optimal care for patients with acute coronary syndromes. 2002.
  948. Mehta RH, Montoye CK, Gallogly M, Baker P, Lount A, Faul J, Roychoudhury C, Borzak S, Fox S, Franklin M, Freundl M, Kline-Rogers E, Lalonde T, Orza M, Parrish R, Satwicz M, Smith MJ, Sabotka P, Winston S, Roiba AA, Eagle KA, on behalf of the GAP Steering Committee of the American College of Cardiology (CP Cannon, GAP Steering Committee Member). Improving quality of care of acute myocardial infarction: The guideline applied in practice (GAP) initiative in Southeast Michigan. JAMA. 2002; 287:1269-1276..
  949. Cannon CP, Cohen DE, Radar D. Targeting multiple pathways for optimal cholestrol management. 2002.
  950. Fuster V, Pickering T, Cannon CP, Ferguson J, Weber M. AHA 2002: Part I. 2002.
  951. Gibson CM, Morrow D, Vicari R, Wong GC, Demopoulos L, DiBattiste P, Murphy S, Cannon CP, Braunwald E. Elevated C reactive protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: A TACTICS TIMI 18 angiographic substudy. J Am Coll Cardiol. 2002; 39:304A.
  952. Cannon CP. Integrating GP IIb/IIIa inhibition and an early invasive strategy for optimal management of acute coronary syndromes. 2002.
  953. Cannon CP. News in ACS from AHA. 2002.
  954. Cannon CP. Efficacy of percutaneous coronary intervention after thrombolysis for acute ST elevation (Q wave) myocardial infarction. 2002.
  955. Cannon CP. New approaches to the prevention of atherothrombotic events in patients with vascular disease. 2002.
  956. Marks DS, Gudapati SB, Kleczka J, Murphy S, Cannon CP, Braunwald E. Electrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarction. J Am Coll Cardiol. 2002; 39:331A.
  957. Cannon CP. New approaches to the prevention on atherothrombotic events in patients with vascular disease. 2002.
  958. Cannon CP. Percutaneous coronary intervention in the clopidogrel in unstable angina to prevent recurrent events (PCI-cure) trial. Cardio Scientific Update. 2002.
  959. Cannon CP. Acute coronary syndrome: A new paradigm for emergency management. 2002.
  960. Cannon CP, Noble JR. Aspirin and clopidogrel is not better than aspirin IIb/IIIa inhibitor for non-ST elevation in acute coronary syndrome. 2002.
  961. Fuster V, Pickering T, Cannon CP, Ferguson J, Weber M. ALLHAT and ALLHAT-LLT. 2002.
  962. Cannon CP. Awesome 2002 ACC/AHA. 2002.
  963. Cannon CP. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial. Pfeffer M, editor. Cardiology Scientific Updates. 2002; 1-6.
  964. Cannon CP. Unstable angina: Clinical presentation. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002.
  965. Fuster V, Cannon CP, Ferguson J, Weber M. Aspirin, ICDs, and MRA. 2002.
  966. Harrington R, Cannon CP. Global effort to transform outcomes of acute coronary syndromes (GET ACS) day in review. 2002.
  967. Cannon CP. Unstable angina/non-ST-elevation myocardial infarction. Intensive Care Medicine. 2002; 377-99.
  968. Cannon CP, Ornato JP. How to develop a critical pathway: The ACS ACTION program. Crit Pathw Cardiol. 2002; 1:53-60.
  969. Cannon CP, Fuster V. Anticoagulant and fibrinolytic therapy for acute coronary syndromes. Antman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2002; 669-93.
  970. Fuster V, Cannon CP, Ferguson J, Weber M. ESC. 2002.
  971. Bhatt D, Cannon CP, Peacock F, Reiner J . AMI 2002: Discovering optimal treatment pathways. 2002.
  972. Cannon CP. Advances in the understanding of acute coronary syndrome. 2002.
  973. Cannon CP. Implications of upstream GP IIb/IIIa inhibition and stenting in the invasive management of UA/NSTEMI: A comparison of TIMI IIIB and TACTICS-TIMI 18. 2002.
  974. Wong SA, Kraimer N, Pai R, James D, Murphy SA, Cannon CP, Gibson CM for the TACTICS-TIMI 18 Study Group. Elevations in Troponin T are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 Substudy. Circulation. 2002; 106:202-7..
  975. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001 Dec 01; 98(12):3256-60. PMID: 11719362.
    View in: PubMed
  976. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJ, Weintraub WS, Mitchell KR, Morrisson SL, Brindis RG, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Ellis SG, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, Riner RN, Schwartz JB, Shaw RE, Shemin RJ, Van Fossen DB, Verrier ED, Watkins MW, Phoubandith DR, Furnelli T. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001 Dec; 38(7):2114-30. PMID: 11738323.
    View in: PubMed
  977. Sekaran NK, Moliterno DJ, Ferguson JJ, Every N, Anderson HV, Aguirre FV, French WJ, Sapp S, Booth JE, Granger CB, Cannon CP. "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. J Thromb Thrombolysis. 2001 Dec; 12(3):207-16. PMID: 11981103.
    View in: PubMed
  978. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001 Nov 21; 286(19):2405-12. PMID: 11712935.
    View in: PubMed
  979. Kloner RA, Das S, Poole WK, Perrit R, Muller J, Cannon CP, Braunwald E. Seasonal variation of myocardial infarct size. Am J Cardiol. 2001 Nov 01; 88(9):1021-4. PMID: 11704000.
    View in: PubMed
  980. Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, Changezi HU, Antman EM, Braunwald E. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6. PMID: 11676942.
    View in: PubMed
  981. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 04; 345(14):1014-21. PMID: 11586953.
    View in: PubMed
  982. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9. PMID: 11560541.
    View in: PubMed
  983. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001 Aug 15; 88(4):347-52. PMID: 11545752.
    View in: PubMed
  984. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald E. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8. PMID: 11545753.
    View in: PubMed
  985. Cannon CP. Importance of TIMI 3 flow. Circulation. 2001 Aug 07; 104(6):624-6. PMID: 11489764.
    View in: PubMed
  986. Srinivas VS, Cannon CP, Gibson CM, Antman EM, Greenberg MA, Tanasijevic MJ, Murphy S, de Lemos JA, Sokol S, Braunwald E, Mueller HS. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Am Heart J. 2001 Jul; 142(1):29-36. PMID: 11431653.
    View in: PubMed
  987. Cannon CP, Goldhaber SZ, Hand M. National heart attack alert program: Highlights. Chestsoundings. 2001; 15:17.
  988. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21; 344(25):1879-87. PMID: 11419424.
    View in: PubMed
  989. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29; 103(21):2550-4. PMID: 11382722.
    View in: PubMed
  990. Kloner RA, Shook T, Cannon CP, Przyklenk K. Ischemic preconditioning: implications for the geriatric heart. Am J Geriatr Cardiol. 2001 May-Jun; 10(3):145-8; quiz 149-51. PMID: 11360839.
    View in: PubMed
  991. Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG, Braunwald E. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50. PMID: 11320361.
    View in: PubMed
  992. Cannon CP, Nelson SD, Panosian CB, Seeger LL, Eilber FR, Eckardt JJ. Soft tissue echinococcosis: a report of two cases and review of the literature. Clin Orthop Relat Res. 2001 Apr; (385):186-91. PMID: 11302313.
    View in: PubMed
  993. O'Rourke RA, Hochman JS, Cohen MC, Lucore CL, Popma JJ, Cannon CP. New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction. Arch Intern Med. 2001 Mar 12; 161(5):674-82. PMID: 11231699.
    View in: PubMed
  994. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001 Mar 01; 87(5):636-9, A10. PMID: 11230853.
    View in: PubMed
  995. Cannon CP. TIMI risk calculator. 2001.
  996. Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001 Feb 15; 87(4):450-3, A6. PMID: 11179533.
    View in: PubMed
  997. Stone GW, Cannon CP, Chronos NA, Ferguson JJ, Gibson CM, King SB, Yeung AC. Therapeutic strategies in acute coronary syndromes: An integrated approach. 2001.
  998. Cannon CP, Moliterno DJ. New pharmacologic strategies for acute myocardial infarction. 2001.
  999. Johnstone MT, Veves A, editors. Diabetes and cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 2001; 438.
  1000. Gibson CM, Murphy S, Cannon C, Braunwald E. Balloon size in percutaneous intervention is associated with abnormal myocardial perfusion: A TACTICS-TIMI 18 angiographic substudy. Eur Heart J. 2001; 22(Suppl):285.
  1001. Cannon CP, McCallister BD. Integrating IIb/IIIa inhibition and early invasive strategy for optimal management of ACS. 2001.
  1002. Cannon CP. Commentary on glycoprotein IIb/IIIa inhibitors to reduce combined endpoints in acute coronary syndromes. ACP Journal Club. 2001; (March/April):49.
  1003. Jurkovitz C, Mahoney EM, Chu H, Robertson DH, Demopoulos L, DiBattiste P, Alexander C, Cannon CP, Weintraub WS. The effect of conservative vs. invasive strategy on outcomes of acute coronary syndromes in diabetics. Diabetes. 2001.
  1004. Cannon CP, Ornato J. ACS ACTION: Acute cardiac team to improve optimal treatment now. 2001.
  1005. Cannon CP. ACS: Tiroban study shows routine catheterization best. 2001.
  1006. Cannon CP. Cath lab for all patient with unstable angina or non-ST-segment elevation myocardial infarction?. 2001.
  1007. Braunwald E, Aghababian R, Anand S, Cannon CP, Popma JJ, Tierstein P. Strategies and therapies for reducing ischemic and vascular events (STRIVE). 2001.
  1008. Otten MHC, Murphy SA, Angela G, Hynes CA, Lim JS, Luu LL, Kermgard SR, Marble SJ, Cannon CP, Braunwald E, Gibson CM. Kinetics of myocardial perfusion in the setting of ST segment elevation acute myocardial infarction vs unstable angina/non-Q wave MI. J Am Coll Cardiol. 2001; 37(Suppl A):333.
  1009. Cannon CP, Topol EJ. Getting it right from the start: Unlocking the ER and CCU. 2001.
  1010. Cannon CP. What are right TACTICS for treatment acute coronary syndromes?. 2001.
  1011. Foody JM, editor. Preventive cardiology: Strategies for the prevention and treatment of coronary artery disease. Cannon CP, series editor. Contemporary Cardiology. 2001; 366.
  1012. Cannon CP, Richards CF. Emergency department critical pathways for acute coronary syndromes. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 15-22.
  1013. Cannon CP. Case presentation in hypertension. 2001.
  1014. Ganz LI, editor. Management of cardiac arrhythmias. Cannon CP, series editor. Contemporary Cardiology. 2001.
  1015. Cannon CP. TIMI risk calculator. 2001.
  1016. Mahoney EM, Jurkovitz C, Chu H, Alexander C, Demopoulos L, DiBattiste P, Robertson D, Cannon C, Weintraub WS. Length of stay for the treatment of acute coronary syndromes: international experience from the TACTICS-TIMI 18 trial. Eur Heart J. 2001; 22(Suppl):223.
  1017. Cannon CP. TIMI risk calculator. 2001.
  1018. Cannon CP, O'Gara PT. Goals, design and implementation of critical pathways in cardiology. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 3-6.
  1019. Simon DI, Rogers C, editors. Vascular disease and injury: Preclinical research. Cannon CP, series editor. Contemporary Cardiology. 2001; 347.
  1020. Cannon CP. Antithrombotic therapy within three months of acute coronary syndromes. 2001.
  1021. Cannon CP. Commentary on new biomarkers for predicting acute cardiac events. Evidence Based Cardiov Med. 2001; 5:6.
  1022. Morrow DA, Cannon CP. Chest pain and biomarkers: Has troponin supplanted CK-MB?. ACC Curr J Rev. 2001; (Jan/Feb):18-21.
  1023. Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest. 2001 Jan; 119(1 Suppl):253S-277S. PMID: 11157653.
    View in: PubMed
  1024. Armstrong P, Gibler B, Cannon CP, Cohen E, Calder L. Determining therapy by risk stratification in ACS. 2001.
  1025. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 259.
  1026. Cannon CP. New developments in acute coronary syndromes. 2001.
  1027. Cannon CP. Commentary on cost-effectiveness of GP IIb/IIIa inhibitors. J Evidence Based Healthcare. 2001; 5:87-8.
  1028. Cannon CP, Gibson CM, Lincoff AM. Determining the combination therapy in acute myocardial infarction. 2001.
  1029. Cannon CP. What's hot in acute coronary syndromes?. 2001.
  1030. Morrow DA, Cannon CP. Low-molecular-weight heparin in the treatment of acute coronary syndromes. Emerg Med. 2001; 33.
  1031. de Lemos JA, Cannon CP, Stone PH. Acute myocardial infarction. Rosendorff E, editor. Essential Cardiology. 2001; 463-504.
  1032. Topol EJ, Cannon CP, Moliterno D. Latest clinical updates: Long-term outcome following contemporary PCI. 2001.
  1033. Cannon CP. Participating in clinical trials after fellowship ends. Cardiovasc Fellows Forum. 2001; 2:12-3.
  1034. Jurkovitz C, Mahoney EM, Spertus J, Chu H, Alexander C, Robertson D, Demopoulos L, DiBattiste P, Cannon C, Weintraub WS. Changes in Seattle Angina Questionnaire (SAQ) following treatment for acute coronary syndromes: A follow-up evaluation from the TACTICS-TIMI 18 trial. Eur Heart J. 2001; 22(Suppl):718.
  1035. Cannon CP, O'Gara PT. Critical pathway for unstable angina. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 131-41.
  1036. White WB, editor. Blood pressure monitoring in cardiovascular medicine and therapeutics. Cannon CP, series editor. Contemporary Cardiology. 2001; 308.
  1037. Cannon CP, Braunwald E. Unstable angina. Braunwald E, Zipes DP, Libby P, editors. Heart Disease: A Textbook of Cardiovascular Medicine. 2001; 1232-63.
  1038. Topol EJ, Cannon CP, Van de Werf F, Ferguson JJ, Califf RM. Acute coronary syndromes: The 360 degree view. 2001.
  1039. Cannon CP. Commentary on GUSTO IV-ACS. Evid Based Cardiovasc Med. 2001; 5:131.
  1040. Cannon CP. Clopidogrel continuing education teleconference workbook. 2001.
  1041. Topol EJ, Cannon CP, Moliterno D. Provocative new data in PCI. 2001.
  1042. Cannon CP, Weintraub WS, Demopoulos L, Vicari R, Bazzino O, Ali N, Robertson DH, DeLucca PT, DiBattiste P, Rifai N, Braunwald E, for the TACTICS-TIMI 18 Investigators. High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Primary results of the TACTICS-TIMI 18 C-Reactive Protein substudy. J Am Coll Cardiol. 2001; 37(Suppl A):315A.
  1043. Cannon CP, Gibson CM, Braunwald E, Antman EM, Ornato J. Integrating the TIMI risk score into ACS. 2001.
  1044. Cannon CP, Alharethi R, O'Gara PT. Critical pathways for acute coronary syndromes. Becker RC, Alpert JS, editors. Cardiovascular Medicine: Practice and Management. 2001; 263-74.
  1045. Wang-Clow F, Fox NL, Cannon CP, Gibson CM, Berioli S, Bluhmki E, Danays T, Braunwald E, Van De Werf F, Stump DC. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001 Jan; 141(1):33-40. PMID: 11136484.
    View in: PubMed
  1046. Sadanandan S, Cannon CP, DiBattiste PM, Demopoulos LA, Robertson D, Kugelmass AD, for the TACTICS - TIMI 18 Investigators . Outcomes of patients with spontaneous versus post pci CK-MB elevation: data from TACTICS-TIMI 18 trial. Circulation. 2001; 104(Suppl II):697.
  1047. Cannon CP, Weintraub WS, Demopoulos L, DiBattiste P, Robertson DH, DeLucca PT, McCabe CH, Antman EM, Braunwald E, for the TACTICS-TIMI 18 Investigators. TIMI risk score to predict 6 month mortality, recurrent cardiac events, and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Results from TACTICS-TIMI 18. J Am Coll Cardiol. 2001; 37(Suppl A):335.
  1048. Cannon CP, McCabe CH, Antman EM, Bentley J, Rifai N, Braunwald E. Are there high-risk patients who are troponin negative? Further risk stratification with the TIMI risk score in patients with acute coronary syndromes: Results from OPUS-TIMI 16. J Am Coll Cardiol. 2001; 37(Suppl A):326.
  1049. Fuster V, Cannon CP, Ferguson J, Weber M. Opening doors to new therapies: Clinical trials at AHA. 2001.
  1050. Cannon CP. Invasive vs conservative strategies in UA/NSTEMI: The right TACTICS in 2001. 2001.
  1051. Cannon CP. Critical pathways for thrombolysis in myocardial infarction. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 57-66.
  1052. Cannon CP, Gibson CM, Topol EJ, Ornato JP, Weintraub WS, King S. New pathways for aggressive management of ACS. 2001.
  1053. Watkins SP, de Lemos JA, Tokol G, Mahoney E, Yegin A, Alexopoulos C, Goldsman D, Goldsman P, Bunt T, Deuson R, Cannon CP, Hamm C, Weintraub W. Cost-effectiveness analysis of tirofiban use in acute coronary syndromes. Circulation. 2001; 104(Suppl II):798.
  1054. Cannon CP, Fuster V. Thrombogenesis, antithrombotic and thrombolytic therapy. Fuster V, Alexander RW, O'Rourke R, Roberts RA, King SB III, Wellens HJJ, editors. Hurst's the Heart. 2001; 1373-436.
  1055. Gibson CM, Anshelevich M, Murphy S, Luu L, Hynes C, Kliris J, Kermgard S, Otten MH, Antman EM, Cannon CP, Braunwald E. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Dec 15; 86(12):1378-9, A5. PMID: 11113418.
    View in: PubMed
  1056. Cannon CP. Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents. Am Heart J. 2000 Dec; 140(6 Suppl):S154-60. PMID: 11100010.
    View in: PubMed
  1057. Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, Cannon CP, Braunwald E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000 Nov 15; 36(6):1812-7. PMID: 11092649.
    View in: PubMed
  1058. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000 Nov 07; 102(19):2329-34. PMID: 11067784.
    View in: PubMed
  1059. Richards CF, Cannon CP. Reducing medication errors: potential benefits of bolus thrombolytic agents. Acad Emerg Med. 2000 Nov; 7(11):1285-9. PMID: 11073480.
    View in: PubMed
  1060. Cannon CP. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol. 2000 Nov; 23 Suppl 6:VI-14-7. PMID: 11129681.
    View in: PubMed
  1061. Cannon CP. Multimodality reperfusion therapy for acute myocardial infarction. Am Heart J. 2000 Nov; 140(5):707-16. PMID: 11054614.
    View in: PubMed
  1062. Cannon CP, Sayah AJ, Walls RM. ER TIMI-19: testing the reality of prehospital thrombolysis. J Emerg Med. 2000 Oct; 19(3 Suppl):21S-25S. PMID: 11050380.
    View in: PubMed
  1063. Cannon CP. Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional Therapies. Am J Geriatr Cardiol. 2000 Oct; 9(5):265-270. PMID: 11416578.
    View in: PubMed
  1064. McKay CR, Rich MW, Vlietstra RE, Kitzman DW, Fleg JL, Krumholz HM, Lakatta EG, Cooke JP, Cannon CP, Ezekowitz MD, Frohlich ED, Jalife J, Kass DA, Kottke BA, Muller JE, Saltin B, Shen WK, Somers VK. Executive Summary: Pivotal Research in Cardiovascular Syndromes in the Elderly. Am J Geriatr Cardiol. 2000 Oct; 9(5):243-250. PMID: 11416575.
    View in: PubMed
  1065. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000 Jul 11; 102(2):149-56. PMID: 10889124.
    View in: PubMed
  1066. Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CM. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am J Cardiol. 2000 Jun 15; 85(12):1409-13. PMID: 10856384.
    View in: PubMed
  1067. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000 Jun 14; 283(22):2941-7. PMID: 10865271.
    View in: PubMed
  1068. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AA, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5. PMID: 10851205.
    View in: PubMed
  1069. Zalenski RJ, Selker HP, Cannon CP, Farin HM, Gibler WB, Goldberg RJ, Lambrew CT, Ornato JP, Rydman RJ, Steele P. National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia. Ann Emerg Med. 2000 May; 35(5):462-71. PMID: 10783408.
    View in: PubMed
  1070. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000 May; 40(5):508-15. PMID: 10806604.
    View in: PubMed
  1071. Cannon CP. Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am J Cardiol. 2000 Apr 27; 85(8A):17C-22C. PMID: 10793176.
    View in: PubMed
  1072. Cannon CP. Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI. J Thromb Thrombolysis. 2000 Apr; 9(3):235-41. PMID: 10728022.
    View in: PubMed
  1073. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Feb 15; 85(4):491-3, A10. PMID: 10728957.
    View in: PubMed
  1074. Cannon CP. Defining acute myocardial infarction by ST segment deviation. Eur Heart J. 2000 Feb; 21(4):266-7. PMID: 10653672.
    View in: PubMed
  1075. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 2000 Feb; 35(2):358-62. PMID: 10676681.
    View in: PubMed
  1076. Every NR, Hochman J, Becker R, Kopecky S, Cannon CP. Critical pathways : a review. Committee on Acute Cardiac Care, Council on Clinical Cardiology, American Heart Association. Circulation. 2000 Feb 01; 101(4):461-5. PMID: 10653841.
    View in: PubMed
  1077. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18; 101(2):125-30. PMID: 10637197.
    View in: PubMed
  1078. Cannon CP. Emerging role of clopidogrel as the cornerstone of treatment in acute coronary syndromes. Cannon CP, editor. Presentations in Focus: Extending Antiplatelet Protection: Optimal Strategies to Reduce Thrombotic Risk. 2000.
  1079. Cannon CP. Case history: Non-ST elevation myocardial infarction. 2000.
  1080. Braunwald E, Califf RM, Cannon CP, Fox KA, Fuster V, Gibler WB, Harrington RA, King SB, Kleiman NS, Theroux P, Topol EJ, Van de Werf F, White HD, Willerson JT. Redefining medical treatment in the management of unstable angina. Am J Med. 2000 Jan; 108(1):41-53. PMID: 11059440.
    View in: PubMed
  1081. Braunwald E, Topol EJ, Cannon CP, Jesse RL, Ohman EM, White HD. Acute coronary syndromes town hall meeting: Applying clinical trials to clinical practice. 2000.
  1082. Cannon CP, Ganz LI, Stone PH, Becker RC. Complicated myocardial infarction. Irwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care Medicine. 2000; 185-93.
  1083. Cannon CP. Acute coronary syndromes: More aggressive is better. 2000.
  1084. Cannon CP. New antiplatelet therapies. 2000.
  1085. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor blockers. In: Ferguson JJ, Chronos NAF, Harrington RA, editors. Antiplatelet Therapy in Clinical Practice. 2000; 163-80.
  1086. Cannon CP. Targeting high-risk patient subsets in acute coronary syndromes: Greater benefit from antithrombotic and interventional therapies. ACS. 2000; 3:42-50.
  1087. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors: Why have they failed so far?. 2000.
  1088. Moliterno D, Cannon CP, Ohman EM, Spinler SA. Improving strategies and outcomes. The Evolving Management of Atherothrombotic and Occlusive Vascular Diseases. 2000.
  1089. The ESPRIT Investigators. Enhanced supression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial (CP Cannon, Chairman, Data Safety Monitoring Board). Lancet. 2000; 356:2037-44..
  1090. Quality of Care and Outcomes Research in CVD and Stroke Working Groups (Cannon CP, Member, Acute Myocardial Infarction Working Group). Measuring and improving quality of care. A report for the AHA/ACC First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. Circulation. 2000; 101:1483-93.
  1091. Cannon CP. Late-breaking trial of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: ESPRIT, PARAGON B, and Second Symphony Series. Pfeffer MA, series editor. Cardiology Scientific Update. 2000.
  1092. Cannon CP, Giugliano RP. TNK-tPA (tenecteplase): The single bolus thrombolytic agent for the new millenium. Pfeffer MA, series editor. Cardiology Scientific Update. 2000.
  1093. Sharis PJ, Cannon DP, editors. Evidence-based Cardiology. 2000; 368.
  1094. Cannon CP. Pharmacology overview platelet glycoprotein IIb/IIIa inhibitors. 2000.
  1095. Cannon CP. Unresolved question in acute coronary syndromes: Rationale for the PROVE IT trial: Future directions in atherosclerosis. 2000.
  1096. Cannon CP, Ganz LI, Stone PH. Complicated myocardial infarction. Irwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care Medicine. 2000.
  1097. Cannon CP. A 1999 approach to unstable angina. 2000.
  1098. Cannon CP. The evolving story of oral platelet glycoprotein IIb/IIIa inhibitors. Curr Opin Card Pulm Renal Invest Drug. 2000; 2:114-23.
  1099. Cannon CP. What is new in acute coronary syndromes?. 2000.
  1100. Cannon CP. The 4th global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO IV-ACS): What happened?. Pfeffer M, editor. Cardiology Scientific Update. 2000; 1-6.
  1101. Cannon CP. Optimizing fibrinolytic therapy in acute myocardial infarction. 2000.
  1102. Cannon CP. TACTICS TIMI 18. 2000.
  1103. Cannon CP, Farkouh M, Gibler B. Guidelines in chest pain emergency departments: The experience and future. 2000.
  1104. Cannon CP. The success and failure of glycoprotein IIb/IIIa receptor blockers. 2000.
  1105. Cannon CP, Gibson CM, Lambrew CT, Tiefenbrunn AJ, Sun H, Malmgren HJ, Frederick P, Every NR, Zalenski R, for the NRMI 2 and 3 Investigators. Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: An analysis of 85,589 patients in the national registry of myocardial infarction 2+3. J Am Coll Cardiol. 2000; 35(Suppl A):376.
  1106. Sharis P, Cannon CP, McCabe CH, Charlesworth A. Prior aspirin use is a univariate, but NOT a multivariate predictor of 1 year mortality in 10,302 patients with acute coronary syndromes: Results from OPUS-TIMI 16. J Am Coll Cardiol. 2000; 35(Suppl A):391.
  1107. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, van de Werf F, Braunwald E. Is the corrected TIMI frame count an independent predictor of adverse outcome?. Circulation. 2000; 102:e19.
  1108. Loscalzo J, Vita JA, editors. Nitric oxide and the cardiovascular system. Cannon CP, series editor. Contemporary Cardiology. 2000; 601.
  1109. Cannon CP. Application of the NHAAP guidelines in chest pain emergency department. 2000.
  1110. Cannon CP. Evidence points to role of bolus fibrinolytic agents in reducing medication errors. New Era Reperfusion. 2000; 4:1-7.
  1111. Cannon CP. Thrombolytic medication dosing errors. 2000.
  1112. Cannon CP. Breaking the thrombolytic barrier: Combining glycoprotein IIb/IIIa receptor inhibitors with thrombolytic therapy in the treatment of acute myocardial infarction. Cardiovasc Rev Rep. 2000; 21:595-601.
  1113. Cannon CP. Case study: Combination GP IIb/IIIa inhibitor plus reduced-dose thrombolytic therapy for acute myocardial infarction. 2000.
  1114. Cannon CP, Stone PH. Acute myocardial infarction. Carruthers SG, Hoffman BB, Melmon KL, Nierenberg, DW, editors. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. 2000; 131-56.
  1115. de Lemos JA, Cannon CP. Angina and coronary heart disease. Sirtori C, editor. Clinical Pharmacology. 2000; 269-85.
  1116. Cannon CP. Global use of strategies: To open occluded arteries (GUSTO) IV in acute coronary syndromes (ACS): What happened?. 2000.
  1117. Cannon CP. Quick reference cards: ACC/AHA unstable angina guidelines. 2000.
  1118. Cannon CP. Combination thrombolytic and antiplatelet therapy. 2000.
  1119. Cannon CP. Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction. Coron Artery Dis. 1999 Dec; 10(8):561-6. PMID: 10599534.
    View in: PubMed
  1120. Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. 1999 Dec; 138(6 Pt 1):1065-72. PMID: 10577436.
    View in: PubMed
  1121. Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999 Nov 15; 84(10):1145-50. PMID: 10569321.
    View in: PubMed
  1122. Cannon CP. Diagnosis and management of patients with unstable angina. Curr Probl Cardiol. 1999 Nov; 24(11):681-744. PMID: 10575552.
    View in: PubMed
  1123. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12. PMID: 10551685.
    View in: PubMed
  1124. Gibson CM, Cannon CP, Murphy SA, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald E. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol. 1999 Nov 01; 84(9):976-80. PMID: 10569649.
    View in: PubMed
  1125. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1395-402. PMID: 10551684.
    View in: PubMed
  1126. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82. PMID: 10520778.
    View in: PubMed
  1127. Cannon CP. Low molecular weight heparin in acute coronary syndromes. Curr Cardiol Rep. 1999 Sep; 1(3):206-11. PMID: 10980843.
    View in: PubMed
  1128. Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol. 1999 Sep; 34(3):739-47. PMID: 10483955.
    View in: PubMed
  1129. Cannon CP. Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV37-43. PMID: 10492852.
    View in: PubMed
  1130. Cannon CP. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV30-6. PMID: 10492851.
    View in: PubMed
  1131. Cannon CP. Breaking the therapeutic barriers: new strategies for acute coronary syndromes. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV1-2. PMID: 10492847.
    View in: PubMed
  1132. Cannon CP, Sayah AJ, Walls RM. Prehospital thrombolysis: an idea whose time has come. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV10-9. PMID: 10492849.
    View in: PubMed
  1133. Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol. 1999 Jul; 39(7):675-84. PMID: 10392322.
    View in: PubMed
  1134. Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EM. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. Am Heart J. 1999 Jun; 137(6):1179-84. PMID: 10347349.
    View in: PubMed
  1135. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald E. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999 May; 137(5):786-91. PMID: 10220625.
    View in: PubMed
  1136. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald E. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999 Apr 20; 99(15):1945-50. PMID: 10208996.
    View in: PubMed
  1137. Dracup KA, Cannon CP. Combination treatment strategies for management of acute myocardial infarction: New directions with current therapies. Crit Care Nur. 1999; Suppl:3-15.
  1138. Cannon CP. Advances in the medical management of acute coronary syndromes. J Thromb Thrombolysis. 1999 Apr; 7(2):171-89. PMID: 10364769.
    View in: PubMed
  1139. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Mar; 33(3):634-9. PMID: 10080462.
    View in: PubMed
  1140. Cannon CP, Dingemanse J, Kleinbloesem CH, Jannett T, Curry KM, Valcke CP. Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers. Circulation. 1999 Feb 16; 99(6):751-6. PMID: 9989959.
    View in: PubMed
  1141. Becker RC, Hochman JS, Cannon CP, Spencer FA, Ball SP, Rizzo MJ, Antman EM. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol. 1999 Feb; 33(2):479-87. PMID: 9973029.
    View in: PubMed
  1142. Weintraub WS, Culler SD, Kosinski A, Becker ER, Mahoney E, Burnette J, Spertus JA, Feeny D, Cohen DJ, Krumholz H, Ellis SG, Demopoulos L, Robertson D, Boccuzzi SJ, Barr E, Cannon CP. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. Am J Cardiol. 1999 Feb 01; 83(3):317-22. PMID: 10072215.
    View in: PubMed
  1143. Cannon CP, Caprini JA, Merli GJ, Hawkins D. Differentiation of low molecular weight heparins: Clinical and economic implications of treatment. 1999.
  1144. Cannon CP. Case study: Use of combination IIb/IIIa inhibition and reduced dose thrombolysis for acute myocardial infarction. 1999.
  1145. Cannon CP, O'Gara PT. Critical pathways for acute coronary syndromes. 1999.
  1146. Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E for the TIMI 10B Investigators. Myoglobin, CK-MB and cardiac troponin - I - 60 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction: Results from TIMI 10B. J Am Coll Cardiol. 1999; 34:739-47..
  1147. Cannon CP. A balanced approach to reperfusion therapy. 1999.
  1148. Cannon CP. Review of Textbook of Cardiovascular Medicine. Circulation. 1999; 100:566-7.
  1149. Cannon CP, Rizzo MJ, Antman EM, McCabe CH, Gibson CM, Braunwald E. Validation of a multivariate model for risk stratification in acute MI: Results from TIMI 9B. J Am Coll Cardiol. 1999; 33(Suppl A):396.
  1150. Cannon CP, O'Gara PT. Critical pathways in acute coronary syndromes. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999; 611-27.
  1151. Cannon CP. The international TIMI 14 trial: Final results. 1999.
  1152. Lincoff AM, Topol EJ, editors. Platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 1999; 368.
  1153. Cannon CP. Platelet glycoprotein IIb/IIIa receptor inhibitors in the management of acute coronary syndromes and coronary intervention. Braunwald E, editor. Heart Disease Updates. 1999; 1-10.
  1154. Cannon CP. Bolus thrombolysis in the new millennium. 1999.
  1155. Cannon CP. Expanding the treatment paradigm for acute myocardial infarction with GP IIb/IIIa inhibitors. New Era of Reperfusion. 1999; 3:1-12.
  1156. Fox NL, Cannon CP, Berioli S, Wang-Clow F, Danays T, Sarelin H, Braunwald E, Van de Werf F. Rates of serious bleeding requiring transfusion in AMI patients treated with TNK-tPA. J Am Coll Cardiol. 1999; 33(Suppl A):353.
  1157. Ericsson CD, Cannon CP, Deutsch E. Unstable angina: Diagnosis and management. 1999.
  1158. Cannon CP. Thrombolysis and medication errors. 1999.
  1159. Oz MC, Goldstein DJ, editors. Minimally invasive cardiac surgery. Cannon CP, series editor. Contemporary Cardiology. 1999; 237.
  1160. Cannon CP. Focus on fragmin. 1999.
  1161. Cannon CP. Case study: "The heart attack" or "A midsummer's night drive". 1999.
  1162. Hochman JS, Becker RC, Berger PP, Borzak S, Califf RM, Cannon CP, Every NR, Gibler WB, Grines CL, Kopecky SL, Newby LK, Ohman EM, O'Neill WW, Ornato JP Weaver WD. Best practices for treating acute myocardial infarction. 1999.
  1163. Fisher G, Cannon CP, Tanasijevic M. Clinical effectiveness of cardiac markers as indicators of coronary artery patency after thrombolysis for acute myocardial infarction. 1999.
  1164. Cannon CP. Thrombolysis and medication errors. 1999.
  1165. Tanasijevic MJ, Cannon CP, Antman EM. The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol. 1999 Jan; 22(1):13-6. PMID: 9929748.
    View in: PubMed
  1166. Cannon CP. Door-to-balloon time versus mortality in patients with acute myocrdial infarction treated with primary angioplasty. 1999.
  1167. Cannon CP, Johnson EB, Cermignani M, Scirica BM, Sagarin MJ, Walls RM. Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction. Clin Cardiol. 1999 Jan; 22(1):17-20. PMID: 9929749.
    View in: PubMed
  1168. Cannon CP, Barnathan E, Fowles R, Jordan R. ReoPro: A powerful and versatile agent in ACS. 1999.
  1169. Cannon CP, Braunwald E. The spectrum of myocardial ischemia: The paradigm of acute coronary syndromes. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999; 3-18.
  1170. Kereiakes DJ, Cannon CP. Oral platelet glycoprotein IIb/IIIa blockade. Lincoff AM, Topol EJ, editors. Platelet IIb/IIIa Inhibitors in Cardiology. 1999; 287-314.
  1171. Coulter SA, McCabe CH, Giugliano RP, Cutler SS, Charlesworth A, Chew PH, Cannon CP. Dosing errors and outcomes in patients receiving single bolus compared to bolus + infusion thrombolytic regimens: An InTIME-II Study. Circulation. 1999; 100(Suppl I):791.
  1172. Cannon CP. New strategies for the treatment of acute coronary syndromes. Pfeffer MA, series editor. Cardiology Scientific Update. 1999.
  1173. Blake TM, editor. Annoted atlas of electrocardiography. Cannon CP, series editor. Contemporary Cardiology. 1999; 368.
  1174. Cannon CP. Low molecular weight heparin in acute coronary syndromes. 1999.
  1175. Cannon CP. Clinical value of the troponins in acute coronary syndromes. 1999.
  1176. Cannon CP, Herrmann H, Ohman EM, Coussement PK, Moliterno DJ, Topol EJ. Bolus thrombolytics erduce medication errors. Medi-Fax. 1999.
  1177. Cannon CP. Clinical trial updates in coronary artery disease. Curr Op Cardiol. 1999; 14:359.
  1178. Cannon CP. Sibrafiban. Drugs. 1999; 57:231-2.
  1179. Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EM. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. Am Heart J. 1999 Jan; 137(1):79-92. PMID: 9878939.
    View in: PubMed
  1180. Cannon CP. Optimizing the medical management of acute coronary syndromes. J Thromb Thrombolysis. 1999; 7:171-89.
  1181. Cannon CP. The era of platelet glycoprotein IIb/IIIa inhibition: Overview. Cor Art Dis. 1999; 10:545-6.
  1182. Cannon CP. Overcoming thrombolytic resistance. 1999.
  1183. Cannon CP. The TIMI 11B troponin substudy. 1999.
  1184. Cannon CP, Braunwald E. TIMI IIB. Fuster V, Nash IS, editors. Efficacy of Myocardial Infarction Therapy: An Evaluation of Clinical Trials Evidence. 1999; 437-452.
  1185. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999.
  1186. Cannon CP, Ornato JP, Antman EM, Braunwald E, Topol EJ, Willerson JT. New perspectives in cardiac care: Thrombolysis 98. 1999.
  1187. Casey M, Fornari C, Bozovich GE, Iglesias Varela ML, Mautner B, Cannon CP. Increased expression of platelet p-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 Study. Circulation. 1999; 100(Suppl I):681.
  1188. Cannon CP. The era of platelet glycoprotein IIb/IIIa inhibition. Cannon CP, editor. Cor Art Dis. 1999; 10:545-94.
  1189. Cannon CP, Loscalzo J. Thrombolytic and antithrombotic therapies for acute coronary syndromes. Gorlin R, Dangas GD, Toutouzas PK, Konstadoulakis MM, editors. Contemporary Concepts in Cardiology: Pathophysiology and Clinical Management. 1999; 142-175.
  1190. Cannon CP. Timely thrombolysis: synergism to open arteries and reduce mortality rates. Am Heart J. 1999 Jan; 137(1):1-3. PMID: 9878929.
    View in: PubMed
  1191. de Lemos JA, Cannon CP. Improving reperfusion in acute myocardial infarction: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. 1999.
  1192. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998 Dec 22-29; 98(25):2805-14. PMID: 9860780.
    View in: PubMed
  1193. Cannon CP. The Ten Most Commonly Asked Questions about Platelet Glycoprotein IIb/IIIa Receptor Antagonists. Cardiol Rev. 1998 Oct; 6(5):252-254. PMID: 10348947.
    View in: PubMed
  1194. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol. 1998 Sep 15; 82(6):731-6. PMID: 9761082.
    View in: PubMed
  1195. Cannon CP. Advances in the medical management of acute coronary syndromes. Curr Opin Cardiol. 1998 Sep; 13(5):327-47. PMID: 9823789.
    View in: PubMed
  1196. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998 Sep 01; 129(5):394-405. PMID: 9735068.
    View in: PubMed
  1197. Kloner RA, Przyklenk K, Shook T, Cannon CP. Protection Conferred by Preinfarct Angina is Manifest in the Aged Heart: Evidence from the TIMI 4 Trial. J Thromb Thrombolysis. 1998 Sep; 6(2):89-92. PMID: 10751789.
    View in: PubMed
  1198. Every NR, Cannon CP, Granger C, Moliterno DJ, Aguirre FV, Talley JD, Booth J, Sapp S, Ferguson JJ. Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. J Am Coll Cardiol. 1998 Aug; 32(2):387-92. PMID: 9708465.
    View in: PubMed
  1199. Sagarin MJ, Cannon CP, Cermignani MS, Scirica BM, Walls RM. Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect. J Emerg Med. 1998 Jul-Aug; 16(4):557-65. PMID: 9696170.
    View in: PubMed
  1200. Cannon CP, Smith M. Advances in Alliteration in Acute Myocardial Infarction: From "Time to Treatment" to "Onset to Opening" J Thromb Thrombolysis. 1998 Jul; 6(1):5-7. PMID: 10751785.
    View in: PubMed
  1201. Cannon CP. Time to treatment of acute myocardial infarction revisited. Curr Opin Cardiol. 1998 Jul; 13(4):254-66. PMID: 10091021.
    View in: PubMed
  1202. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun; 31(7):1460-5. PMID: 9626820.
    View in: PubMed
  1203. Goel M, Dodge Jr , Rizzo M, McLean C, Ryan KA, Daley WL, Cannon CP, Gibson CM. The Open Artery Hypothesis: Past, Present, and Future. J Thromb Thrombolysis. 1998 May; 5(2):101-112. PMID: 10767103.
    View in: PubMed
  1204. Canon CP. "Super-aggressive" management of acute myocardial infarction. Medical Roundtable. 1998; 3-4.
  1205. Cannon CP. Bolus thrombolysis: r-PA, t-PA, n-PA. Medical Roundtable. 1998; 4-5.
  1206. Cannon CP. The right mix for improve acute myocardial infarction survival: Pre-hospital bolus thrombolysis, lytics + PTCA + GP IIb/IIIa inhibitors. Medical Roundtable. 1998.
  1207. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, McCabe CH, Braunwald E. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998 Mar 24; 97(11):1042-5. PMID: 9531250.
    View in: PubMed
  1208. Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, Henry T, Hochman JS, Fuchs J, Antman EM, McCabe C, Braunwald E. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998 Mar 15; 81(6):678-81. PMID: 9527073.
    View in: PubMed
  1209. Cannon CP. Double-bolus alteplase was not equivalent to accelerated infusion in patients with acute MI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):16-7. PMID: 16379781.
    View in: PubMed
  1210. Cannon CP. Reteplase was not better than alteplase in reducing 30-day mortality among patients with acute MI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):16-7. PMID: 16379780.
    View in: PubMed
  1211. Wieczorek RR, Price MR, Cannon C. A pharmacology review for private duty nurses using computers and self learning concepts. J Nurs Staff Dev. 1998 Mar-Apr; 14(2):95-7. PMID: 9592435.
    View in: PubMed
  1212. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998 Feb 03; 97(4):340-9. PMID: 9468207.
    View in: PubMed
  1213. Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol. 1998 Feb; 31(2):326-30. PMID: 9462575.
    View in: PubMed
  1214. Ericsson CD, Cannon CP, Deutsch E. Unstable angina: Diagnosis and management. 1998.
  1215. de Lemos JA, Cannon CP. Reocclusion after AMI: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. Callif RM, editor. Thrombolytic Therapy: New Standards of AMI/ACS Care, Part 6: Patients with Complicating Cardiac Conditions. 1998; 3-11.
  1216. Cannon CP. Case history of non-ST elevation myocardial infarction. 1998.
  1217. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost. 1998 Jan; 79(1):134-9. PMID: 9459338.
    View in: PubMed
  1218. Cannon CP. Prehospital management of acute myocardial infarction. Topol EJ, editor. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 1998; 485-98.
  1219. Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown RG, Collen D, Mahan E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO, Zaret BL. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Am Heart J. 1998 Jan; 135(1):29-37. PMID: 9453518.
    View in: PubMed
  1220. Cannon CP. Aggrastat to treat unstable angina. Curr Pract Med. 1998; 1:55-58.
  1221. Cannon CP. Incorporating IIb/IIIa inhibitors into today's critical pathways. 1998.
  1222. Cannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald E. PIA2 polymorphism of the platelet IIb/IIIa receptor: Increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: Results from TIMI 12. Circulation. 1998; 98(Suppl I):171.
  1223. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Pepine CJ, Ferry DR, Chow BK, Lavori PW, for the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators (CP Cannon, Chairman, Endpoints Committee) . Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative strategy. N Engl J Med. 1998; 338:1785-92..
  1224. Block PC, Cannon CP. IIb/IIIa inhibition in acute coronary syndromes. 1998.
  1225. Callas PW, Tracy RP, Bovill EG, Cannon CP, Braunwald E. The association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis In Myocardial Infarction Phase II (TIMI II) Trial. J Thromb Thrombolysis. 1998; 5:53-60..
  1226. Cannon CP. Bolus thrombolysis: r-PA, t-PA, n-PA and TNK-tPA. New Era of Reperfusion. 1998; 2:1-3.
  1227. Cannon CP. What is the evidence that chest pain centers improve outcomes and cost-effectiveness?. 1998.
  1228. Cannon CP. Commentary on GUSTO III and COBALT. Evidence-based Cardiovascular Medicine. 1998; 2:17.
  1229. Cannon CP. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Cardiology Rounds. 1998; 2:1-8.
  1230. Cannon CP, Krakowski FM. Diagnosis and therapy of acute myocardial infarction: Today's look at tomorrow's therapies and outcomes. 1998.
  1231. Rizzo MJ, Ryan K, Cannon CP, Braunwald E. Onset of chest pain between 6PM and 6AM is associated with poorer outcomes following thrombolysis. Circulation. 1998; 98(Suppl I):764.
  1232. Cannon CP. ST depression V1-V2: Anterior ischemia of posterior infarction?. 1998.
  1233. Cannon CP. Spectrum of acute coronary syndromes: The paradigm of myocardial ischemia. 1998.
  1234. Gibson CM, Dodge JT, Goel M, Al-Mousa EN, Rizzo M, McLean C, Ryan K, Sparano A, Marble SJ, Daley WL, Cannon CP, Antman EM. Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flow. Am J Cardiol. 1997 Dec 15; 80(12):1536-9. PMID: 9416931.
    View in: PubMed
  1235. Cannon CP. Clinical perspectives on the use of composite endpoints. Control Clin Trials. 1997 Dec; 18(6):517-29; discussion 546-9. PMID: 9408715.
    View in: PubMed
  1236. Nichol G, Walls R, Goldman L, Pearson S, Hartley LH, Antman E, Stockman M, Teich JM, Cannon CP, Johnson PA, Kuntz KM, Lee TH. A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. 1997 Dec 01; 127(11):996-1005. PMID: 9412306.
    View in: PubMed
  1237. Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald E. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997 Oct; 134(4):622-30. PMID: 9351728.
    View in: PubMed
  1238. Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, Shah PK, Sequeira RF, Greene RM, Perritt RL, Poole WK, Braunwald E. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction. Am J Cardiol. 1997 Sep 15; 80(6):696-9. PMID: 9315571.
    View in: PubMed
  1239. Gibson CM, Marble SJ, Rizzo MJ, Moynihan J, McLean C, Ryan K, Sparano A, Piana RN, McCabe C, Cannon CP. Relation between injections before 90-minute angiography and coronary patency: results of the thrombolysis in myocardial infarction 4 trial. Am Heart J. 1997 Sep; 134(3):351-4. PMID: 9327688.
    View in: PubMed
  1240. Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya F, Diver DJ, Baim DS, Braunwald E. Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am J Cardiol. 1997 Jul 01; 80(1):21-6. PMID: 9205014.
    View in: PubMed
  1241. Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald E. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1997 Jul; 30(1):141-8. PMID: 9207635.
    View in: PubMed
  1242. Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, Pearce DJ, Diver DJ, Kells C, Feldman T, Williams M, Gibson RS, Kronenberg MW, Ganz LI, Anderson HV, Braunwald E. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997 Jul; 30(1):133-40. PMID: 9207634.
    View in: PubMed
  1243. Anderson HV, Gibson RS, Stone PH, Cannon CP, Aguirre F, Thompson B, Knatterud GL, Braunwald E. Management of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Am J Cardiol. 1997 Jun 01; 79(11):1441-6. PMID: 9185630.
    View in: PubMed
  1244. Cannon CP. Acute myocardial infarction - the first 73 hours. 1997.
  1245. Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Tofler GH, Kleiman NS, Cannon C, Braunwald E. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol. 1997 Feb 15; 79(4):391-6. PMID: 9052337.
    View in: PubMed
  1246. Cannon CP, McCabe CH, Stone PH, Schactman M, Thompson B, Theroux P, Gibson RS, Feldman T, Kleiman NS, Tofler GH, Muller JE, Chaitman BR, Braunwald E. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol. 1997 Feb 01; 79(3):253-8. PMID: 9036740.
    View in: PubMed
  1247. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997 Jan 21; 95(2):351-6. PMID: 9008448.
    View in: PubMed
  1248. Cannon CP. TNK-tPA: Easier thrombolysis?. 1997.
  1249. Block PC, Cannon CP, Hochman JS. Thrombolytic strategy in myocardial infarction. 1997.
  1250. Cannon CP. Teaching case of acute myocardial infarction. 1997.
  1251. Cannon CP, Hutter AM. The TIMI 10B and ASSENT-I trials with TNK-tPA. 1997.
  1252. Braunwald E, Cannon CP. Predictive survival markers as surrogate end points in thrombolytic trials of acute myocardial infarction. Thrombolytic Therapy: New Standards of Care. Califf RM, editor. 1997; 3-10.
  1253. Cannon CP, Antman EA. Heparin and low molecular weight heparin in acute coronary syndromes and angioplasty. Cardiology Clinics: Annual of Drug Therpay. Crawford MH, editor. 1997; 105-19.
  1254. Cannon CP. Teaching case of non-ST elevation myocardial infarction. 1997.
  1255. Ornato JP, Cannon CP, Gibler WB, Gonzales ER. Critical pathways for the evaluation and treatment of chest pain. 1997.
  1256. Oberg KC, Cannon CP, Plutzky J. Focus on reteplase: A newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarction. Formulary. 1997; 32:37-45.
  1257. Cannon CP. The glycoprotein IIb/IIIa inhbitors in the treatment of acute coronary syndromes. New Era of Reperfusion. 1997; 1:1-8.
  1258. Ornato JP, Cannon CP, Gibler WB, Gonzales ER. Critical pathways for the evaluation and treatment of chest pain. 1997.
  1259. Antman EM, Tanasijevic MJ, Cannon CP. Cardiac troponins in acute coronary syndromes. N Engl J Med. 1997; 336:1259.
  1260. Thrombolysis in myocardial infarction (TIMI) 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol. 1997; 29:1474-82..
  1261. Cannon CP, Goldhaber SZ. Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol. 1996 Nov 15; 78(10):1149-51. PMID: 8914880.
    View in: PubMed
  1262. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996 Oct 31; 335(18):1342-9. PMID: 8857017.
    View in: PubMed
  1263. Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo J. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Am J Cardiol. 1996 Sep 01; 78(5):503-10. PMID: 8806332.
    View in: PubMed
  1264. Birnbaum Y, Kloner RA, Sclarovsky S, Cannon CP, McCabe CH, Davis VG, Zaret BL, Wackers FJ, Braunwald E. Distortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction and correlation with infarct size and long-term prognosis (Thrombolysis in Myocardial Infarction 4 Trial). Am J Cardiol. 1996 Aug 15; 78(4):396-403. PMID: 8752182.
    View in: PubMed
  1265. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, Braunwald B. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial) Am J Cardiol. 1996 Jul 15; 78(2):142-7. PMID: 8712133.
    View in: PubMed
  1266. Kloner RA, Gibson M, Cannon C, Braunwald E. Preinfarction angina. N Engl J Med. 1996 Jul 04; 335(1):59-60; author reply 60-1. PMID: 8637553.
    View in: PubMed
  1267. Braunwald E, Cannon CP. Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy? J Am Coll Cardiol. 1996 May; 27(6):1333-4. PMID: 8626940.
    View in: PubMed
  1268. Walls RM, Cannon CP, Teich J. Thrombolysis "door-to-drug" interval. Acad Emerg Med. 1996 Mar; 3(3):285; author reply 286-7. PMID: 8673790.
    View in: PubMed
  1269. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996 Mar 01; 93(5):879-88. PMID: 8598078.
    View in: PubMed
  1270. Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, Randall AM, Knatternud G, Braunwald E. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J. 1996 Mar; 131(3):421-33. PMID: 8604620.
    View in: PubMed
  1271. Kloner RA, Gibson CM, Cannon CP, Braunwald E. Preinfarction angina (letter). N Eng J Med. 1996; 335:59-60..
  1272. Cannon CP. New thrombolytic and antithrombotic approaches: TNK, hirudin, low molecular weight heparin. 1996.
  1273. Cannon CP. Hirulog. In: Messerli FH, editor. Cardiovascular Drug Therapy. 1996; 1498-505.
  1274. Antman EM, McCabe CH, Cannon CP, Barbash GI, Mueller HS, Gallo P. Prevention of Q-wave development with thrombolytic therapy does not predict better short-term prognosis. Circulation. 1996; 94(Suppl I):381.
  1275. Cannon CP. Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(3):249-255. PMID: 10613990.
    View in: PubMed
  1276. Cannon CP, Braunwald E. Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(2):117-125. PMID: 10602552.
    View in: PubMed
  1277. Becker RC, Hebert J, Hurley T, Ma Y, Cannon CP, for the TIMI 5 Hemostasis and Thrombosis Study Group. Early PTT measurement are not a surrogate for in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulation. J Am Coll Cardiol. 1996; 27(Suppl A):11-12.
  1278. Cannon CP. Time as an adjunctive agent to thrombolysis. Clinical Courier. 1996; 14:4-5.
  1279. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation. 1996; 94:911-21..
  1280. Kloner RA, Gibson CM, Cannon CP, Braunwald E. Preinfarction antina. N Engl J Med. 1996; 335:59-60.
  1281. Moliterno DJ, Aguirre FV, Cannon CP, Every NR, Granger CB, Sapp SK, Booth JE, Ferguson JJ, forthe GUARANTEE Investigators. The global unstable angina registry and treatment evaluation (GUARANTEE) study. Circulation. 1996; 94(Suppl I):195.
  1282. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, Thompson B, Willerson JT, Braunwald E. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995 Dec; 26(7):1643-50. PMID: 7594098.
    View in: PubMed
  1283. Hall C, Cannon CP, Forman S, Braunwald E. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. J Am Coll Cardiol. 1995 Nov 15; 26(6):1452-6. PMID: 7594070.
    View in: PubMed
  1284. Boisjolie CR, Sharkey SW, Cannon CP, Brunette D, Haugland JM, Thatcher JL, Henry TD. Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department. Am J Cardiol. 1995 Aug 15; 76(5):396-8. PMID: 7639167.
    View in: PubMed
  1285. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995 Aug 15; 92(4):727-33. PMID: 7641350.
    View in: PubMed
  1286. Cannon CP. Thrombin inhibitors in acute myocardial infarction. Cardiol Clin. 1995 Aug; 13(3):421-33. PMID: 7585777.
    View in: PubMed
  1287. Cannon CP, Walls RM. Waiting for Godot: use of chemical markers in the emergency department evaluation of chest pain. J Emerg Med. 1995 Jul-Aug; 13(4):533-5. PMID: 7594376.
    View in: PubMed
  1288. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995 Jun; 25(7 Suppl):30S-37S. PMID: 7775712.
    View in: PubMed
  1289. Cannon CP, Thompson B, McCabe CH, Mueller HS, Kirshenbaum JM, Herson S, Nasmith JB, Chaitman BR, Braunwald E. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. Am J Cardiol. 1995 May 15; 75(15):977-81. PMID: 7747698.
    View in: PubMed
  1290. Cannon CP. Improved management of unstable angina and non-Q-wave MI. Contemp Intern Med. 1995 May; 7(5):11-2, 15-6, 19-24. PMID: 10150348.
    View in: PubMed
  1291. Cannon CP, Braunwald E, McCabe CH, Antman EM. The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. J Interv Cardiol. 1995 Apr; 8(2):117-35. PMID: 10155224.
    View in: PubMed
  1292. Cannon CP, Goldhaber SZ. The importance of rapidly treating patients with acute myocardial infarction. Chest. 1995 Mar; 107(3):598-600. PMID: 7874923.
    View in: PubMed
  1293. Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CH, Flaker GC, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1995 Mar 01; 25(3):582-9. PMID: 7860900.
    View in: PubMed
  1294. Zahger D, Cercek B, Cannon CP, Jordan M, Davis V, Braunwald E, Shah PK. How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) Am J Cardiol. 1995 Feb 01; 75(4):232-6. PMID: 7832129.
    View in: PubMed
  1295. Zahger D, Cercek B, Cannon CP, Jordan M, Shah PK, for the TIMI-4 Investigators. Thrombolytic therapy for acute myocardial infraction in patients with prior coronary bypass surgery: Results from the Thrombolysis In Myocardial Infarction (TIMI) 4 Trial. J Thromb Thrombolysis. 1995; 2:45-50..
  1296. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995 Jan 01; 91(1):37-45. PMID: 7805217.
    View in: PubMed
  1297. Lee LV, for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol. 1995; 75:7-13..
  1298. Cannon CP. Hirudin in Acute Myocardial Infarction. J Thromb Thrombolysis. 1995; 1(3):259-267. PMID: 10608003.
    View in: PubMed
  1299. Cannon CP, Tracy R. Clotting for the clinician: An overview of thrombosis and antithrombotic therapy. J Thromb Thrombolysis. 1995; 2:95-106.
  1300. Cannon CP, Ganz LI, Stone PH. Complicated myocardial infarction. Rippe JM, Irwin RS, Fink MP, Cerra FB, editors. Intensive Care Medicine. 1995; 477-99.
  1301. Henry TD, Becker RC, Cannon CP, McCabe CH, Loscalzo J, for the TIMI 5 Investigators. Is there a circadian variation in anticoagulant response to hirudin following acute myocardial infarction. J Am Coll Cardiol. 1995; 310A.
  1302. Cannon CP, Tracy R. Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy. J Thromb Thrombolysis. 1995; 2(2):95-106. PMID: 10608011.
    View in: PubMed
  1303. Cannon CP. Optimizing the Treatment of Unstable Angina. J Thromb Thrombolysis. 1995; 2(3):205-218. PMID: 10608025.
    View in: PubMed
  1304. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994 Dec; 24(7):1602-10. PMID: 7963104.
    View in: PubMed
  1305. Cannon CP. Advances in the treatment of acute MI. Contemp Intern Med. 1994 Aug; 6(8):11-5, 20-6. PMID: 10150659.
    View in: PubMed
  1306. Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction. Arch Intern Med. 1994 Jul 11; 154(13):1492-6. PMID: 8018004.
    View in: PubMed
  1307. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994 Apr; 23(5):993-1003. PMID: 8144799.
    View in: PubMed
  1308. Cannon CP. Adjunctive agents for myocardial infarction thrombolysis. 1994.
  1309. Cannon CP, McCabe CH, Braunwald E. The thrombolysis in myocardial infarction (TIMI) trials. Becker RC, editor. Modern Era of Coronary Thrombolysis. 1994; 53-67.
  1310. Cannon CP. Pharmacology of thrombolytic, anticoagulant, and antiplatelet agents. 1994.
  1311. Cannon CP, Antman EM, Walls R, Braunwald E. Time: An adjunctive agent to thrombolysis. 1994.
  1312. Cannon CP, Antman EM, Walls R, Braunwald E: Le Temps. Un adjuvant a la thrombolyse. 1994.
  1313. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. Circulation. 1994; 89:1545-56..
  1314. Becker R, Tracy R, Bovill E, Thompson B, Randall A, Cannon CP, Braunwald E. Should PTT assays be standardized in multicenter clinical trials designed to investigate the benefits of heparin. J Am Coll Cardiol. 1994; 57A.
  1315. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an Adjunctive Agent to Thrombolytic Therapy. J Thromb Thrombolysis. 1994; 1(1):27-34. PMID: 10603508.
    View in: PubMed
  1316. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994; 90:1624-30..
  1317. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol. 1994; 49(1):1-8. PMID: 8184639.
    View in: PubMed
  1318. Cannon CP, Becker RC, Loscalzo J, Gallo P, Henis M, Edwards SJ, McCabe CH, Braunwald E, for the TIMI 5 Investigators. Usefulness of APTT to predict bleeding for hirudin (and heparin). Circulation. 1994; 90(Part 2):563.
  1319. Anderson HV, Williams DO, Powers E, Cannon CP, Stone P, Sharaf B, Thompson B, Schactman M, Willerson JT, for the TIMI-IIIB Investigators. Coronary thrombus seen on early angiography in unstable angina non-Q-wave MI: TIMI-IIIB results. Circulation. 1994; 90(Part 2):664.
  1320. Becker RC, Cannon CP. Hirudin: Its Biology and Clinical Use. J Thromb Thrombolysis. 1994; 1(1):7-16. PMID: 10603506.
    View in: PubMed
  1321. Braunwald E, Cannon CP, McCabe CH. Use of composite endpoints in thrombolysis trials of acute myocardial infarction. Am J Cardiol. 1993 Dec 16; 72(19):3G-12G. PMID: 8279357.
    View in: PubMed
  1322. Smith SR, Kubacki VB, Rakhit A, Martin LL, Schaffer AV, Jasani MK, Hefty DJ, Johnston T, Cannon C, Bennett WM, et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation. 1993 Dec; 56(6):1422-6. PMID: 8279014.
    View in: PubMed
  1323. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993 Apr 01; 71(10):778-82. PMID: 8456753.
    View in: PubMed
  1324. Barr SA, Zaret BL, Cannon CP, Wackers FJT, and the TIMI 4 and 5 Investigators. Does decreasing defect size in serial quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction correlate with improved left ventricular function. Circulation. 1993; 88(I):486.
  1325. Wackers FJT, Cannon CP, McMahon M, Zaret BL, and TIMI Investigators. Natural history of serial intrahospital quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1993; 21(Suppl A):249.
  1326. Cannon CP. Pharmacology of anticoagulation. Cardiac Surgery: State of the Art Reviews. 1993; 1-20.
  1327. Braunwald E, Cannon CP, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. Circulation. 1992 Aug; 86(2):683-7. PMID: 1638732.
    View in: PubMed
  1328. Abendschein DR, Puleo PR, Cannon CP, and the TIMI IV and V Investigators. Noninvasive detection of early coronary artery patency based on plasma MM and MB creatine kinase (CK) isoforms. Circulation. 1992; 86(Suppl I):266.
  1329. Liaw CW, Cannon C, Power MD, Kiboneka PK, Rubin LL. Identification and cloning of two species of cadherins in bovine endothelial cells. EMBO J. 1990 Sep; 9(9):2701-8. PMID: 2390969; PMCID: PMC551975.
  1330. Van Adelsberg J, Edwards JC, Herzlinger D, Cannon C, Rater M, al-Awqati Q. Isolation and culture of HCO3- -secreting intercalated cells. Am J Physiol. 1989 May; 256(5 Pt 1):C1004-11. PMID: 2541617.
    View in: PubMed
  1331. Van Adelsberg J, Edwards JC, Herzlinger D, Cannon C, Rater M, Al-Awqati Q. Isolation and culture of HC03 secreting cells. Am J Physiol (Cell Physiol). 1989; 256:C1004-11..
  1332. Cannon C, van Adelsberg J, Kelly S, Al-Awqati Q. Carbon-dioxide-induced exocytotic insertion of H+ pumps in turtle-bladder luminal membrane: role of cell pH and calcium. Nature. 1985 Apr 4-10; 314(6010):443-6. PMID: 2858819.
    View in: PubMed
  1333. Cannon C, Van Adelsberg J, Kelly S, Al-Awqati Q. Carbon dioxide-induced exocytotic insertion of H+ pumps in the turtle-bladder membrane: Role of cell pH and cell calcium. Nature. 1985; 314:443-6..
  1334. Al-Awqati Q, Gluck S, Reeves W, Cannon C. Regulation of proton transport in urinary epithelia. J Exp Biol. 1983 Sep; 106:135-41. PMID: 6197505.
    View in: PubMed
  1335. Gluck S, Cannon C, Al-Awqati Q. Exocytosis regulates urinary acidification in turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci U S A. 1982 Jul; 79(14):4327-31. PMID: 6289300; PMCID: PMC346664.
  1336. Gluck S, Cannon C, Al-Awqati Q. Exocytosis regulates rinary acidification in the turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci USA. 1982; 79:4327-31.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_